Download to read offline
![Scientific Programme
Identification of new cortical lesions on longitudinal 7-Tesla MP2RAGE subtraction MRI in
multiple sclerosis
D. Harrison (Baltimore, US)
Application of Neurite Orientation Dispersion and Density Imaging (NODDI) in clinically
isolated syndrome (CIS)
S. Collorone (London, UK)
The impact of CNS inflammation on the GABAergic system: a multi-ligand PET study utilizing
[11C] flumazenil and [11C] PK11195
Y. Kang (New York, US)
Cortical mantle thinning in the visual cortex in pediatric-onset multiple sclerosis
R. Datta (Philadelphia, US)
Coordinate based random effect size meta-analysis shows regions of GM atrophy do not
develop independently in MS and CIS
C. Tench (Nottingham, UK)
Longitudinal study to measure iron deposit in basal ganglia and related structures in
patients with clinically isolated syndrome
A. Rovira (Barcelona, ES)
Evolution of venous narrowing in acute MS lesions
A. Gass (Mannheim, DE)
Normative data of MRI-derived thalamic volumes from a large dataset of healthy subjects
G. Gentile (Siena, IT)
Spinal cord ring enhancement patterns in neuromyelitis optica spectrum disorder:
comparison with multiple sclerosis
Y.-M. Lim (Seoul, KR)
Myelin deterioration occurs in relapsing remitting multiple sclerosis patients meeting
criteria for “no evidence of disease activity”
A. Harel (New York, US)
Resting state fMRI and graph theory for the automatic classification of relapsing remitting
multiple sclerosis with different disease duration
G. Castellazzi (Pavia, IT)
3T FLAIR* MRI improve the differentiation between multiple sclerosis and CNS vasculitis
white matter lesions
P. Maggi (Bruxelles, BE)
Mapping neuroeconomic decisions in multiple sclerosis: a connectivity approach
S. Llufriu (Barcelona, ES)
Probing myelin and axonal integrity in multiple sclerosis brains
G. Franco (Nashville, US)
Comparative study of brain atrophy measures in CIS and MS patients: preliminary results of
a cross-sectional analysis
S. Cappelle (Barcelona, ES)
Page 37 / 108](https://image.slidesharecdn.com/ectrimsactrims-170904222404/85/Ectrims-actrims-37-320.jpg)
![Scientific Programme
14:00 - 14:20 Myelin repair and neurodegeneration in MS: lessons from PET studies
B. Bodini (Paris, FR)
14:20 - 14:40 Ultra-high field MRI in multiple sclerosis
M. Inglese (New York, US)
14:40 - 14:52 3T MRI detection of 7T paramagnetic rims in multiple sclerosis lesions: a
step toward the clinical application
M. Absinta (Bethesda, US)
14:52 - 15:04 A gradient of periventricular microglial activation suggests a CSF-derived
neurodegenerative component in MS
E. Poirion (Paris, FR)
15:04 - 15:16 Two years progression of neurodegeneration in RRMS: metabolic
abnormalities topography using 3D MRSI
M. Donadieu (Marseille, FR)
15:16 - 15:28 [18F]GE-180, a novel TSPO-PET tracer for visualization of inflammatory
CNS-activity in MS
C. Mahler (München, DE)
Poster Sessions, Poster Exhibition
Poster Session 2
Characteristics of acute transverse myelitis in CLIPPERS
G. Taieb (Montpellier, FR)
Neuromyelitis optica spectrum disorders: short myelitis lesions on magnetic resonance
imaging in a cohort of Latin American patients
E.G. Carnero Contentti (Buenos Aires, AR)
2015 International Panel for NMO diagnosis criteria improves early NMOSD diagnosis in a
Colombian cohort
M. Zuluaga (Medellin, CO)
HoxB3, a novel biomarker that predicts conversion to multiple sclerosis
E. Tüzün (Istanbul, TR)
Omics-based approach reveals complement-mediated inflammation in CLIPPERS and
potential biomarkers differentiating from RRMS
Z. Illes (Odense, DK)
The utility of brain lesion distribution criteria at onset in the distinction of multiple
sclerosis, neuromyelitis optica spectrum disorder and MOG-IgG encephalomyelitis
J.-W. Hyun (Goyang, KR)
Rates and predictors of misdiagnosis in primary progressive multiple sclerosis (PPMS) in
Europe and the United States
J. White (London, UK)
Page 68 / 108](https://image.slidesharecdn.com/ectrimsactrims-170904222404/85/Ectrims-actrims-68-320.jpg)
![Scientific Programme
Brain volume loss in individuals over time: sources of variance and limits of detectability
K. Nakamura (Cleveland, US)
The clinical relevance of the network-derived metrics in multiple sclerosis
T. Charalambous (London, UK)
CSF markers of blood-brain barrier integrity forecast disease progression in early MS
J. Kroth (Mainz, DE)
Ultrasmall superparamagnetic iron oxide nanoparticle-enhanced MRI at 7-tesla in multiple
sclerosis
M.K. Schindler (Bethesda, US)
[18F]GE180 PET as a sensitive imaging tool to monitor diffuse brain injury
A. Nack (Munich, DE)
Thalamic white matter in MS: an MRI study combining DTI and quantitative susceptibility
mapping
N. Bergsland (Buffalo, US)
Corpus callosum alterations revealed by Diffusion Basis Spectrum Imaging (DBSI) in all
stages of multiple sclerosis
A.H. Cross (St. Louis, US)
Depression in multiple sclerosis: structural and functional disconnection in the fronto-limbic
system
Q. van Geest (Amsterdam, NL)
Whole white matter integrity predicts information processing speed in clinically isolated
syndrome and early MS
R.M. Giess (Berlin, DE)
Morphologic MRI phenotyping of multiple sclerosis associates with altered brain function
D. Pinter (Graz, AT)
On the construction of a 3D-printed brain phantom as gold standard for the validation of
brain segmentations
A. Altermatt (Basel, CH)
Cognitive impairment in MS: between cognitive reserve and cerebral atrophy: a
neuropsychological and MRI study
G. Fenu (Cagliari, IT)
Disrupted cerebellar network dynamics and cognitive impairment in progressive multiple
sclerosis
M.M. Schoonheim (Amsterdam, NL)
Diffuse reduced axonal density in normal appearing white matter in early multiple sclerosis:
novel insights from multi-shell diffusion MRI
C. Mainero (Boston, US)
Deep learning to normalize conventional T1w MRI for quantitative longitudinal assessment
of tissue health in MS
R.A. Brown (Montreal, CA)
Page 82 / 108](https://image.slidesharecdn.com/ectrimsactrims-170904222404/85/Ectrims-actrims-82-320.jpg)
![Scientific Programme
Cognition in multiple sclerosis: an international multidisciplinary consensus group identifies
obstacles in the field and research priorities for the future
J.F. Sumowski (New York, US)
Accessing early neurodegeneration in multiple sclerosis: biomarkers for diagnostics and
phenotypic characterization
L. Novakova (Gothenburg, SE)
Intrathecal autologous cell therapy is associated with changes in cerebrospinal fluid
biomarkers in patients with progressive multiple sclerosis
V.K. Harris (New York, US)
Cerebrospinal fluid levels of cell-free mitochondrial DNA in patients with multiple sclerosis
M. Comabella (Barcelona, ES)
Long non coding RNA expression profile in Peripheral Blood Mononuclear Cells from multiple
sclerosis patients: potential biomarkers of disease susceptibility and progression
E. Oldoni (Milan, IT)
CircularRNA profiling reveals that circularRNAs from ANXA2 could be new biomarkers for
multiple sclerosis
L. Iparraguirre (San Sebastian, ES)
Metabolic imaging of hyperpolarized [1-13C] pyruvate can detected neuroinflammation in
the cuprizone model of MS
M. Chaumeil (San Francisco, US)
Altered erythrocyte MicroRNA profiles in relapsing-remitting multiple sclerosis
K. Groen (Callaghan, AU)
Normalization of neurofilament light chain levels after treatment with dimethyl fumarate
T. Sejbaek (Odense, DK)
Serum exosomes microRNA-122-5p, miRNA-196b-5p, miRNA-301a-3p and miRNA-532-5p
represent a biomarkers of multiple sclerosis
I. Selmaj (Lodz, PL)
Capillary isoelectric focusing immunoassay for the detection of oligoclonal IgG- and IgM
bands in cerebrospinal fluid
S. Halbgebauer (Ulm, DE)
Novel molecular markers associated with cognitive dysfunction in multiple sclerosis
A. Iacoangeli (New York, US)
Utility of fMRI metrics in assessment of RRMS disease progress and severity
M.P. Turner (Richardson, US)
Cerebrospilnal fluid-Actin related protein 2/3 complex subunit 4 as an astrocytic foot
process damage marker of aquaporin-4-IgG positive neuromyelitis optica spectrum
disorders
S. Nishiyama (Sendai, JP)
Page 87 / 108](https://image.slidesharecdn.com/ectrimsactrims-170904222404/85/Ectrims-actrims-87-320.jpg)
![Scientific Programme
Natalizumab is associated with stable or improved cognitive function, health-related quality
of life, and work capacity in anti-JC virus seronegative patients with early relapsing-
remitting multiple sclerosis: a 2-year analysis of STRIVE
J. Perumal (New York, US)
Everyday technology use in MS: limitations and opportunities in using everyday technology
in persons with MS
Y. Goverover (New York, US)
Qualitative factors on initiation, satisfaction and adherence to aquatic exercise in the
community among persons with multiple sclerosis
C. Santoyo (Barcelona, ES)
Understanding patient underreporting of MS relapses: insights from patients with multiple
sclerosis from the Harris Poll 2017 survey
E.N. Banfe (Hampton, US)
Increased adherence and better satisfaction outcomes with oral treatments in relapsing-
remitting multiple sclerosis patients
I. González-Suárez (Madrid, ES)
Employment status and health-related quality of life of MS patients in a never treated and
only ever treated with IFNβ-1a sc cohorts: an exploratory study
S. Hum (Montreal, CA)
The association between energy cost of walking and leisure-time physical activity in people
with multiple sclerosis
A. Kalron (Herzeliya, IL)
Evaluation of a web-based fall prevention program among people with multiple sclerosis
M. Kannan (Portland, US)
Expanding our understanding of daily life activity impact in patients with multiple sclerosis
J. Petrillo (Cambridge, US)
Multicenter open-label non-interventional study assessing the alteration of activity in
ambulatory patients with relapsing forms of MS (RMS) under treatment with COPAXONE®
40 mg tiw - results of an interim analysis of the NIS COPTIVITY
T. Ziemssen (Dresden, DE)
Enhanced regional cerebral perfusion following acetazolamide: preliminary results
J.A. Lincoln (Houston, US)
[F-18]PBR06 PET to assess TSPO binding and its association with brain atrophy and
disability in multiple sclerosis
T. Singhal (Boston, US)
Elevated adiponectin levels induce pro-inflammatory myeloid- and T-cell responses linking
adiposity and predisposition to pediatric MS
G. Fadda (Montreal, CA)
Big Multiple Sclerosis Data Network: impact of early treatment on long term disability
accumulation in relapsing remitting multiple sclerosis patients
P. Iaffaldano (Bari, IT)
Page 98 / 108](https://image.slidesharecdn.com/ectrimsactrims-170904222404/85/Ectrims-actrims-98-320.jpg)
![Scientific Programme
Vitamin D levels in a multiple sclerosis population treated with rituximab
P. Sundström (Umeå, SE)
Short-term memory loss correlates with mean diffusivity and free-water in recently
diagnosed multiple sclerosis patients
Ø. Bergmann (Bergen, NO)
An antigen-specific semi-therapeutic treatment with local delivery of tolerogenic factors
through a dual-sized microparticle system blocks experimental autoimmune
encephalomyelitis, a mouse model of multiple sclerosis
J. Cho (Gainesville, US)
Advanced imaging detects variations in myelin content and thickness in the corpus
callosum of neuromyelitis optica patients and healthy controls
S. Abel (Vancouver, CA)
Corpus callosum atrophy in MS is halted by autologous haematopoietic stem cell
transplantation
A. Tolf (Uppsala, SE)
Epstein-Barr virus induced G-protein coupled receptor 2 (GPR 183) in B lymphocyte can be
associated with the relapse of neuromyelitis optica spectrum disorder with AQP4-IgG
S.-M. Kim (Seoul, KR)
Comparison of skin cell immunity in patients receiving treatment with gilenya (fingolimod)
and healthy controls
S. Newman (Plainview, US)
Comparative effectiveness of dimethyl fumarate, teriflunomide, interferon-beta and
glatiramer acetate on newly diagnosed patients: a propensity score-matched analysis from
a multicenter Italian group
A. Signori (Genova, IT)
Repeated administrations of macrocyclic gadolinium based contrast agents do not cause
increased signal intensity in dentate nucleus and globus pallidus on T1-weighted
unenhanced magnetic resonance images: confirmed safety in multiple sclerosis
A. Sartori (Trieste, IT)
Flowy cytometric assay for antibody to myelin oligodendrocyte glycoprotein in chronic
relapsing inflammatory optic neuropathy (CRION)
B. Kim (Seoul, KR)
What is the best home-based walking exercise prescription for people with multiple
sclerosis? A randomized controlled clinical trial
N. Aghaei (Tehran, IR)
[F-18]PBR06 vs. [C-11]PBR28 PET for assessing white matter TSPO binding in multiple
sclerosis
T. Singhal (Boston, US)
Cladribine controls multiple sclerosis via memory B cell depletion
B. Ceronie (London, UK)
Pro-inflammatory monocyte subsets are augmented in incipient and progressed multiple
sclerosis
M.C. Gjelstrup (Aarhus, DK)
Page 101 / 108](https://image.slidesharecdn.com/ectrimsactrims-170904222404/85/Ectrims-actrims-101-320.jpg)
More Related Content
Ectrims actrims
- 1. Scientific Programme Wednesday, 25October 2017 Teaching Courses, Hall C 08:30 - 10:00 Teaching Course 1: Disease modifying treatment Chairs R.J. Fox (Cleveland, US) L. Kappos (Basel, CH) 08:30 - 09:00 DMTs 2017: new MS treatments and updates on established treatments R.J. Fox (Cleveland, US) 09:00 - 09:30 Defining what is working: choosing when and how to escalate therapy L. Kappos (Basel, CH) 09:30 - 10:00 Clinical trial statistics: pearls and lessons from MS trials M.P. Sormani (Genoa, IT) Teaching Courses, Hall D 08:30 - 10:00 Teaching Course 2: MS and reproduction: from contraception to post conception reproductive epidemiology and planning a pregnancy in women with MS Chairs K. Hellwig (Bochum, DE) A. Langer Gould (Pasadena, US) 08:30 - 09:00 Counselling of women with MS in the reproductive age – from contraception to conception-general recommendations M.K. Houtchens (Brookline, US) 09:00 - 09:30 Multiple sclerosis and pregnancy management in 2017: medications and lactation K. Hellwig (Bochum, DE) 09:30 - 10:00 Reproductive epidemiology in multiple sclerosis (puberty, pregnancy, breastfeeding, assisted reproductive techniques and menopause) A. Langer Gould (Pasadena, US) Teaching Courses, Hall E 08:30 - 10:00 Teaching Course 5: Biomarkers in MS Chairs B. Hemmer (Munich, DE) M. Comabella (Barcelona, ES) Page 1 / 108
- 2. Scientific Programme 08:30 -09:00 General considerations to develop and use biomarkers in MS B. Hemmer (Munich, DE) 09:00 - 09:30 Biomarkers of neuroinflammation M. Comabella (Barcelona, ES) 09:30 - 10:00 Biomarkers of CNS neurodegeneration M. Otto (Ulm, DE) Teaching Courses, Hall F 08:30 - 10:00 Teaching Course 4: Myelin repair: scientific background and clinical implications Chairs B. Stankoff (Paris, FR) L. Leocani (Milan, IT) 08:30 - 09:00 Mechanisms leading to success or failure of myelin repair in the central nervous system R. Franklin (Cambridge, UK) 09:00 - 09:30 Evaluation of myelin repair: electrophysiological outcomes L. Leocani (Milan, IT) 09:30 - 10:00 Evaluation of myelin repair: imaging outcomes B. Stankoff (Paris, FR) Teaching Courses, Hall G 08:30 - 10:00 Teaching Course 3: Advanced MS genetics and immunology Chairs R. Liblau (Toulouse, FR) F. Zipp (Mainz, DE) 08:30 - 09:00 The MS genomic map: translating genetic architecture into a roadmap for dissecting neuroimmune mechanisms P. De Jager (New York, US) 09:00 - 09:30 Immunology of MS: how does the pathogenic adaptive immune response develop? R. Liblau (Toulouse, FR) 09:30 - 10:00 Immunology of MS: innate and adaptive immune events within the CNS F. Zipp (Mainz, DE) Page 2 / 108
- 3. Scientific Programme Teaching Courses,Hall C 10:30 - 12:00 Teaching Course 6: Controversy in management Chairs A.E. Miller (New York, US) X. Montalban (Barcelona, ES) 10:30 - 11:00 Case 1: relapsing MS A.E. Miller (New York, US) 11:00 - 11:30 Case 2: progressive MS X. Montalban (Barcelona, ES) 11:30 - 12:00 Case 3: neuromyelitis optica spectrum disorder (NMOSD) I. Katz Sand (New York, US) Teaching Courses, Hall D 10:30 - 12:00 Teaching Course 7: Symptomatic therapy of gait disturbances, spasticity, bladder dysfunction and paroxysmal symptoms Chairs T. Berger (Innsbruck, AT) M. Pakzad (London, UK) 10:30 - 11:00 Bladder dysfunction: pitfalls and challenges M. Pakzad (London, UK) 11:00 - 11:30 Spasticity and walking impairment: early to recognise and to treat C. Oreja-Guevara (Madrid, ES) 11:30 - 12:00 Paroxysmal symptoms: often neglected, but treatment needed T. Berger (Innsbruck, AT) Teaching Courses, Hall E 10:30 - 12:00 Teaching Course 8: Brain atrophy in clinical practice: evidence base and barriers to implementation Chairs F. Barkhof (Amsterdam, NL) J. Sastre-Garriga (Barcelona, ES) 10:30 - 11:00 Natural history & clinical relevance of brain volume changes in patients with MS F. Barkhof (Amsterdam, NL) 11:00 - 11:30 Value of brain volume changes to predict treatment response in patients with MS J. Sastre-Garriga (Barcelona, ES) Page 3 / 108
- 4. Scientific Programme 11:30 -12:00 Barriers to brain volume measurement in the real world M. Battaglini (Siena, IT) Teaching Courses, Hall F 10:30 - 12:00 Teaching Course 9: Cognition Chairs M.P. Amato (Florence, IT) J. DeLuca (New Orange, US) 10:30 - 11:00 Epidemiology of cognitive impairment: an update M.P. Amato (Florence, IT) 11:00 - 11:30 Current approaches to management J. DeLuca (New Orange, US) 11:30 - 12:00 Cognition as a clinical outcome measure in clinical trials on DMDs R.H. Benedict (Buffalo, US) Teaching Courses, Hall G 10:30 - 12:00 Teaching Course 10: Progressive multiple sclerosis and the relationship to relapsing disease - how neuroglial inter- actions underlie the pathogenesis and treatment Chairs S. Ludwin (Kingston, CA) H. Lassmann (Wien, AT) 10:30 - 11:00 Oxidative injury to glial cells and neurons as a basis for progressive disease H. Lassmann (Wien, AT) 11:00 - 11:30 Astrocyte patho-biology and interactions with other glia and neurons in the development of PMS S. Ludwin (Kingston, CA) 11:30 - 12:00 Targeting glia as the basis of treating progressive PMS V.W.W. Yong (Calgary, CA) Satellite Symposia, Hall B 12:30 - 13:30 European Charcot Foundation - Reconsidering the concept of induction therapy Chairs G. Comi (Milan, IT) Page 4 / 108
- 5. Scientific Programme 12:30 -12:50 The concept M.S. Freedman (Ottawa, CA) 12:50 - 13:10 The evidence G. Edan (Rennes, FR) 13:10 - 13:30 The problems and the future perspectives H.-P. Hartung (Duesseldorf, DE) Teaching Courses, Hall C 12:30 - 14:00 Teaching Course 11: Differential diagnoses Chairs S. Fredrikson (Stockholm, SE) A. Siva (Istanbul, TR) 12:30 - 13:00 Diagnostic and differential diagnostic dilemmas in MS S. Fredrikson (Stockholm, SE) 13:00 - 13:30 MRI-diagnostic possibilities and pitfalls A. Siva (Istanbul, TR) 13:30 - 14:00 NMOSD including antiMOG related disorders as differential diagnoses to MS B. Weinshenker (Rochester, US) Teaching Courses, Hall D 12:30 - 14:00 Teaching Course 12: Neuromyelitis optica spectrum disorders Chairs D.M. Wingerchuk (Scottsdale, US) K. Fujihara (Sendai, JP) 12:30 - 13:00 Update on pathogenesis of NMOSD K. Fujihara (Sendai, JP) 13:00 - 13:30 Diagnostic issues with AQP4-IgG-seropositive and -seronegative NMOSD D.M. Wingerchuk (Scottsdale, US) 13:30 - 14:00 Optimising treatment of NMOSD in various situations R. Marignier (Lyon, FR) Page 5 / 108
- 6. Scientific Programme Teaching Courses,Hall E 12:30 - 14:00 Teaching Course 13: Imaging the non-MS lesion in MS Chairs D. Reich (Bethesda, US) A. Rovira (Barcelona, ES) 12:30 - 13:00 Atypical imaging presentations of MS and other idiopathic demyelinating diseases A. Rovira (Barcelona, ES) 13:00 - 13:30 Imaging the complications of MS therapies D. Reich (Bethesda, US) 13:30 - 14:00 The central vein sign on MRI P. Sati (Bethesda, US) Teaching Courses, Hall F 12:30 - 14:00 Teaching Course 14: OCT in clinical practice Chairs S. Galetta (New York, US) L. Balcer (New York, US) 12:30 - 13:00 OCT in MS: what have we learned so far? L. Balcer (New York, US) 13:00 - 13:30 OCT in MS: what is new? S. Saidha (Baltimore, US) 13:30 - 14:00 OCT in the clinic: case by case S. Galetta (New York, US) Teaching Courses, Meeting Room 315 12:30 - 14:00 Case-based Teaching Course 15: Paediatric MS Chairs B. Banwell (Philadelphia, US) K. Deiva (Paris, FR) 12:30 - 13:15 Case presentation 1 B. Banwell (Philadelphia, US) 13:15 - 14:00 Case presentation 2 K. Deiva (Paris, FR) Page 6 / 108
- 7. Scientific Programme Parallel Sessions,Hall B 14:00 - 15:30 Parallel Session 1: Prevalence and phenotype evolution of MS in different continents Chairs P. Duquette (Montréal, CA) M.A.A. Sahraian (Tehran, IR) 14:00 - 14:20 Asia Y. Takashi (Tokyo, JP) 14:20 - 14:40 Africa-Middle East R. Gouider (Manouba, TN) 14:40 - 15:00 Latin America L. Negrotto (Buenos Aires, AR) 15:00 - 15:20 Australia and New Zealand H. Butzkueven (Melbourne, AU) 15:20 - 15:30 The clinical course, therapeutic responses, and outcomes in relapsing MOG antibody-associated demyelination S. Ramanathan (Sydney, AU) Young Scientific Investigators’ Sessions, Hall C 14:00 - 15:30 Young Scientific Investigators' Session 1 Chairs P. Calabresi (Baltimore, US) V. Zujovic (Paris, FR) 14:00 - 14:15 Brain atrophy rates in multiple sclerosis changes along disease course are sensitive to image processing method: not ready for NEDA-4 yet? M. Andorrà (Barcelona, ES) 14:15 - 14:30 Altered default-mode network dynamics in cognitively impaired MS patients A.J. Eijlers (Amsterdam, NL) 14:30 - 14:45 Ganglion cell layer atrophy starts one week after onset of acute optic neuritis and progress over 18 months E.H. Martinez-Lapiscina (Barcelona, ES) 14:45 - 15:00 Predicting performance improvements with visuomotor training in MS using a multi-modal clinical and neuroimaging approach I. Lipp (Cardiff, UK) 15:00 - 15:15 Enlargement of white matter MS lesions is associated with lesional microglial activation measured in vivo C. Benoit (Paris, FR) Page 7 / 108
- 8. Scientific Programme 15:15 -15:30 Independent contributions of cervical cord lesions and thalamic, cerebellar, and putaminal volumes to upper extremity function in early multiple sclerosis A. Harel (New York, US) Nurses Sessions, Hall E 14:15 - 15:30 Nurses' Session 1: Impact of MS nursing across Europe Chairs A. Winslow (Dublin, IE) 14:15 - 14:25 Introduction and welcome D. Miller (London, UK) A. Winslow (Dublin, IE) 14:25 - 14:40 MS Nurse Pro – Launch of the rehabilitation module N. Abel (Birmingham, UK) 14:40 - 15:30 Core challenges, opportunities and impact of MS nursing across Europe (panel-debate) A. Perrin Ross (Maywood, US) V. Matthews (Herts, UK) K. Harrison (Blaricum, NL) R. Motta (Genoa, IT) M. Skrzypek (Gdansk, PL) J. Hlavacova (Prague, CZ) J. Sastre-Garriga (Barcelona, ES) Teaching Courses, Meeting Room 315 14:15 - 15:45 Case-based Teaching Course 16: Induction treatment in very active multiple sclerosis: why, how, when? Chairs G. Edan (Rennes, FR) E. Le Page (Rennes, FR) 14:15 - 15:00 Case presentation 1 G. Edan (Rennes, FR) 15:00 - 15:45 Case presentation 2 E. Le Page (Rennes, FR) Page 8 / 108
- 9. Scientific Programme Teaching Courses,Meeting Room 313/314 14:15 - 15:45 Case-based Teaching Course 17: Definition of non- responders Chairs M. Tintoré (Barcelona, ES) A. Ruet (Bordeaux, FR) 14:15 - 15:00 Case presentation 1: failing to first line treatment: NEDA vs MEDA A. Ruet (Bordeaux, FR) 15:00 - 15:45 Case presentation 2: definition on treatment response in second line treatment: how to face pregnancy desire while being on treatment M. Tintoré (Barcelona, ES) Teaching Courses, Meeting Room 311/312 14:15 - 15:45 Case-based Teaching Course 18: Progressive MS: whom to treat, with what and for how long? Chairs B.A. Cree (San Francisco, US) F. Paul (Berlin, DE) 14:15 - 15:00 Progressive MS: whom to treat, with what and for how long? B.A. Cree (San Francisco, US) 15:00 - 15:45 Case presentation 2 F. Paul (Berlin, DE) Hot Topic Sessions, Hall B 16:00 - 16:45 Hot Topic 1: Progressive MS alliance: what’s new Chairs W.M. Carroll (Nedlands, AU) A.J. Thompson (London, UK) 16:00 - 16:15 Selected project D.L. Arnold (Montréal, CA) 16:15 - 16:30 Bioinformatics and cell reprogramming to develop an in vitro platform to discover new drugs for progressive multiple sclerosis (BRAVEinMS) G. Martino (Milan, IT) 16:30 - 16:45 Development of a drug discovery pipeline for secondary progressive MS F.J. Quintana (Boston, US) Page 9 / 108
- 10. Scientific Programme Young ScientificInvestigators’ Sessions, Hall C 16:00 - 17:15 Young Scientific Investigators' Session 2 Chairs M. Comabella (Barcelona, ES) S. Zamvil (San Francisco, US) 16:00 - 16:15 Loss of tolerance of thyroid-specific B cells as a biomarker for increased risk for AITD in anti-CD52 treated MS patients M.J. Smith (Aurora, US) 16:15 - 16:30 Propionic acid modulates T effector cell balance and function in MS patients A. Duscha (Bochum, DE) 16:30 - 16:45 Proposed NASSC classification criteria provide labels for patients with early Susac syndrome but do not meet EuSaC diagnostic criteria G.R. Paton (Vancouver, CA) 16:45 - 17:00 Different patterns of structural and microstructural damage in Neuromyelitis Optica Spectrum Disorders A. d'Ambrosio (Milan, IT) 17:00 - 17:15 Monitoring treatment response in MS by serum NFL reflect treatment efficacy L. Novakova (Gothenburg, SE) Hot Topic Sessions, Hall D 16:00 - 16:45 Hot Topic 2: e-MS and patients related outcomes Chairs M. Trojano (Bari, IT) P.A. Gourraud (San Francisco, US) 16:00 - 16:15 Interests and needs of health intervention technology in chronic diseases T. Ziemssen (Dresden, DE) 16:15 - 16:30 Utilizing mobile technology in the assessment and monitoring of MS patients J. Alberts (Cleveland, US) 16:30 - 16:45 Pros and cons of web based outcomes measures to monitor disease progression G. Giovannoni (London, UK) Page 10 / 108
- 11. Scientific Programme Nurses Sessions,Hall E 16:00 - 17:15 Nurses' Session 2: Nurses leading the translation of research into practice Chairs A.K. Krakau Hansen (Copenhagen, DK) N. Barker (London, UK) 16:00 - 16:25 Adolescents’ experiences on coping with parental multiple sclerosis T. Mauseth (Bergen, NO) 16:25 - 16:50 A nurses guide to MS brain health: practical strategies for implementing MS brain health into everyday clinical practice J. Haartsen (Melbourne, AU) 16:50 - 17:15 A comprehensive approach to meeting the needs and demands of people with multiple sclerosis. Translational results of an ECTRIMS Nurse MS Fellowship M.A. Robles Sanchez (Barcelona, ES) Satellite Symposia, Hall A 17:30 - 18:30 Satellite Symposium - Navigating choice. Can real world evidence (RWE) deliver personalised medicine? Supported by Biogen International Chairs S. Vukusic (Lyon, FR) 17:30 - 18:30 Interactive Session S. Braune (Prien, DE) J. Hillert (Stockholm, SE) T. Kalincik (Melbourne, AU) T. Ziemssen (Dresden, DE) Satellite Symposia, Hall A 18:45 - 19:45 Satellite Symposium - Understanding neuropreservation: how does it translate to clinical outcomes? Supported by Sanofi Genzyme Chairs G. Edan (Rennes, FR) 18:45 - 18:50 Introduction G. Edan (Rennes, FR) 18:50 - 19:15 How is neuropreservation in MS evaluated? F. Barkhof (Amsterdam, NL) Page 11 / 108
- 12. Scientific Programme 19:15 -19:40 Preserving brain and improving clinical outcomes: how are they related? A. Traboulsee (Vancouver, CA) 19:40 - 19:45 Close G. Edan (Rennes, FR) Page 12 / 108
- 13. Scientific Programme Thursday, 26October 2017 Satellite Symposia, Hall D 07:45 - 08:45 Satellite Symposium - New horizons in progressive multiple sclerosis Supported by MedDay Pharmaceuticals Chairs J. Antel (Montreal, CA) D.J. Mahad (Edinburgh, UK) 07:45 - 08:00 New classification and challenges in progressive MS B.A. Cree (San Francisco, US) 08:00 - 08:10 Update on mechanisms involved in neuronal degeneration M. Kerschensteiner (Munich, DE) 08:10 - 08:20 Innovation in progressive MS: the metabolic approach O. Gout (Paris, FR) 08:20 - 08:30 Rehabilitation in progressive MS: from evaluation to treatment M. Haupts (Isselburg-Anholt, DE) 08:30 - 08:45 Q&A and closure of the meeting Plenary Sessions, Hall A 09:00 - 10:15 Plenary Session 1 - Welcome and ECTRIMS-ACTRIMS Opening Lecture Chairs D. Miller (London, UK) J. Antel (Montreal, CA) C. Lubetzki (Paris, FR) 09:00 - 09:30 Welcome to MSParis2017 incl. cultural feature D. Miller (London, UK) C. Lubetzki (Paris, FR) V. Pecresse (Paris, FR) 09:30 - 10:15 ECTRIMS-ACTRIMS Opening Lecture: From neuropathology to new patho- physiological concepts and clinical perspectives H. Lassmann (Wien, AT) Page 13 / 108
- 14. Scientific Programme Parallel Sessions,Hall A 10:45 - 12:15 Parallel Session 2: The new MS criteria Chairs A.H. Cross (St. Louis, US) S. Chandran (Edinburgh, UK) 10:45 - 11:05 2017 proposed revisions to the McDonald diagnostic criteria for multiple sclerosis J.A. Cohen (Cleveland, US) 11:05 - 11:25 Impact of the new criteria on disease management J. Chataway (London, UK) 11:25 - 11:37 The added value of oligoclonal bands in the multiple sclerosis diagnostic criteria G. Arrambide (Barcelona, ES) 11:37 - 11:49 Revised McDonald 2010 versus MAGNIMS 2016 MRI criteria in CIS patients suggestive of MS: a multicenter study M. Filippi (Milano, IT) 11:49 - 12:01 Comparative evaluation of successive criteria for neuromyelitis optica R. Marignier (Lyon, FR) 12:01 - 12:13 Impact of including optic nerve lesions in dissemination in space in diagnostic criteria for multiple sclerosis W.J. Brownlee (London, UK) Parallel Sessions, Hall B 10:45 - 12:15 Parallel Session 3: Update on MS prognostic markers Chairs D. Brassat (Toulouse, FR) C. Teunissen (Amsterdam, NL) 10:45 - 11:05 Prognostic biomarkers in multiple sclerosis E. Thouvenot (Nîmes, FR) 11:05 - 11:25 Prognostic imaging markers of MS C. Azevedo (Los Angeles, US) 11:25 - 11:37 New spinal cord and infratentorial lesions in early relapse-onset MS are predictive of secondary progressive disease course after 15 years W.J. Brownlee (London, UK) 11:37 - 11:49 Temporal variability profile of serum neurofilament light levels in multiple sclerosis patients P. Calabresi (Baltimore, US) 11:49 - 12:01 Association between psychiatric comorbidity and disability progression of multiple sclerosis K.A. McKay (Vancouver, CA) Page 14 / 108
- 15. Scientific Programme 12:01 -12:13 Structural MRI predictors of cognitive decline in MS A.J. Eijlers (Amsterdam, NL) Parallel Sessions, Hall C 10:45 - 12:15 Parallel Session 4: Axon/myelin injury in MS lesions and experimental models Chairs M. Friese (Hamburg, FR) P. Stys (Calgary, CA) 10:45 - 11:05 Immune mediated injury of axon-myelin unit M. Simons (Göttingen, DE) 11:05 - 11:25 Evolution of the MS plaques C. Lucchinetti (Rochester, US) 11:25 - 11:37 Connexins in neuromyelitis optica: a link between astrocytopathy and demyelination C. Richard (Lyon, FR) 11:37 - 11:49 Influx of extracellular calcium drives axonal degeneration in an animal model of multiple sclerosis M.E. Witte (Munich, DE) 11:49 - 12:01 The staging of astrocytopathy in neuromyelitis optica spectrum disorders with aquaporin4-IgG Y. Takai (Sendai, JP) 12:01 - 12:13 Evaluation of the neuroprotective properties of alpha-lipoic acid by optical coherence tomography in a model of experimental autoimmune encephalomyelitis-optic neuritis P. Albrecht (Düsseldorf, DE) Parallel Sessions, Hall D 10:45 - 12:15 Parallel Session 5: The blood brain barriers in MS Chairs K. Akassoglou (San Francisco, US) P.-O. Couraud (Paris, FR) 10:45 - 11:05 The brain barriers control immune privilege of the CNS B. Engelhardt (Berne, CH) 11:05 - 11:25 Blood brain barrier adhesion molecules as therapeutic targets in MS A. Prat (Montreal, CA) 11:25 - 11:37 Integrin alpha8 is a novel mediator of proinflammatory T lymphocyte migration across the CNS barriers E.M. Gowing (Montreal, CA) Page 15 / 108
- 16. Scientific Programme 11:37 -11:49 Antigen expression by endothelial cells of the blood brain barrier elicits activation and pathogenicity of CD8 T cells in the central nervous system C. Meyer (Toulouse, FR) 11:49 - 12:01 EGFL7 is a novel player in multiple sclerosis that beneficially regulates CNS infiltration C. Larochelle (Montreal, CA) 12:01 - 12:13 Astrocytic tight junctions control inflammatory CNS lesion pathogenesis C. Chapouly (New York, US) Satellite Symposia, Hall B 12:45 - 13:45 Satellite Symposium - Beyond the lightbulb: exploring the known unknown Supported by Roche 12:45 - 12:50 Welcome and introduction M. Duddy (Newcastle upon Tyne, UK) 12:50 - 13:05 Chronic features of MS pathology in image: from the tissue to MRI and then back D.L. Arnold (Montréal, CA) 13:05 - 13:20 From acute and chronic inflammation to disability outcomes? S. Hauser (San Francisco, US) 13:20 - 13:35 Are we seeing but not recognising disease progression in clinical practice? D. Horakova (Prague, CZ) 13:35 - 13:45 Questions and answers session M. Duddy (Newcastle upon Tyne, UK) D.L. Arnold (Montréal, CA) S. Hauser (San Francisco, US) D. Horakova (Prague, CZ) Satellite Symposia, Hall D 12:45 - 13:45 Satellite Symposium - Neuro-restoration in multiple sclerosis: science fiction or reality? Supported by AbbVie Chairs B.A. Cree (San Francisco, US) G. Giovannoni (London, UK) J. Kesselring (Valens, CH) Page 16 / 108
- 17. Scientific Programme 12:45 -13:00 How does the biology of neuro-restoration differ from disability progression in MS? G. Giovannoni (London, UK) 13:00 - 13:15 Recent insights from progressive MS clinical trials: what will a neurorestoration study look like? B.A. Cree (San Francisco, US) 13:15 - 13:30 Managing expectations of patients with progressive MS J. Kesselring (Valens, CH) 13:30 - 13:45 Panel discussion Parallel Sessions, Hall A 14:00 - 15:30 Parallel Session 6: Therapeutic perspectives in progressive MS Chairs R. Kapoor (London, UK) J.S. Wolinsky (Houston, US) 14:00 - 14:20 Prognostic factors in progressive MS G. Edan (Rennes, FR) 14:20 - 14:40 Therapeutic advances and failures in progressive MS F. Lublin (New York, US) 14:40 - 14:52 The effect of disease-modifying treatments on conversion to secondary progressive multiple sclerosis J.W.L. Brown (Cambridge, UK) 14:52 - 15:04 Effects of siponimod on MRI outcomes in patients with secondary progressive multiple sclerosis: results of the phase 3 EXPAND study R.J. Fox (Cleveland, US) 15:04 - 15:16 MD1003 in progressive multiple sclerosis: 24-month brain MRI results of the MS-SPI trial D.L. Arnold (Montréal, CA) 15:16 - 15:28 Natalizumab improves walking and upper-limb disability compared with placebo in patients with secondary progressive multiple sclerosis: an integrated, post hoc area under the outcome-time curve analysis from the ASCEND trial G. Giovannoni (London, UK) Page 17 / 108
- 18. Scientific Programme Parallel Sessions,Hall B 14:00 - 15:30 Parallel Session 7: Paediatric MS Chairs A. Boyko (Moscow, RU) M. Tardieu (Paris, FR) 14:00 - 14:20 Longterm prognosis of pediatric MS R. Hintzen (Rotterdam, NL) 14:20 - 14:40 Treatment of pediatric MS E. Waubant (San Francisco, US) 14:40 - 14:52 Regional grey matter atrophy in pediatric patients with multiple sclerosis: a longitudinal MRI study E. De Meo (Milan, IT) 14:52 - 15:04 Cognitive reserve is associated with better cognitive outcome and socio- professional attainment in both adult and pediatric-onset multiple sclerosis L. Pasto' (Florence, IT) 15:04 - 15:16 Effect of age and gender on disease progression in pediatric multiple sclerosis population M. Gurevich (Ramat-Gan, IL) 15:16 - 15:28 Serial MRI detects presence and evolution of a 'surface-in' gradient of thalamic damage in paediatric-onset MS, which is recapitulated in adult MS autopsy G. Fadda (Montreal, CA) Parallel Sessions, Hall C 14:00 - 15:30 Parallel Session 8: Immune cells in injury and repair Chairs F. Zipp (Mainz, DE) A. Bar-Or (Philadelphia, US) 14:00 - 14:20 New insight into immune related CNS injury L. Steinman (Standford, US) 14:20 - 14:40 Immune checkpoint blockade in combating Alzheimer's disease M. Schwartz (Rehovot, IS) 14:40 - 14:52 Adaptive immunity drives remyelination failure or success in multiple sclerosis C. Sanson (Paris, FR) 14:52 - 15:04 Patterns of microglia/macrophage polarization in multiple sclerosis and stroke lesions T. Zrzavy (Vienna, AT) Page 18 / 108
- 19. Scientific Programme 15:04 -15:16 Unexpected role of neutrophil granulocytes during both murine and human central nervous system autoimmunity B. Knier (München, DE) 15:16 - 15:28 B cell-mediated experimental CNS autoimmunity is modulated by inhibition of Bruton's tyrosine kinase S. Torke (Goettingen, DE) Parallel Sessions, Hall D 14:00 - 15:30 Parallel Session 9: New insight into grey matter pathology in MS Chairs C. Stadelmann (Göttingen, DE) B. Trapp (Cleveland, US) 14:00 - 14:20 Synaptic pathology in cortex of multiple sclerosis D. Merkler (Geneva, CH) 14:20 - 14:40 Connection between inflammation and cortical neuronal pathology in MS and EAE D. Centonze (Rome, IT) 14:40 - 14:52 The axon initial segment: a novel site of neuronal dysfunction in multiple sclerosis M. Davenne (Paris, FR) 14:52 - 15:04 Thalamic MRI and histopathologic correlations in advanced multiple sclerosis K. Mahajan (Cleveland, US) 15:04 - 15:16 Neural correlates of cognitive phenotypes in multiple sclerosis V.M. Leavitt (New York, US) 15:16 - 15:28 Meningeal inflammation is linked to subpial cortical demyelination in progressive multiple sclerosis with ongoing white matter pathology V. Ramaglia (Toronto, CA) Poster Sessions, Poster Exhibition Poster Session 1 Diagnostic criteria for Susac syndrome M. Ringelstein (Düsseldorf, DE) Time influences the performance of diagnostic criteria for multiple sclerosis W.J. Brownlee (London, UK) Evaluation of the sensitivity of the 2016 MAGNIMS MRI criteria for dissemination in space in children Y. Hacohen (London, UK) Page 19 / 108
- 20. Scientific Programme Lesion topographiesin the multiple sclerosis diagnostic criteria: a reappraisal B. Arrambide (Barcelona, ES) Brain and spinal cord imaging features in neuromyelitis optica spectrum disorder L. Cacciaguerra (Milan, IT) Performance of 2010 McDonald criteria and 2016 MAGNIMS guidelines in the diagnosis of primary progressive multiple sclerosis A. Gajofatto (Verona, IT) Brain microglial activation detected by TSPO PET at the pre-symptomatic stage of MS E. Poirion (Paris, FR) Clinical and prognosis profile of paraneoplastic neuromyelitis optica spectrum disorders N. Sola-Valls (Barcelona, ES) Susac syndrome: clinical features, laboratory testing and treatment responses of 20 cases C. Boz (Trabzon, TR) Epidemiology of neuromyelitis optica spectrum disorders in Catalonia: a population-based study A. Saiz (Barcelona, ES) Double seronegative longitudinally extensive transverse myelitis: preliminary study on 17 patients E. Maillart (Paris, FR) Immunoglobulin free light chains in saliva: a new marker of multiple sclerosis? E. Ganelin-Cohen (Petach Tikva, IL) Application of the 2015 diagnostic criteria for neuromyelitis optica spectrum disorders in a cohort of Latin American patients: the impact on diagnostic rates E.G. Carnero Contentti (Buenos Aires, AR) A molecular-based approach using long, non-coding RNA and enhancer-associated lncRNA gene expression signatures to classify multiple sclerosis using peripheral whole blood C.F. Spurlock, III (Nashville, US) New possibilities in multiple sclerosis imaging evaluation: studying the performance of Phase Sensitive Inversion Recovery (PSIR) in juxtacortical lesions M.C.A. Vecino (Porto Alegre, BR) Myelin oligodendrocyte glycoprotein antibodies predict a favourable outcome in neuromyelitis optica related disorders A. Cobo-Calvo (Lyon, FR) Myelin oligodendrocyte glycoprotein antibodies spectrum disorder: clinical features and prognostic factors in a cohort of 150 adult patients A. Cobo-Calvo (Lyon, FR) Prognostic factor for therapeutic response of attacks in anti-AQP4, anti-MOG seropositive and NMO seronegative patients N. Collongues (Strasbourg, FR) Page 20 / 108
- 21. Scientific Programme Complement activationis associated with microscopic pathology in the placentas of women with NMO R. Bove (San Francisco, US) Neuromyelitis optica spectrum disorders: 20 year single centre observational data with treatment analysis D.B. Bichuetti (Sao Paulo, BR) Anti-MOG antibodies induce complement mediated demyelination in isolated optic neuritis and myelitis C. Tortorella (Bari, IT) Ethnic differences in clinical manifestation and outcome of neuromyelitis optica spectrum disorder S.-H. Kim (Goyang, KR) Clinical, MRI and laboratory features of myelin oligodendrocyte glycoprotein (MOG)-antibody-associated neurologic disease: a study of 259 cases K. Kaneko (Sendai, JP) NMOSD relapses: an analysis of 328 episodes in 75 cases S.A. Broadley (Griffith University, AU) Multiple sclerosis AHI1 genetic risk promotes IFNg+ CD4+ T cells W. Elyaman (New York, US) Double inversion recovery MRI in the evaluation of the anterior visual pathway in patients with multiple sclerosis and neuromyelitis optica spectrum disorders E. Saji (Niigata, JP) What could be the clinical and MRI spectrum of anti-MOG associated disorders? V. Papp (Aarhus, DK) Disease course and immunotherapies responses in children with relapsing myelin oligodendrocyte glycoprotein antibodies (MOG-Ab)-associated disease Y. Hacohen (London, UK) Psychiatric morbidity develops after onset of pediatric multiple sclerosis: a Danish nationwide population-based study M.S. Boesen (Copenhagen, DK) Childhood multiple sclerosis is associated with reduced brain volumes at disease onset and brain growth failure F. Bartels (Berlin, DE) Executive dysfunction in paediatric-onset multiple sclerosis: deficits above and beyond slowed processing speed E. Barlow-Krelina (Toronto, CA) Clinical significance of anti-MOG antibodies in the evaluation of children with a first demyelinating episode: prospective Spanish national cohort T. Armangue (Barcelona, ES) Page 21 / 108
- 22. Scientific Programme Implications ofthe international paediatric multiple sclerosis study group consensus criteria for paediatric acute disseminated encephalomyelitis: a Danish nationwide population-based study M.S. Boesen (Copenhagen, DK) Continuous accelerometry as a measure of physical activity impairment in paediatric-onset multiple sclerosis subjects versus healthy controls J.N. Brenton (Charlottesville, US) Chitinase 3-like 1 and neurofilament light chain in the cerebrospinal fluid predict pediatric acquired CNS demyelinating disease M.S. Boesen (Copenhagen, DK) Evaluation of teriflunomide in children and adolescents with relapsing MS: TERIKIDS phase 3 study design, enrolment update, and baseline data T. Chitnis (Boston, US) Risk of secondary progressive multiple sclerosis: a longitudinal study T. Kalincik (Melbourne, AU) Characteristics of radiologically isolated syndrome (RIS) national French cohort C. Lebrun-Frenay (Nice, FR) Predicting MS disease progression remains a significant challenge: results from advanced statistical models of RCT placebo arms M. Copetti (S. Giovanni Rotondo, IT) Looking back: patients with “aggressive MS” (EDSS 6.0 at 10 years) in the Barcelona CIS cohort M. Tintoré (Barcelona, ES) Miscarriage induces reactivation of inflammation in relapsing-remitting multiple sclerosis D. Landi (Rome, IT) How common is truly benign MS? E.C. Tallantyre (Cardiff, UK) Long term outcomes of neuromyelitis optica: a systematic literature review Z. Nasr (Rochester, US) Description of patients with benign multiple sclerosis in the treatment era A. Bouley (Providence, US) Cognitive impairment can help to predict long-term disease course in benign multiple sclerosis patients: a 12 year follow-up study L. Razzolini (Florence, IT) Long-term treatment effect over disability progression in patients with relapsing multiple sclerosis B. Casanova Estruch (València, ES) Increased incidence of psychiatric disorders five years before diagnosis in multiple sclerosis R.A. Marrie (Winnipeg, CA) Page 22 / 108
- 23. Scientific Programme A largecohort study of physical and psychological impacts of smoking on PwMS via the UK MS Register J. Rodgers (Swansea, UK) A nationwide survey of the influence of month of birth on the risk of developing multiple sclerosis in Sweden and Iceland O. Eliasdottir (Gothenburg, SE) Observatoire Français de la Sclérose en Plaques (OFSEP): a powerful epidemiological tool R. Casey (Lyon, FR) The multiple sclerosis partners advancing technology and health solutions (MS PATHS) patient cohort E.M. Mowry (Baltimore, US) Social networks in persons at risk for developing multiple sclerosis P. De Jager (New York, US) Decline in PPMS diagnosis? The German view D. Ellenberger (Göttingen, DE) Concussion in adolescence and multiple sclerosis risk T. Olsson (Stockholm, SE) Clinical characteristics and treatment patterns of relapsing-remitting multiple sclerosis patients with high disease activity T. Spelman (Parkville, AU) Factors impacting mortality rates in a large French Canadian MS population: a review of 4 decades of data M.-C. Rousseau (Laval, CA) Understanding the timing of environmental exposures in the risk of MS B. Taylor (Hobart, AU) Determining the incidence of MS in a Swedish county - overcoming challenges in using registry data I. Boström (Linköping, SE) The prevalence of multiple sclerosis in the United States: a population-based healthcare database approach M.T. Wallin (Washington, US) A population-based assessment of “no evident disease activity” (NEDA) in multiple sclerosis N.E. Parks (Rochester, US) Use of the new oral disease-modifying therapies among the multiple sclerosis population in British Columbia, Canada over a five-year period (2011 - 2015) S. Setayeshgar (Vancouver, CA) Incidence and follow-up of acquired demyelinating syndromes in Dutch children - update of a nationwide and prospective study C.L. de Mol (Rotterdam, NL) Page 23 / 108
- 24. Scientific Programme The associationbetween disease activity and disability progression in patients with relapsing-remitting multiple sclerosis T. Spelman (Parkville, AU) Sex related differences of fetal maternal cross-talk modify phenotypic characteristics in women with multiple sclerosis P. Ragonese (Palermo, IT) Harnessing electronic medical records to advance research on multiple sclerosis V. Damotte (San Francisco, US) Comparison of case-mix in multiple sclerosis patients participating in randomized control trials, prospective observational studies, and multiple sclerosis partners advancing technology and health solutions (MS PATHS) F. Pellegrini (Zug, CH) Assisted reproductive technologies and relapse risk: a new case series and pooled analysis of existing studies R. Bove (San Francisco, US) Pregnancy incidence and therapy exposure in relapsing forms of MS: a 12-year retrospective multicentre analysis V.G. Jokubaitis (Parkville, AU) Alemtuzumab and pregnancy - a case series from the German MS and Pregnancy Registry - K. Hellwig (Bochum, DE) X chromosome wide association analysis identified a novel FRMPD4 locus that differentially effects MS risk by sex Y. Zhou (Hobart, AU) Infertility diagnosis and treatment in women with and without multiple sclerosis M.K. Houtchens (Brookline, US) Neonatal and delivery outcomes of babies to mothers with multiple sclerosis in Sweden K. Fink (Solna, SE) Unplanned pregnancy risk in a United States multiple sclerosis patient cohort A.L. Smith (Cleveland, US) Randomized controlled trial of two group programs in multiple sclerosis: 12-month (long- term) follow-up effects on fatigue and self-efficacy C. Hugos (Portland, US) Abdominal massage in the self-management of constipation in people with multiple sclerosis D. McClurg (Glasgow, UK) Perceived cognitive function in people with MS and its relationship to objective neuropsychological measurement with BICAMS N. McNicholas (Dublin, IE) Cognitive impairment and brain atrophy in multiple sclerosis: a 10-year follow-up study C.O. Jacobsen (Stavanger, NO) Page 24 / 108
- 25. Scientific Programme Factors thataffect computerized cognitive screening in people with MS: diurnal variation, location and practice effects D. Merlo (Melbourne, AU) Fatigue acceptance mediates cross-sectional and longitudinal associations between fatigue and sleep disturbance in multiple sclerosis A.J. Hughes (Baltimore, US) Self-reported sleep disturbance and cognitive function in MS: mediating effects of depressed mood and fatigue A.J. Hughes (Baltimore, US) Repeatability and validity of neurophysiological correlates of fatigue in people with multiple sclerosis P.M. Ellison (Newcastle Upon Tyne, UK) Depressive symptoms are associated with more negative functional outcomes than anxiety symptoms in persons with multiple sclerosis S.A. Morrow (London, CA) Neuroradiological characterization of multiple sclerosis patients with chronic pain D. Plantone (Rome, IT) Objective speech marker correlates with clinical scores in non-dysarthric MS G. Noffs (Melbourne, AU) Cognitive flexibility in multiple sclerosis patients may be dependent on information processing speed K. Zebenholzer (Vienna, AT) Association between self-reported upper limb, lower limb and cognitive functioning and functional performance in MS PATHS (multiple sclerosis partners advancing technology and health solutions) patients D. Miller (Cleveland, US) Factors associated with fatigue in the NARCOMS registry A. Salter (St. Louis, US) Factors driving social withdrawal across multiple sclerosis disease types R.J. Mills (Preston, UK) The Expanded Timed Get Up and Go is a more sensitive predictor of disability than the Timed 25-foot walk in people with multiple sclerosis B. Weinstock-Guttman (Buffalo, US) Intensive neurorehabilitation is associated with improved gait kinematic analysis in progressive multiple sclerosis C. Zanetta (Milano, IT) Can we trust self-reported walking distance when determining EDSS scores? - A part of the Danish MS Hospitals Rehabilitation Study A.G. Skjerbaek (Ry, Haslev, DK) Page 25 / 108
- 26. Scientific Programme Continuous wrist-wornaccelerometry captures change in average daily step count in people with multiple sclerosis over one year V.J. Block (San Francisco, US) Convergent validity of acceleration-derived parameters from iPad®-based walking and balance testing F. Bethoux (Cleveland, US) McArdle sign: a specific sign of multiple sclerosis B. Weinshenker (Rochester, US) How useful is the Hospital Anxiety and Depression Scale (HADS) in multiple sclerosis? V.P. Patel (Toronto, CA) Subclinical motor impairment assessed by an engineered glove correlates with MRI brain damage in radiologically isolated syndromes L. Bonzano (Genoa, IT) Reliability and validity of a new, sensor-based system for gait analysis in patients with multiple sclerosis F. Flachenecker (Erlangen, DE) Risk factors for cognitive impairment in multiple sclerosis as defined by the symbol digit modalities test: a retrospective analysis of the University of Calgary Multiple Sclerosis Clinic Database T. Brust (Calgary, CA) Fully automated detection, segmentation and quantification of mean cross-sectional area of the spinal cord F. Weiler (Bremen, DE) Decreased articulation rate in multiple sclerosis and its relationship to overall disease disability and cognitive function B. Benova (Prague, CZ) Phonatory dysfunction in multiple sclerosis B. Benova (Prague, CZ) Assessing upper extremity function and mobility with multiple clinical tests of the Assess MS system C.E. van Munster (Amsterdam, NL) Disability measures used in multiple sclerosis patients: correlations with MRI-derived global and microstructural damage D. Jakimovski (Buffalo, US) A Comparison of participant supplied EDSS scores and clinically submitted data via the UK MS Register R.M. Middleton (Swansea, UK) Information processing speed on the SDMT is predicted by saccadic eye movement dysfunction in patients with multiple sclerosis N. Pawlak (New York, US) Page 26 / 108
- 27. Scientific Programme Validation ofautomated cortical and subcortical multiple sclerosis lesion detection using a single 7T MP2RAGE scan M.J. Fartaria (Lausanne, CH) Validity of routine administration of Neuro-QoL in multiple sclerosis partners advancing technology and health solutions (MS PATHS) A. Boster (Columbus, US) Reliability of BICAMS (Arabic version) in Egyptian multiple sclerosis patients N. Kishk (Cairo, EG) Timed up and go and brain atrophy: a preliminary MRI study to assess functional mobility performance in multiple sclerosis L. Lorefice (Cagliari, IT) An investigation into the cognitive impact on physical disability in the community in people with multiple sclerosis (PwMS) M. Gudesblatt (Patchogue, US) Health-related quality of life attributes associated with work productivity loss and caregiver burden in multiple sclerosis C. Hategeka (Vancouver, CA) The burden of relapsing remitting multiple sclerosis on workers in the United States J. Nicholas (Columbus, US) Estimating MS-related work productivity loss and factors associated with labour force participation in a representative Australian sample of people with multiple sclerosis J. Chen (Hobart, AU) Multiple sclerosis relapses: budget impact analysis of oral high-dose corticosteroids D. Veillard (Rennes, FR) The changing landscape of disease modifying treatments: cost implications for healthcare systems A. Zarkali (Canterbury, UK) Pattern ERG related to ganglion cell loss and impaired visual function in patients multiple sclerosis H. Jiang (Miami, US) Mapping focal loss of the ganglion cell-inner plexiform layer in patients multiple sclerosis J. Wang (Miami, US) Outer retinal function and structure in multiple sclerosis J.V.M. Hanson (Zurich, CH) Temporal dynamics of structural and functional retinal damage in acute optic neuritis C.A. Wicki (Zurich, CH) A new, sensitive visual test for the diagnosis of acute optic neuritis G. Pihl-Jensen (Glostrup, DK) Self-monitoring visual function via a smartphone application N. Dubuisson (London, UK) Page 27 / 108
- 28. Scientific Programme The impactof depression and anxiety symptoms on information processing speed in MS and other immune-mediated inflammatory diseases C. Whitehouse (Halifax, CA) Movement disorders in demyelinating diseases C. Candeias da Silva (Sao Paulo, BR) A change in multiple sclerosis morbidity spectrum R. Hernández Clares (Murcia, ES) Self-reported smoking status associated with clinical disease worsening in CombiRx S.S. Cofield (Birmingham, US) Neuropsychological impairment in newly diagnosed early multiple sclerosis: clinical and neuropsychological characterization of a German cohort of 1124 patients A. Salmen (Bochum, DE) Altered grey matter networks in young patients with MS at genetic risk for Alzheimer's disease G. Gonzalez-Escamilla (Mainz, DE) Prevalence of restless legs syndrome/Willis-Ekbom disease in multiple sclerosis: a case- control study in Argentina E.G. Carnero Contentti (Buenos Aires, AR) Prevalence of sleep apnea in multiple sclerosis patients meeting clinical eligibility criteria for the Sleep Apnea in Multiple Sclerosis Positive Airway Pressure (SAMSPAP) trial S. Khadadah (Montreal, CA) Excess of neurological and psychiatric comorbidity in multiple sclerosis patients as compared to the general population in Catalonia, Spain M.-A. Passarell (Barcelona, ES) Blockade of MCAM on TH17 cells impedes their CNS infiltration over the choroid plexus J. Breuer (Münster, DE) Paraneoplastic neuromyelitis optica: an update on a single center cohort with cases of histological validation R. Carruthers (Vancouver, CA) Inflammation effectively eliminates JC virus during progressive multifocal leukoencephalopathy L. Stork (Göttingen, DE) Alterations of minicolumnar cytoarchitecture and axonal loss in multiple sclerosis cortex M. Vercellino (Torino, IT) The impact of high level of perivenular inflammation on active white matter lesions and disease progression in multiple sclerosis R. Magliozzi (Verona, IT) Neuromyelitis optica: distinct staining patterns of sera containing AQP4- and MOG- antibodies in the murine visual system F. Graz (Bochum, DE) Page 28 / 108
- 29. Scientific Programme Focal corticalastrocytopathy lesions with demyelination and inflammatory cell infiltrates in neuromyelitis optica spectrum disorder: a neuropathological study of eleven autopsied cases S. Hayashida (Fukuoka, JP) In vivo modeling of the nascent multiple sclerosis lesion: epsilon toxin induced mechanisms of blood brain barrier permeability J.R. Linden (New York, US) Focal overexpression of FGF9 in rat cortex induces de- and dysmyelination C. Wrzos (Goettingen, DE) Neutrophils mediate blood-brain barrier disruption in a rat model of neuromyelitis optica A. Winkler (Göttingen, DE) Critical role of GM-CSF, not IL-17, in relapsing experimental auto-immune encephalomyelitis L. D'Auria (Chicago, US) Subtle biochemical myelin pathology triggers secondary inflammatory demyelination in mouse brain A.V. Caprariello (Calgary, CA) Visual evoked potentials reflect optic nerve demyelination in EAE S. Marenna (Milan, IT) Amelioration of secondary progressive experimental autoimmune encephalomyelitis by restoring mitochondrial energy production in a GOT2-dependent manner M. Kinoshita (Osaka, JP) Immunomodulatory therapy in genetic mouse models of progressive multiple sclerosis J. Groh (Wuerzburg, DE) Transcriptomic analysis of disease reversal in EAE: comparison of laquinimod and FTY-720 J. Kaye (Netanya, IL) Potential beneficial effect of neuroinflammation on experimental stroke K. Guse (Bern, CH) Optical coherence tomography identifies structural retinal damage in experimental autoimmune encephalomyelitis P. Manogaran (Zurich, CH) Diffusion tensor imaging of the afferent visual pathway as an in vivo tool to assess neurodegeneration in experimental autoimmune encephalomyelitis C. Egger (Zurich, CH) MicroRNA-146a deficiency protects against cuprizone-induced demyelination Z. Illes (Odense, DK) Investigating blood-brain barrier integrity, immune cell infiltration and disease-related gender differences in a spontaneous transgenic mouse model for multiple sclerosis C. Lachance (Montreal, CA) Page 29 / 108
- 30. Scientific Programme IL-15 enhancespro inflammatory T cell responses in multiple sclerosis and experimental autoimmune encephalomyelitis C. Laurent (Montreal, CA) Preferential axonal accumulation of mitochondria during cuprizone-induced demyelination S. Schmutz (Munich, DE) Development of an in vitro myelination assay using mouse oligodendrocytes and a 3D scaffold of engineered nanofibers Y. Yang (Cleveland, US) Effect of ozanimod (RPC1063) on action potential parameters in adult human Purkinje fibres N. Abi-Gerges (San Diego, US) Differential effects of primary and secondary progressive MS cerebrospinal fluid on motor function and spinal cord pathology J.K. Wong (New York, US) NINJ2 as a novel protein involved in response to Interferon-β in multiple sclerosis S. Peroni (Milan, IT) An alternatively spliced isoform of HLA-DRA may be implicated in multiple sclerosis V. Damotte (San Francisco, US) Association of smoking but not HLA-DRB1*15:01, APOE, or body mass index with brain atrophy in early multiple sclerosis F. Luessi (Mainz, DE) A whole-genome sequencing study associates GRAMD1B with multiple sclerosis risk and disease activity F. Martinelli Boneschi (Milan, IT) Genotype is predicting multiple sclerosis lesion activity in autopsy cohort of the Netherlands Brain Bank N.L. Fransen (Amsterdam, NL) Investigating the role of the major histocompatibility complex on multiple sclerosis in an admixed Hispanic population A. Beecham (Coral Gables, US) A genetic risk variant for multiple sclerosis modulates the processing of CD58 mRNA and microRNA-548ac from the same transcript N. Boxberger (Rostock, DE) Expression profile of long non-coding RNAs (lncRNAs) in serum of patients with progressive multiple sclerosis V. Nociti (Rome, IT) An integrated candidate gene study of response to fingolimod in relapsing remitting multiple sclerosis patients F. Esposito (Milan, IT) Understanding progression in multiple sclerosis through transcriptomics and DNA methylation in CD4+ and CD8+ T cells S. Fernandes (Solna, SE) Page 30 / 108
- 31. Scientific Programme DICAM: anew player in multiple sclerosis pathogenesis C. Grasmuck (Montreal, CA) Non-canonical autophagy drives CD4+ T cell reactivation during autoimmune CNS inflammation C.W. Keller (Zurich, CH) The TH17-associated cytokine IL-26 enhances BBB integrity: implications for MS E. Peelen (Montreal, CA) CNS-transmigration of distinct B-cell subsets through the choroid plexus in patients with multiple sclerosis J. Haas (Heidelberg, DE) Gene-expression analysis of blood memory CD8+T cells at the single-cell level reveals a specific pattern of clonally expanded cells in multiple sclerosis patients E. Dugast (Nantes, FR) Microglia engulf invading living Th17 cells during neuroinflammation B. Wasser (Mainz, DE) Persistent clonally related CSF B cells in multiple sclerosis: a longitudinal immune repertoire study A.L. Greenfield (San Francisco, US) The nuclear receptor Nur77 restricts T cell responses and limits central nervous system autoimmunity L. Klotz (Münster, DE) Anti-MOG antibodies from NMO-SD patients facilitate low dose antigen recognition promoting activation of peripheral auto-reactive T cells S. Kinzel (Göttingen, DE) Progressive multiple sclerosis: selective involvement of the CD30/CD153 signalling pathway in innate immunity R. Carruthers (Vancouver, CA) Metabolic control of macrophage-mediated myelin phagocytosis: implications for multiple sclerosis Y.H. Lin (Montreal, CA) Activation of the aryl hydrocarbon receptor in dendritic cells is sufficient for the UV-B- induced amelioration of experimental autoimmune encephalomyelitis N. Mykicki (Münster, DE) Fingolimod-induced changes in the peripheral immune repertoire and their potential as biomarkers of treatment response in multiple sclerosis M. Ghadiri (Montreal, CA) Multiple sclerosis risk variants alter expression of co-stimulatory genes in B cells I. Smets (Leuven, BE) Insulin and leptin impair regulatory T cell function in obese multiple sclerosis patients J. Correale (Buenos Aires, AR) Page 31 / 108
- 32. Scientific Programme Histone deacetylaseSIRT1 mediates C5b-9-induced cell cycle in oligodendrocytes A. Tatomir (Baltimore, US) CD70 expression defines a subset of pro-inflammatory and pathogenic T cells that are implicated in multiple sclerosis T. Dhaeze (Montréal, CA) Amplified STAT phosphorylation signaling in peripheral blood mononuclear cells from MS patients in response to interferon alpha E. Canto (San Francisco, US) Role of intestinal IgA-producing cells at regulating neuroinflammation in EAE O. Rojas (Toronto, CA) Single cell transcriptomics identifies multiple sclerosis-specific expression profiles of cerebrospinal fluid cells G. Meyer zu Hörste (Münster, DE) Novel anti-neuronal antibodies in multiple sclerosis J.D.E. Parratt (Sydney, AU) Concerted T cell response in experimental autoimmune encephalomyelitis and multiple sclerosis N. Saligrama (Stanford, US) A distinct repertoire of the γδ T cell population is associated with disease severity of multiple sclerosis K. Shinoda (Fukuoka, JP) Inflammatory mediators regulate ARNT2 expression in CNS and peripheral immune populations and influence their pathogenic or protective properties in MS and in models of inflammatory neurodegeneration J. Quandt (Vancouver, CA) Cytotoxic CD4+CD28null T cell expansions are associated with worse disease progression in patients with relapsing remitting multiple sclerosis L.M. Peeters (Diepenbeek, BE) Oxysterols impair IL-10 secretion and induces cholesterol accumulation in regulatory TR1 cells via LXR signalling to favour autoimmunity C. Pot (Lausanne, CH) PARP-1 deregulation in MS M. Meira (Basel, CH) Protein kinase CK2 controls CD4+ T-cell differentiation and is critical for pathogenicity in autoimmune neuroinflammation E. Benveniste (Birmingham, US) The lysosomal K+ channel KCNK6 correlates with upregulated T cell autophagy in MS patients F. Steffen (Mainz, DE) Intrathecal oligoclonal bands synthesis: is it always a prognostic factor? J. Frau (Cagliari, IT) Page 32 / 108
- 33. Scientific Programme Gut-brain axis:deciphering the role of mucosal and systemic IgA in gut dysbiosis associated with multiple sclerosis A.-K. Pröbstel (San Francisco, US) A bidirectional association between the gut microbiota and CNS disease in a progressive bisphasic murine model of multiple sclerosis L. Kasper (Hanover, US) CD4+ T cells from multiple sclerosis patients acquire regulatory characteristics following exposure to a gut commensal-derived antigen L. Kasper (Hanover, US) Vitamin D levels and MS features in progressive multiple sclerosis D. Ontaneda (Cleveland, US) Impact of smoking on treatment response in multiple sclerosis patients receiving disease modifying therapies J. Sequeira (Barcelona, ES) Latent γHV-68 infection facilitates MS-like symptoms through memory B cells in EAE A.C. Márquez (Vancouver, CA) Synergistic effects of combined sodium chloride and saturated long chain fatty acid challenge on differentiation of Th17 cells in neuroinflammation A. Hammer (Erlangen, DE) Fresh fish consumption is associated with a lower risk of multiple sclerosis independent of serum 25OHD levels A. Langer Gould (Pasadena, US) Short-term exposure to ambient air pollution and occurrence of multiple sclerosis relapses M. Jeanjean (Rennes, FR) Different environmental stimuli may activate common biological processes potentially involved in multiple sclerosis R. Mechelli (Rome, IT) Post-vaccination autoimmune CNS demyelination in a family with MOG antibodies - genes or environment? A.-K. Pröbstel (Basel, CH) Salt-sensitive alterations in gut microbiota impact Th17 cells and neuroinflammation S. Jörg (Erlangen, DE) Comparison of humoral immunity against acid-fast bacilli lipophilic antigens in patients with Japanese MS and NMOSD K. Yokoyama (Tokyo, JP) Smoking is associated with increased relapse rate in natalizumab-treated MS E.R. Petersen (Copenhagen, DK) Vaccines increase the risk of relapses in neuromyelitis optica spectrum disorder among untreated patients M.A. Mealy (Baltimore, US) Page 33 / 108
- 34. Scientific Programme Relevance ofthe microbiota during the autoimmune phase in a viral model of multiple sclerosis L. Mestre (Madrid, ES) Smoking on disability accumulation in neuromyelitis optica and multiple sclerosis S. Messina (Oxford, UK) Rapid and efficient generation of human oligodendrocytes from induced pluripotent stem cells to model demyelinating diseases L. Starost (Münster, DE) Interleukin 17 affects hippocampal plasticity and cognition in multiple sclerosis M. Di Filippo (Perugia, IT) Astrocytic Junctional Adhesion Molecule-A promotes CNS inflammatory lesion pathogenesis C. Chapouly (New York, US) Proteomic analysis of CNS-derived microvescicles in the cerebrospinal fluid of MS M. Puthenparampil (Padua, IT) MS as a transmissible protein misfolding disorder S. Tsutsui (Calgary, CA) CD320-vitamin B12 links to MS thru S1P1 signaling in activated astrocytes J. Chun (La Jolla, US) Demyelination controls epigenetic changes in multiple sclerosis hippocampus R. Dutta (Cleveland, US) Longitudinal follow up of optical coherence tomography determined MS phenotypes with retinal and brain imaging N. Gonzalez Caldito (Baltimore, US) Serpina3n: potential biomarker in patients with progressive multiple sclerosis N. Fissolo (Barcelona, ES) VEGF in cerebrospinal fluid from patients with RRMS, PPMS and ALS R. Dersch (Freiburg, DE) Leptomeningeal contrast enhancement in multiple sclerosis is associated with grey matter atrophy and higher disability G. Makshakov (Saint-Petersburg, RU) Human stem cell-based screen for small molecules that promote oligodendrocyte differentiation, myelination, and neuronal survival D.J. Zack (Baltimore, US) Reconstruction of the pan-glial network during induced pluripotent stem cell-derived remyelination process S. Mozafari (Paris, FR) Nodes of Ranvier reclustering can precede remyelination: a role in repair? M. Thetiot (Paris, FR) Page 34 / 108
- 35. Scientific Programme Relationships betweenreorganization of functional brain network topology and cognition in clinically isolated syndrome: a 1 year Resting-state fMRI longitudinal study I. Koubiyr (Bordeaux, FR) The severity of functional and structural brain pathology reflects information processing speed deficits in multiple sclerosis K.A. Meijer (Amsterdam, NL) Cortical lesions and their correlates in multiple sclerosis: findings from a large cohort at 7T C.A. Treaba (Charlestown, US) Neuroinflammatory component of cerebellar pathology in multiple sclerosis by 11C-PBR28 MR-PET V. Barletta (Boston, US) Preferential spinal cord volume loss in primary progressive multiple sclerosis C. Tsagkas (Basel, CH) Dynamic functional network connectivity in CIS patients: a longitudinal study M. Hidalgo de la Cruz (Milan, IT) Impact of removing facial features from MR images of MS patients on automatic lesion and atrophy metrics A. de Sitter (Amsterdam, NL) Impact of deep grey matter volume loss on neurological impairment in patients with multiple sclerosis: a 6-year follow-up study with annual MRI S. Magon (Basel, CH) Whole brain magnetic resonance fingerprinting in multiple sclerosis S. Llufriu (Barcelona, ES) Longitudinal structural network reorganisation in early relapsing-remitting multiple sclerosis V. Fleischer (Mainz, DE) Multiple sclerosis patients who improve in their disability over time develop less brain atrophy compared to those who remain stable or progress E. Ghione (Buffalo, US) Predicting clinical progression in multiple sclerosis six and twelve years after onset I. Dekker (Amsterdam, NL) Improved visualization of cortical lesions in multiple sclerosis using MP2RAGE at 7T E.S. Beck (Bethesda, US) Lesions with hyperintense rim on quantitative susceptibility mapping demonstrate more inflammation on PET-PK11195 U. Kaunzner (New York, US) Pattern recognition for neuroimaging toolbox PRoNTo: a pilot study in predicting clinically isolated syndrome conversion D. Pareto (Barcelona, ES) Page 35 / 108
- 36. Scientific Programme Normative ratesof healthy age-related brain volume changes as assessed by SIENA on a large MRI dataset M. Battaglini (Siena, IT) Contrast enhanced susceptibility-weighted imaging of acute and chronic MS lesions A. Gass (Mannheim, DE) Within patient fluctuation of brain volume estimates from short-term repeated MRI measurements using SIENA/FSL R. Opfer (Hamburg, DE) Quantitative MRI texture analysis of enhancing and non-enhancing T1-hypointense lesions without application of contrast agent in multiple sclerosis S.M. Nabavi (Tehran, IR) Age-dependent cut-off for pathological brain volume loss measured with SIENA/FSL R. Opfer (Hamburg, DE) Associations between low conscientiousness and cognitive impairment in MS may be due to shared pathophysiology: structural network disruption of frontal cortex regions T. Fuchs (Buffalo, US) Altered subcortical sensorimotor integration in multiple sclerosis: a combined neurophysiological and MRI study C. Giannì (Rome, IT) Dynamic volumetric changes of hippocampal subfields in CIS patients: a 2-year MRI study L. Cacciaguerra (Milan, IT) Leptomeningeal enhancement on Gadolinium-enhanced 3D-FLAIR MRI in MS vs. non-MS patients: demographic characteristics, and relationship to disease modifying therapy and white matter disease activity D.S. Titelbaum (Brockton, US) Defining a minimal meaningful lesion size in multiple sclerosis S. Grahl (Munich, DE) Column-specific demyelination in spinal cord normal appearing white matter occurring in multiple sclerosis: a preliminary study using inhomogeneous magnetization transfer and diffusion tensor imaging H. Rasoanandrianina (Marseille, FR) MRI myelin water fraction provides evidence of long-term neuro-recovery in alemtuzumab treated multiple sclerosis patients I.M. Vavasour (Vancouver, CA) Lesion-based disruption of connections between the amygdala and surrounding ipsilateral structures may be protective against fatigue in multiple sclerosis T. Fuchs (Buffalo, US) Occurrence of diffusely abnormal white matter in individuals with clinically isolated syndromes suggestive of multiple sclerosis C. Laule (Vancouver, CA) Page 36 / 108
- 37. Scientific Programme Identification ofnew cortical lesions on longitudinal 7-Tesla MP2RAGE subtraction MRI in multiple sclerosis D. Harrison (Baltimore, US) Application of Neurite Orientation Dispersion and Density Imaging (NODDI) in clinically isolated syndrome (CIS) S. Collorone (London, UK) The impact of CNS inflammation on the GABAergic system: a multi-ligand PET study utilizing [11C] flumazenil and [11C] PK11195 Y. Kang (New York, US) Cortical mantle thinning in the visual cortex in pediatric-onset multiple sclerosis R. Datta (Philadelphia, US) Coordinate based random effect size meta-analysis shows regions of GM atrophy do not develop independently in MS and CIS C. Tench (Nottingham, UK) Longitudinal study to measure iron deposit in basal ganglia and related structures in patients with clinically isolated syndrome A. Rovira (Barcelona, ES) Evolution of venous narrowing in acute MS lesions A. Gass (Mannheim, DE) Normative data of MRI-derived thalamic volumes from a large dataset of healthy subjects G. Gentile (Siena, IT) Spinal cord ring enhancement patterns in neuromyelitis optica spectrum disorder: comparison with multiple sclerosis Y.-M. Lim (Seoul, KR) Myelin deterioration occurs in relapsing remitting multiple sclerosis patients meeting criteria for “no evidence of disease activity” A. Harel (New York, US) Resting state fMRI and graph theory for the automatic classification of relapsing remitting multiple sclerosis with different disease duration G. Castellazzi (Pavia, IT) 3T FLAIR* MRI improve the differentiation between multiple sclerosis and CNS vasculitis white matter lesions P. Maggi (Bruxelles, BE) Mapping neuroeconomic decisions in multiple sclerosis: a connectivity approach S. Llufriu (Barcelona, ES) Probing myelin and axonal integrity in multiple sclerosis brains G. Franco (Nashville, US) Comparative study of brain atrophy measures in CIS and MS patients: preliminary results of a cross-sectional analysis S. Cappelle (Barcelona, ES) Page 37 / 108
- 38. Scientific Programme Altered cerebellarfunctional connectivity is associated to clinical disability in multiple sclerosis S. Tommasin (Rome, IT) Independent component analysis of cerebral blood flow reveals MS-specific spatial patterns associated with clinical disability N. Bergsland (Buffalo, US) Microstructural alterations precede subcortical deep grey matter volume loss in patients with clinically isolated syndrome I. Koubiyr (Bordeaux, FR) Characterization of spinal cord pathology and its correlates at ultra-high field MRI R. Ouellette (Charlestown, US) Distinct associations of cross-sectional spinal cord areas with clinical disability in Japanese patients with multiple sclerosis and neuromyelitis optica spectrum disorder with aquaporin-4-IgG Y. Nakamura (Fukuoka, JP) Regional patterns of brain atrophy development in pediatric and adult multiple sclerosis patients: a 3.5 year study E. De Meo (Milan, IT) Regional brain atrophy differences and relationship to disability in NMOSD and MS E. Russell (Vancouver, CA) Longitudinal characterization of MRI phenotypes based on cerebral lesions and atrophy in multiple sclerosis: a five year study C. Hemond (Boston, US) A semi-automatic method to segment multiple sclerosis lesions on FLAIR magnetic resonance images L. Storelli (Milan, IT) Trans-synaptic neurodegeneration 12 months following optic neuritis - a longitudinal OCT and DTI study J.B. McKee (Headington, UK) Characterization of the haemodynamic response function in multiple sclerosis A.A. Alahmadi (London, UK) Metabolic substrates of efficiency reduction in the frontoparietal network in multiple sclerosis E. Solana (Barcelona, ES) Reduced dynamism of functional connectivity is associated with cognitive impairment in MS patients: a dynamic functional connectivity study in a multi-center setting A. d'Ambrosio (Milan, IT) Do multiple sclerosis lesions affect automatic brain structure segmentation? X. Llado (Girona, ES) Page 38 / 108
- 39. Scientific Programme Presence offocal and diffuse cervical cord tissue damage in early relapsing-remitting MS: a magnetization transfer study A. Kerbrat (Rennes, FR) Accelerated thalamic atrophy occurs following acute optic neuritis E.S. Sotirchos (Baltimore, US) The relationship between network measures and magnetic resonance imaging metrics in multiple sclerosis T. Charalambous (London, UK) Automated detection of central vein sign in white matter lesions for the diagnosis of MS J.D. Dworkin (Philadelphia, US) Statistical separation of spatially confluent but temporally distinct white matter lesions J.D. Dworkin (Philadelphia, US) Shrinking of T2-hyperintense white matter lesions in early multiple sclerosis V. Biberacher (München, DE) Evidence for progressive neurodegeneration in the cervical cord of patients with early primary progressive MS during 3-year follow-up R. Cortese (London, UK) Cervical spinal cord volume and diffuse spinal cord abnormalities distinguish multiple sclerosis patients with different levels of disability already 5 years after disease onset M. Andelova (Prague, CZ) Structure and function of the corticospinal tract and motor cortex in multiple sclerosis J.Y. Garber (Sydney, AU) Individual profiles of microglial activation drive the progression of clinical disability in MS B. Bodini (Paris, FR) Phase 1 safety study of ferumoxytol, an ultrasmall superparamagnetic iron oxide nanoparticle, in multiple sclerosis and healthy volunteers at 7-tesla M.K. Schindler (Bethesda, US) Sources of variability in brain atrophy measurements in individual MS patients A. Tsang (Cambridge, US) Automated, modular MRI processing for multiple sclerosis using the BRAINMAP framework B.E. Dewey (Baltimore, US) Grey matter connectivity in clinically isolated syndromes D. Pareto (Barcelona, ES) Improving the accuracy of brain tissue loss assessment in patients with multiple sclerosis: a role for diffusion imaging? C. Wang (Sydney, AU) Investigating resting-state BOLD variability in early multiple sclerosis G. Bommarito (Genoa, IT) Page 39 / 108
- 40. Scientific Programme Validation offully automated machine-learning algorithm for T2 lesion segmentation from clinical MRI in multiple sclerosis J.J. Feng (Cleveland, US) Comparison between the 2010 McDonald and 2016 MAGNIMS MRI criteria for dissemination in space in patients with a clinically isolated syndrome. Does the recent recommendation regarding the current criteria improve diagnostic accuracy? R. Lamas Pérez (Sevilla, ES) Increased between-network functional connectivity as a compensatory mechanism to maintain walking ability in MS patients S. Ruggieri (Rome, IT) Larger maximal lifetime brain growth is associated with faster motor speed in early relapsing multiple sclerosis C. Riley (New York, US) Dark rims around white matter lesions using Gray-Matter Double-Inversion-Recovery MRI: A novel specific imaging marker for multiple sclerosis J.-M. Tillema (Rochester, US) Structural MRI correlates of hand motor performance in patients with multiple sclerosis C. Cordani (Milan, IT) Retinal inner nuclear layer volume: a potential new outcome measure for optic neuritis treatment trials in MS L.J. Balk (Amsterdam, NL) Visual evoked potentials are more sensitive than optical coherence tomography in clinically isolated syndrome L. Leocani (Milan, IT) Silent retinal atrophy in multiple sclerosis is mainly due to silent optic nerve lesions O. Outteryck (Lille, FR) Association of retinal layer architecture and the development of neuropsychological deficits in early multiple sclerosis C. Wetzlmair (Munich, DE) A multidisciplinary assessment through OCT and correlations to brain pathology and endothelial factors in multiple sclerosis R. Lanzillo (Naples, IT) Examining cross-sectional relationships of optical coherence tomography, cervical cord MRI and disability in secondary progressive MS F. De Angelis (London, UK) Retinal changes in aquaporin-4 antibody seropositive neuromyelitis optica spectrum disorders: a longitudinal study F.C. Oertel (Berlin, DE) Spectrum of stiff person syndrome expands with presence of retinal pathology T. Shoemaker (Baltimore, US) Page 40 / 108
- 41. Scientific Programme Retinal ganglioncell layer thickness predicts disease activity in clinically isolated syndrome H.G. Zimmermann (Berlin, DE) Optical coherence tomography as a marker of disease severity and disability in pediatric multiple sclerosis N.M. Shukla (Houston, US) An investigation into the relationship between Optical Coherence Tomography (OCT) and cognitive fatigue in people with multiple sclerosis M. Gudesblatt (Patchogue, US) Cognitive impairment as prognostic factor in pediatric and juvenile multiple sclerosis R. Lanzillo (Naples, IT) Neurophysiological measures of fatigue in multiple sclerosis S.S. Ayache (Créteil, FR) The triple stimulation technique: a potential surrogate marker for motor axonal loss in multiple sclerosis X. Giffroy (Esneux, BE) Fatigue in multiple sclerosis:Is it related to cytokines and hypothalamic-puituitary-adrenal axis? A. Akcali (Gaziantep, TR) Cognitive impairment in multiple sclerosis is associated with slowing of resting state oscillatory activity on magnetoencephalography E.M. Strijbis (Amsterdam, NL) Chronic 4-aminopyridine treatment enhances intracortical glutamatergic transmission in progressive multiple sclerosis S. Gelibter (Milan, IT) Are we underestimating the severity of cognitive dysfunction in MS? M. Weber (Cleveland, US) Gray matter atrophy and microstructural white matter abnormalities underlying cognitive impairment in benign MS M.A. Rocca (Milan, IT) Cognitive impairment in multiple sclerosis: the contribution of cognitive reserve and regional gray matter volumes A. Bisecco (Napoli, IT) Neuroticism is linked to smaller hippocampal volume and worse memory in early multiple sclerosis V.M. Leavitt (New York, US) Dissociable neural correlates of speed and memory in early multiple sclerosis: a latent variable approach J.F. Sumowski (New York, US) Evolution of cognitive function in MS and its relationship to physical disability and MRI metrics D. Pinter (Graz, AT) Page 41 / 108
- 42. Scientific Programme Basal gangliastructural and functional abnormalities in multiple sclerosis are related to cognitive impairment Á.J. Cruz-Gómez (Castellón de la Plana, ES) Cognitive status of patients with multiple sclerosis is associated to cognitive reserve better than conventional MRI measures A. Gallo (Naples, IT) Intensive neurorehabilitation is associated with improved fatigue and depression in patients with progressive MS M. Congiu (Milan, IT) Specific rehabilitation improves information processing speed and attention in MS: a randomized trial against non-specific training with semi-ecological evaluation D. Lamargue-Hamel (Bordeaux, FR) Problem solving in patients with multiple sclerosis - analysing information and optimising strategies under different conditions K. Zebenholzer (Vienna, AT) The symbol digit modalities test and the frontal systems behaviour scale: a one-year follow- up study L. Querol (Barcelona, ES) Neuropsychological and anatomical correlates of theory of mind in patients with multiple sclerosis M.A. Chalah (Créteil, FR) Evidence for flattened emotional experience in patients with clinically isolated syndrome and early multiple sclerosis F. Paul (Berlin, DE) Cerebrospinal fluid neurofilament light chain is a marker of disease activity in multiple sclerosis E. Poletto (Verona, IT) Autoantibodies to neurofilament light protein as a potential biomarker of treatment response and disease progression in multiple sclerosis F. Puentes (London, UK) Differential gene expression in stable and active MS patients treated with fingolimod H. Bach Søndergaard (Copenhagen, DK) Anticipation of long-term disability progression in PPMS using MRI: a 15-year longitudinal study M.A. Rocca (Milan, IT) Serum neurofilament light levels at the time of a clinically isolated syndrome are associated with long-term clinical and radiological outcome T. Plavina (Cambridge, US) High neurofilament light chain levels in CSF are associated with CDMS diagnosis in children and adults with CIS R.M. van der Vuurst de Vries (Rotterdam, NL) Page 42 / 108
- 43. Scientific Programme Serum glialfibrillary acidic protein correlates with disease severity and neuroaxonal demise in multiple sclerosis: a pilot study using Simoa technology A. Abdelhak (Ulm, DE) Relationship between different cerebrospinal fluid biomarkers in multiple sclerosis: meaning and use in clinical practice B. Casanova (València, ES) Lower baseline levels of vitamin D are associated with a higher risk of new lesion development in patients with relapsing multiple sclerosis G.J. Opiteck (San Diego, US) Neuroinflammation and neuroaxonal damage in multiple sclerosis: a cross-sectional cerebrospinal fluid-based proteomic study L. Gaetani (Perugia, IT) Neurofilament light chain in CSF and serum in relation to disease activity and brain volume loss during four years of follow-up in a cohort of patients with CIS and RRMS I. Håkansson (Linköping, SE) Serum neurofilament light chain correlates with disease activity and predicts clinical and MRI outcomes in MS C. Barro (Basel, CH) Neurofilament light chain in human blood is a predictor of disease worsening in relapsing- remitting multiple sclerosis J. Kuhle (Basel, CH) Intrathecal B-cell inflammation influences CSF macrophage activity and the degree of cortical pathology in multiple sclerosis R. Magliozzi (Verona, IT) MS treatment effects on plasma cytokine receptor levels S.K. Bedri (Stockholm, SE) Serum neurofilament light chain as a biomarker for acute and chronic neuronal damage in early relapsing-remitting multiple sclerosis N. Siller (Mainz, DE) Baseline cerebellar volume predicts subsequent clinical disability in multiple sclerosis: MRI findings from the CombiRx trial M. Petracca (New York, US) Serum exosomes expression of myelin proteins is a biomarker of the multiple sclerosis activity M.P. Mycko (Lodz, PL) Intrathecal immunoglobulin synthesis as a predictive marker for disability progression in multiple sclerosis C. Gasperi (Munich, DE) Decreased cerebrospinal fluid antioxidative capacity is associated with disease severity and progression in early multiple sclerosis M.M. Voortman (Graz, AT) Page 43 / 108
- 44. Scientific Programme Change ofolfactory function as a marker of inflammatory activity and disability progression in MS G. Bsteh (Innsbruck, AT) Multiple sclerosis: structure-function correlations in the cerebral cortex H. Beadnall (Sydney, AU) Conduction velocity in demyelinated cerebral white matter: a structure-function correlation study in optic radiation C. Wang (Sydney, AU) Elucidation of pro-resolving lipid mediators in the cerebrospinal fluid: implications for multiple sclerosis pathogenesis G. Kooij (Amsterdam, NL) Single-cell mRNA marker analysis reveals appearance of t-SNE-defined new B-cell clusters in cynomolgus monkeys in response to ofatumumab treatment P. Couttet (Basel, CH) The neutrophil-to-lymphocyte ratio is associated with multiple sclerosis I.C. Hasselbalch (Copenhagen, DK) Delayed-release dimethyl fumarate demonstrated no evidence of difference in clinical outcomes vs fingolimod in patients with RRMS: a propensity-matched comparative effectiveness analysis of the German NeuroTransData registry S. Braune (Prien, DE) Sustained disease remission in multiple sclerosis after autologous haematopoietic stem cell transplantation. The Italian experience G. Boffa (Genova, IT) Naturally or induced immunization against CCL20 confer protection against experimental autoimmune encephalomyelitis A. Karni (Tel Aviv, IL) Ocrelizumab reduces disability progression independent of relapse activity in patients with relapsing multiple sclerosis L. Kappos (Basel, CH) Long-term lymphocyte counts in patients with relapsing-remitting multiple sclerosis (RRMS) treated with cladribine tablets 3.5 mg/kg: total lymphocytes, B and T cell subsets P. Soelberg Sorensen (Copenhagen, DK) Characterization of the efficacy of ORY-2001, a novel epigenetic drug for the treatment of multiple sclerosis, during the effector phase of the EAE model T. Maes (Cornella de Ll., ES) Subcutaneous low dose ofatumumab in cynomolgus monkeys induced changes in lymphocyte subsets and reversible cytoarchitectural changes in lymph nodes D. Theil (Basel, CH) Rescue therapy with propionic acid reverts the pro-inflammatory effects of a high-fat-diet in neuroinflammation J. Mäurer (Erlangen, DE) Page 44 / 108
- 45. Scientific Programme Ocrelizumab doesnot modulate peripheral T cell functionality or prevalence in a small subset of relapsing MS patients enrolled in OPERA I, a phase III double-blind double-dummy interferon beta-1a-controlled study H.-C. von Buedingen (Basel, CH) Dimethyl fumarate reduces the frequency of antigen-experienced B cells in patients with multiple sclerosis R.H. Hansen (Copenhagen, DK) Efficacy of delayed-release dimethyl fumarate in newly diagnosed patients with relapsing- remitting multiple sclerosis: eight-year follow-up of an integrated analysis of DEFINE, CONFIRM, and ENDORSE R. Gold (Bochum, DE) Peginterferon beta-1a improves clinical and radiological disease outcomes in patients who are newly diagnosed with relapsing multiple sclerosis: subgroup analysis of ADVANCE S.D. Newsome (Baltimore, US) Comparative effectiveness and discontinuation of dimethyl fumarate and fingolimod in two large academic medical centers at 24-month follow-up C.M. Hersh (Las Vegas, US) Real life use of natalizumab and fingolimod - data from the nation-wide Austrian Multiple Sclerosis Treatment Registry M. Guger (Linz, AT) Dimethyl fumarate vs. fingolimod in multiple sclerosis: an independent, multi-centre, real world, quasi-randomized study L. Prosperini (Rome, IT) Rates of lymphopenia year-by-year in patients with relapsing multiple sclerosis treated and retreated with cladribine tablets 3.5mg/kg S. Cook (Newark, US) Effects of cladribine tablets on CD4+ T cell subsets in the ORACLE-MS study: results from an analysis of lymphocyte surface markers O. Stuve (Dallas, US) T-cell population changes and serious infection rates in the controlled periods of the pivotal phase III trials of ocrelizumab in multiple sclerosis P. Vermersch (Lille, FR) Two years real life safety, tolerability and efficacy of dimethyl fumarate in an Italian multicentre study G. Mallucci (Pavia, IT) Rituximab real life efficacy in MS: an observational multicentre study S. Malucchi (Orbassano, IT) Slowing of cortical grey matter atrophy with teriflunomide is associated with delayed conversion to clinically definite MS R. Zivadinov (Buffalo, US) Confirmed disability improvement in patients treated with fingolimod in phase 3 and extension trial programmes for up to 96 months B.A. Cree (San Francisco, US) Page 45 / 108
- 46. Scientific Programme Comparison ofrituximab and highly effective second line disease modifying therapies after breakthrough disease activity in relapsing-remitting multiple sclerosis J. Salzer (Umeå, SE) Relapse rates and disability in the modern treatment era of neuromyelitis optica: data from a specialist UK centre D.H. Whittam (Liverpool, UK) Design of a phase II dose range finding, efficacy and safety study of the Bruton's tyrosine kinase inhibitor evobrutinib (M2951) in relapsing multiple sclerosis patients X. Montalban (Barcelona, ES) Safety of ocrelizumab in multiple sclerosis: updated analysis in patients with relapsing and primary progressive multiple sclerosis S. Hauser (San Francisco, US) Effectiveness of fingolimod, dimethyl fumarate and teriflunomide in relapsing-remitting multiple sclerosis: a comparative longitudinal study T. Kalincik (Melbourne, AU) T cell mediated experimental CNS autoimmunity induced by PLP in SJL mice is modulated by Evobrutinib (M2951) a novel Bruton's tyrosine kinase inhibitor U. Boschert (Billerica, US) Real world efficacy and safety of teriflunomide in patients with relapsing-remitting multiple sclerosis C. Boz (Trabzon, TR) Comparative efficacy and discontinuation of dimethyl fumarate and fingolimod in relapsing- remitting multiple sclerosis in clinical practice at 24-month follow-up C.M. Hersh (Las Vegas, US) An observational study of alemtuzumab-treated relapsing MS patients at the UBC MS Clinic H.Y. Yong (Vancouver, CA) Safety, tolerability, and pharmacodynamics of intravenous and subcutaneous doses of the anti-CD52 antibody GLD52 in patients with progressive MS: a randomised, controlled, single ascending dose trial D.H. Margolin (Cambridge, US) Dimethyl fumarate therapy is associated with immune-deviation and anti-inflammatory cytokine profiles in B and T cells in patients with multiple sclerosis E. Najjar (Haifa, IL) Changing disease modifying therapy switching dynamics for relapsing-remitting multiple sclerosis patients C. Wakeford (Cambridge, US) Evaluation of the long-term treatment effect of teriflunomide on cognitive outcomes and association with brain volume change: data from TEMSO and its extension study T. Sprenger (Basel, CH) Incidence rates of malignancies in patients with multiple sclerosis in clinical trials and epidemiological studies S. Hauser (San Francisco, US) Page 46 / 108
- 47. Scientific Programme Subgroup analysesof annualised relapse rates in patients with relapsing multiple sclerosis who received ocrelizumab or interferon beta-1a in the Phase III OPERA I and OPERA II studies C. Papeix (Paris, FR) Subgroup analyses of no evidence of disease activity in patients with relapsing multiple sclerosis who received ocrelizumab or interferon beta-1a in the Phase III OPERA I and OPERA II studies B. Turner (London, UK) Efficacy and safety of alemtuzumab versus fingolimod in RRMS patients after switch from natalizumab: a retrospective analysis S. Pfeuffer (Münster, DE) Cladribine tablets produce selective and discontinuous reduction of B and T lymphocytes and natural killer cells in patients with early and relapsing multiple sclerosis (ORACLE-MS, CLARITY and CLARITY Extension) O. Stuve (Dallas, US) A central role of B cells in MS control and causing autoimmunity after alemtuzumab D. Baker (London, UK) Monomethyl fumarate treatment impairs maturation of human myeloid dendritic cells and their ability to activate T cells M.A. Mazzola (Boston, US) Effect of ocrelizumab on B and T cell immune repertoires in patients with relapsing multiple sclerosis S. Laurent (San Francisco, US) The immune receptor expression pattern in peripheral-blood associated with JCV seropositivity in patients with multiple sclerosis is not affected by natalizumab A. Harrer (Salzburg, AT) Achievement of no evidence of disease activity with daclizumab beta versus intramuscular interferon beta-1a treatment across patient subgroups in DECIDE G. Giovannoni (London, UK) Immunosuppressive potential of human Wharton jelly mesenchymal stem cells in multiple sclerosis patients M. Swiderek-Matysiak (Lodz, PL) “Real-life” outcomes in a monocentric cohort of highly active multiple sclerosis patients treated with alemtuzumab L. Moiola (Milan, IT) Efficacy and safety of generic glatiramer acetate Timexon®: results of the 12-month extension of BCD-063-1 international double-blind randomized placebo-controlled clinical study of efficacy and safety of Timexon® in comparison with Copaxone® C. Tursunova (Saint-Petersburg, RU) Secukinumab in relapsing multiple sclerosis: experience in two cases with concomitant ankylosing spondylitis R. Robles Cedeño (Girona, ES) Page 47 / 108
- 48. Scientific Programme A cost-effectivenessanalysis using real-world data from the MSBase Registry: comparing natalizumab to fingolimod in patients with inadequate response to disease modifying therapies in relapsing-remitting multiple sclerosis in Scotland C. Acosta (Zug, CH) Teriflunomide: immunomodulatory effect on adaptive and innate immune cell subsets I. Gandoglia (Genoa, IT) Fingolimod induces BAFF and expands circulating transitional B cells without activating memory B cells and plasma cells in multiple sclerosis Y. Miyazaki (Sapporo, JP) Induction of disease remission with one cycle of alemtuzumab in relapsing remitting multiple sclerosis D.E. Klein (Middletown, US) Real-life experience with rituximab for the treatment of multiple sclerosis: report from two MS referral centres F.C. Pérez Miralles (Valencia, ES) Ozanimod does not impact cytotoxic T lymphocyte function in vitro demonstrating differentiation from fingolimod's activity on SET-PP2A D. Guimond (San Diego, US) In vitro data reveals potential novel mechanism of action of teriflunomide on CNS microglia and astrocytes A. Edling (Framingham, US) Teriflunomide use in European clinical practice in patients with relapsing forms of multiple sclerosis: an overview of regional real-world studies A. Chan (Bern, CH) EVOLVE-MS-2: A randomized, double-blind, phase 3 study of the gastrointestinal tolerability of ALKS 8700 versus dimethyl fumarate in relapsing-remitting multiple sclerosis R.T. Naismith (Saint Louis, US) Spanish registry of patients with multiple sclerosis treated with fingolimod (GILENYA Registry): safety and effectiveness after four years of registry J. Meca-Lallana (Murcia, ES) An update on pregnancy outcomes following ocrelizumab treatment in patients with multiple sclerosis and other autoimmune diseases S. Vukusic (Lyon, FR) Sustained modifications of subsets and capacities of cytokine production of B cells under interferon-β in multiple sclerosis T. Guerrier (Lille, FR) Rituximab in multiple sclerosis, frequency and clinical relevance of anti-rituximab drug antibodies A. Juto (Stockholm, SE) Once daily oral CHS-131, a novel PPARγ agonist, reduces both neuroinflammation and gray matter volume depletion in patients with relapsing-remitting multiple sclerosis: a randomized, placebo controlled double-blind, Phase 2b, multicenter study D. Weinstein (Redwood City, US) Page 48 / 108
- 49. Scientific Programme Investigating neuroprotectiveeffects of phenytoin on optic nerve magnetization transfer ratio (MTR) in acute optic neuritis A.T. Toosy (London, UK) Dimethyl fumarate (DMF) improves behavioral outcomes in a mouse model of progressive multiple sclerosis B. Bai (Cleveland, US) Patterns of regional gray matter and white matter atrophy in patients starting fingolimod or natalizumab: a 2-year tensor-based morphometry study P. Preziosa (Milan, IT) Blocking LINGO family promotes axon regeneration in the optic nerve crush model S. Mi (Cambridge, US) Predictors of an opicinumab treatment effect and identification of an efficacy subpopulation: a post hoc analysis of the SYNERGY study S. Sheikh (Cambridge, US) Keeping mitochondria on the road: teriflunomide maintains mitochondrial motility levels in axons challenged with oxidative stress E. Bros (Berlin, DE) Selective estrogen receptor modulators significantly enhance remyelination in an estrogen receptor-independent manner R. Bove (San Francisco, US) Phase I/II clinical trials testing multiple dosing of intrathecal mesenchymal stem cell- derived neural progenitors in patients with progressive multiple sclerosis S.A. Sadiq (New York, US) Fingolimod-mediated axonal protection during demyelination facilitates myelin increase during recovery B. Bai (Cleveland, US) Protection of mitochondrial function by dimethyl fumarate in an animal model of multiple sclerosis D. Schiza (London, UK) Alemtuzumab reduced MRI lesions and slowed brain volume loss in CARE-MS II patients switching from SC IFNB-1a: 5-year follow-up after alemtuzumab (TOPAZ study) D. Pelletier (Los Angeles, US) Predictors of relapses and disability progression after stopping disease-modifying therapies for multiple sclerosis I. Kister (New York, US) Alemtuzumab after Natalizumab SWitch in Evolving Rapidly Severe Multiple Sclerosis (ANSWERS MS) P.J. Gallagher (Glasgow, UK) Efficacy of a third course of alemtuzumab in patients with active relapsing-remitting multiple sclerosis who experienced disease activity after the initial two courses: pooled analysis of CARE-MS I and II A. Traboulsee (Vancouver, CA) Page 49 / 108
- 50. Scientific Programme Alemtuzumab decreasedMRI disease activity and slowed brain volume loss over 5 years after switching from SC IFNB-1a: follow-up of CARE-MS I (TOPAZ study) A. Rovira (Barcelona, ES) Effectiveness, health outcomes and cost-effectiveness of first generation disease-modifying drugs in relapsing-onset multiple sclerosis: Nova Scotia evidence 1979-2010 M.G. Brown (Halifax, CA) Sustained efficacy of daclizumab beta over up to 6 years of treatment and improvements in efficacy outcomes in relapsing MS patients who switched from intramuscular interferon beta-1a to daclizumab beta: interim results from EXTEND L. Kappos (Basel, CH) Disease modifying therapy improves disability outcomes in relapsing-remitting multiple sclerosis over 22 years T. Kalincik (Melbourne, AU) Clinical outcomes were better for patients who remained on natalizumab compared to those who switched to oral or injectable therapies after 2 years in the TYSABRI Observational Program H. Butzkueven (Melbourne, AU) Less frequent retreatment of rituximab is sufficient to maintain remission of neuromyelitis optica spectrum disorder after long-term treatment of rituximab H.J. Kim (Goyang, KR) A Swedish nationwide pharmaco-epidemiological study of the long-term safety and effectiveness of natalizumab (IMSE 1) S. Kågström (Stockholm, SE) Durable improvements in clinical outcomes with alemtuzumab in patients with active RRMS in the absence of continuous treatment: 7-year follow-up of CARE-MS II patients (TOPAZ study) B. Singer (St. Louis, US) Lateral ventricular volume as a proxy for brain volume loss in the assessment of no evidence of disease activity: results from a longitudinal, multicentre, real-world study R. Zivadinov (Buffalo, US) Big Multiple Sclerosis Data network: data sharing among five large MS registries P. Iaffaldano (Bari, IT) Serum neurofilament light chain levels are increased at the onset of PML in natalizumab treated MS patients G. Dalla Costa (Milan, IT) Improved precision of automatic brain volume measurements in patients with clinically isolated syndrome and multiple sclerosis using edema correction M. Warntjes (Linköping, SE) Patients with active RRMS experience durable reductions in MRI disease activity and slowing of brain volume loss with alemtuzumab: 7-year follow-up of CARE-MS II patients (TOPAZ study) D. Pelletier (Los Angeles, US) Page 50 / 108
- 51. Scientific Programme Effect ofteriflunomide on lymphocyte counts and infections over the long-term in the pooled TEMSO and TOWER extension studies G. Comi (Milan, IT) Lymphocyte decline and reconstitution after discontinuation in patients with severe, prolonged lymphopenia treated with delayed-release dimethyl fumarate R.J. Fox (Cleveland, US) Outcomes of discontinuing disease modifying therapy in patients with multiple sclerosis over age 60 L.H. Hua (Las Vegas, US) 5 years effectiveness of fingolimod in daily clinical practice: results of the non- interventional study PANGAEA C. Cornelissen (Nürnberg, DE) Characteristics of real-world disability improvement in relapsing-remitting multiple sclerosis patients treated with natalizumab in the TYSABRI® Observational Program H. Wiendl (Münster, DE) Comparative effectiveness of first line treatment strategies for multiple sclerosis M. Granqvist (Solna, SE) A Swedish nationwide pharmaco-epidemiological study of the long-term safety and effectiveness of fingolimod (IMSE 2) Å. Leandersson (Stockholm, SE) Pregnancy outcomes in patients with RRMS treated with alemtuzumab from the clinical development program D. Rog (Manchester, UK) Breakthrough disease under high-dose biotin treatment in progressive multiple sclerosis F. Granella (Parma, IT) The ultrasensitive JCV DNA Tri-Plex qPCR* detects JCV specific genomic sequences in T protein, distinguishes pathogenic from non-pathogenic variants using the NCCR (Non- Coding Control Region) and identifies the virion capsid protein gene (VP1) E.O. Major (Besthesda, US) Pregnancy planning and outcome in MS patients after Mitoxantrone therapy J. Frau (Cagliari, IT) Does IgG level impact JC virus index value? H. Zéphir (Lille, FR) Cardiac safety of ozanimod in a QT/QTc trial and a phase 2 trial in RMS G. Comi (Milan, IT) Patient initiation of fingolimod treatment: comparison of cardiac monitoring in-clinic and in the Gilenya@Home program J. Osborne (Grapevine, US) Point of no return: outcomes from acute relapses of neuromyelitis optica depend on severity M. Levy (Baltimore, US) Page 51 / 108
- 52. Scientific Programme First reportedcase of aquired hemophilia A (AHA) as secondary autoimmune disease following alemtuzumab treatment in multiple sclerosis L. Moiola (Milan, IT) Is the risk of progressive multifocal leukoencephalopathy the real reason for natalizumab discontinuation in patients with multiple sclerosis? J. Krämer (Münster, DE) Safety of alemtuzumab for multiple sclerosis after exposure to chemotherapeutic agents for patients with multiple sclerosis - experience of a single MS center D.A. Pimentel Maldonado (Worcester, US) How best to communicate clinical trial information about DMD risks and benefits to MS patients? G. Reen (Egham, UK) Alopecia totalis following alemtuzumab treatment in relapsing-remitting multiple sclerosis J. Zimmermann (Bonn, DE) Third Japanese case of fingolimod-associated PML in natalizumab-naïve MS: coincidence or alarm bell? J. Nakahara (Tokyo, JP) Ozanimod has an improved nonclinical safety profile relative to fingolimod S. Meier-Davis (San Diego, US) First dose effects of fingolimod: final results of an in-depth ECG and Holter study in 6,998 German RRMS patients V. Limmroth (Köln, DE) Pregnancy outcomes in patients with multiple sclerosis and exposure to branded glatiramer acetate during all three trimesters O. Neudorfer (Petach Tikva, IL) Characterizing the cytokine profile before and after antiCD20 infusions: c comparison of rituximab versus ocrelizumab E. Alvarez (Aurora, US) Evaluation of a protocol to improve DMD risk and benefit understanding in MS patients: a randomised crossover trial G. Reen (Egham, UK) An application of a novel statistical approach to predict patient-specific treatment responses to DMTs based on a continuous score F. Bovis (Genova, IT) Minimal or no evidence of disease activity: which target to prevent long-term disability in multiple sclerosis? L. Prosperini (Rome, IT) Disease activity as assessed by the MAGNIMS Score predicts long-term clinical disease activity free status and disability progression in patients treated with subcutaneous interferon beta-1a M.P. Sormani (Genoa, IT) Page 52 / 108
- 53. Scientific Programme Defining areasof cognitive impairment in relapsing-remitting multiple sclerosis (RRMS) - baseline analysis of a longitudinal multicenter study in 15 German practice centers M. Stumpfe (Berg, DE) Long-term disease outcomes in multiple sclerosis patients categorised by baseline brain volume and with no disease activity over 2 years M.H. Barnett (Sydney, AU) Comparison between central and whole brain atrophy in multiple sclerosis measured by structural image evaluation using normalization of atrophy (SIENA) T. Sinnecker (Basel, CH) Association of brain volume loss and NEDA outcomes in patients with relapsing multiple sclerosis in the OPERA I and OPERA II studies A. Traboulsee (Vancouver, CA) Permeability of the blood-brain barrier predicts no evidence of disease activity at two years after natalizumab or fingolimod treatment in relapsing-remitting multiple sclerosis S.P. Cramer (Glostrup, DK) Patient reported disease modifying therapy adherence in the clinic: a reliable metric? D.S. Conway (Cleveland, US) Overall response score: a novel disability endpoint that allows for the integrated assessment of improvement and worsening over time in patients with MS I. Chang (Cambridge, US) The effect of dimethyl fumarate treatment on hippocampal metabolite levels in RRMS using 1H-MR spectroscopy K.A. Ribbons (New Lambton, AU) Silent lesions on MRI - shifting goal post for treatment decisions in MS M. Min (Newcastle, AU) Consensus statement on the use of gadolinium for magnetic resonance imaging used in the diagnosis and follow-up of patients with multiple sclerosis A. Traboulsee (Vancouver, CA) A comparative-effectiveness analysis applying a 3 way propensity matching to real-world data from MSBase Registry in preparation for a cost effectiveness model: patients switching within firstline agents or to natalizumab or fingolimod in active RRMS T. Spelman (Parkville, AU) Efficacy of siponimod on disability progression in SPMS patients with and without on-study relapses L. Kappos (Basel, CH) Anti-inflammatory disease modifying treatment and disability progression in primary progressive multiple sclerosis J. Lorscheider (Melbourne, AU) Contribution of inflammation to disability accrual in primary progressive multiple sclerosis T. Kalincik (Melbourne, AU) Page 53 / 108
- 54. Scientific Programme Safety andclinical improvement in a phase I trial of autologous Epstein-Barr virus-specific T- cell therapy in patients with progressive multiple sclerosis M.P. Pender (Brisbane, AU) Effect of MD1003 (High-Dose Biotin) for the treatment of progressive MS: 36-month follow- up data A. Tourbah (Reims, FR) Effect of MD1003 (High-Dose Biotin) in spinal progressive multiple sclerosis (MS-SPI): subgroup analyses A. Tourbah (Reims, FR) A multicentre, randomized, double-blind, non-inferiority clinical trial to compare the clinical and radiological efficacy of 625 mg versus 1250 mg of oral methylprednisolone in patients with relapse of multiple sclerosis: the Oral-CORTEM trial C. Ramo-Tello (Badalona, ES) MS FIRST - utilising a longitudinal, prospective, comparative drug safety module for use in everyday MS clinical practice to evaluate and track incidence and characteristics of safety outcomes in MS patients on therapy over the long term J. Haartsen (Melbourne, AU) Effect of early switch to fingolimod from other oral therapies in patients with relapsing- remitting multiple sclerosis T. Ziemssen (Dresden, DE) The rapid efficacy of natalizumab vs fingolimod in patients with active relapsing-remitting multiple sclerosis: results from REVEAL, a randomised, head-to-head phase 4 study H. Butzkueven (Melbourne, AU) Probiotic VSL3 induces changes in the gut microbiome function and promotes an anti- inflammatory peripheral immune response in multiple sclerosis patients S. Tankou (Boston, US) Patient characteristics, safety, and preliminary results of a placebo controlled, phase 2a multicenter study of ublituximab (UTX), a novel glycoengineered anti-CD20 monoclonal antibody (mAb), in patients with relapsing forms of multiple sclerosis E.J. Fox (Round Rock, US) Variability in adverse event reporting and reasons for discontinuations with dimethyl fumarate: results from a generalized linear mixed model F. Pellegrini (Zug, CH) Overcoming therapeutic inertia in multiple sclerosis care: a pilot randomized trial evaluating an educational intervention G. Saposnik (Toronto, CA) Siponimod pharmacokinetics, safety and tolerability in combination with the CYP2C9/3A4 inducer, rifampin in healthy subjects A. Gardin (Basel, CH) No evidence of disease activity status among patients with relapsing-remitting multiple sclerosis on long-term natalizumab treatment: data from a real-world cohort in the Czech Republic D. Horakova (Prague, CZ) Page 54 / 108
- 55. Scientific Programme Preliminary resultsof phase 2 multicenter study of ublituximab (UTX), a novel glycoengineered anti-CD20 monoclonal antibody (mAb), in patients with relapsing forms of multiple sclerosis (RMS) demonstrates rapid Gd-enhancing lesions decrease M. Inglese (New York, US) Treatment of neuromyelitis optica spectrum disorders with methotrexate: experience of a specialist center in Brazil M.S. Pitombeira (Sao Paulo, BR) Pilot results of a web based patient decision aid for first-line treatment of relapsing- remitting multiple sclerosis patients E. Lapointe (Vancouver, CA) U.S. payers' views on expansion of patient access to disease-modifying therapies (DMTs) for multiple sclerosis D. Robertson (Tampa, US) The effect of fampridine treatment on cognition: two year prospective study S. Ozakbas (Izmir, TR) Efficacy of an internet-based program (MS Intakt) to promote physical activity after inpatient rehabilitation in persons with multiple sclerosis - a randomized controlled study P. Flachenecker (Bad Wildbad, DE) Aspirin improves exercise endurance in multiple sclerosis: pilot findings from a double-blind randomized placebo-controlled crossover trial V.M. Leavitt (New York, US) Relapse prevalence, symptoms and healthcare engagement: insights from patients with multiple sclerosis from the multiple sclerosis in America 2017 survey T. Nazareth (Hampton, US) Remotely supervised transcranial direct current stimulation (RS-tDCS) improves fatigue in multiple sclerosis L.E. Charvet (New York, US) Walking economy, as measured by decreased oxygen demand, is improved in multiple sclerosis patients responding to fampridine K.J. Riess (Edmonton, CA) A systematic review of everyday memory measures in multiple sclerosis R. das Nair (Nottingham, UK) MS relapse treatments and relapse resolution: retrospective study results from a US health plan T. Nazareth (Hampton, US) Fampridine effects on upper limbs motor function and quality of life A.N. Lagorio (Santiago de Compostela, ES) Mental processment velocity in patients on treatment with fampridine M. Puente Hernández (Santiago de Compostela, ES) Page 55 / 108
- 56. Scientific Programme Intrathecal baclofenis an effective treatment for ambulatory subjects with MS related spasticity Y. Sammaraiee (London, UK) Comparative effectiveness of natalizumab and fingolimod treatment on cognitive outcomes in relapsing multiple sclerosis patients P. Iaffaldano (Bari, IT) Comparing patient and healthcare professional perceptions on multiple sclerosis management and care - where do their priorities differ? Results from a qualitative survey P. Rieckmann (Bamberg, DE) Intensive social-cognitive program (Can Do Treatment) in patients with relapsing remitting multiple sclerosis and low disability: a randomized controlled trial P.J. Jongen (Groningen, NL) Octogenarians with MS: a study describing lifestyle factors of the oldest old living with multiple sclerosis M. Ploughman (St. John's, CA) Laughing matters: the role of humor on psychological well-being, health & quality of life in multiple sclerosis (MS) L. Strober (West Orange, US) Combined T25FW and MSWS12 response improves identification of persistent response to PR-Fampridine in people with MS R.A.L. Ewe (London, UK) Preliminary findings in persons with multiple sclerosis with cognitive impairment show improvement with computerized three-dimensional multiple object tracking training J.R. St.Onge (Regina, CA) High levels of alexithymia may contribute to the complex affective traits found in patients with multiple sclerosis Y.D. Fragoso (Santos, BR) Validation of MUSIQOL among Arabic-speaking MS patients treated with high dose INF-β 1a sc injection New Formulation M. Al Jumah (Riyadh, SA) Equivalence of the electronic versus paper-based short version of the MSQOL-54 (MSQOL-29) A. Solari (Milan, IT) Cladribine tablets treating multiple sclerosis orally (CLARITY): an independent analysis of the quality of life data D. Afolabi (London, UK) Coping strategies, health-related quality of life and life satisfaction among persons with multiple sclerosis M. Bassi (Milano, IT) Patient satisfaction and quality of life during treatment with fingolimod in multiple sclerosis: results from the 'DIAMOND' non-interventional, prospective, observational study in Greece E. Zafeiropoulou (Athens, GR) Page 56 / 108
- 57. Scientific Programme RebiQoL: Atelemedicine patient support program on health related quality of life and adherence in MS patients treated with Rebif A.-M. Landtblom (uppsala, SE) Physical activity impacts positively on depression and objective sleep in patients with MS D. Sadeghi Bahmani (Basel, CH) Profiles of patient-reported outcomes as predictors of treatment type in multiple sclerosis: a discriminant function analysis of disease modifying treatment L.D. Medina (Aurora, US) Social Media Session, Hall D 15:45 - 16:45 Burning Debate - Rumble in the jungle: B cells vs. T cells This burning debate will address the topical issue of MS being a T-cell mediated disease and that B-cells are less important. Votes will be cast via twitter using #burningdebate Chairs D. Wraith (Birmingham, UK) 15:45 - 15:50 Introduction D. Wraith (Birmingham, UK) 15:50 - 16:03 Against S. Hauser (San Francisco, US) 16:03 - 16:16 For D.A. Hafler (North Haven, US) 16:16 - 16:41 Discussion S. Hauser (San Francisco, US) D.A. Hafler (North Haven, US) 16:41 - 16:45 Summary Hot Topic Sessions, Hall A 17:00 - 17:45 Hot Topic 3: Controversy 1: RIS: should it be treated? Chairs O. Kantarci (Rochester, US) A. Siva (Istanbul, TR) 17:00 - 17:20 Radiologically isolated syndrome should be treated with disease- modifying therapy D.T. Okuda (Dallas, US) 17:20 - 17:40 Radiologically isolated syndrome: should it be treated? «No» C. Lebrun (Nice, FR) Page 57 / 108
- 58. Scientific Programme 17:40 -17:45 Summary O. Kantarci (Rochester, US) Hot Topic Sessions, Hall B 17:00 - 17:45 Hot Topic 4: New insight in neurobiology / how the active brain stimulates repair? Chairs A. Baron-Van Evercooren (Paris, FR) D. Fields (Bethesda, US) 17:00 - 17:15 Effect of in vivo neuronal activity on remyelination M.C. Angulo (Paris, FR) 17:15 - 17:30 How neuronal activation can impact myelination and function in vivo B. Emery (Portland, US) 17:30 - 17:45 Can brain stimulation influence repair in MS? L. Leocani (Milan, IT) Hot Topic Sessions, Hall C 17:00 - 17:45 Hot Topic 5: Cognition and cognitive remediation in MS Chairs B. Brochet (Bordeaux, FR) M.P. Amato (Florence, IT) 17:00 - 17:15 Brain connectivity and cognitive impairment in MS C. Louapre (Paris, FR) 17:15 - 17:30 Psychiatric disorders and their relationship (interplay) with cognitive impairment in MS A. Feinstein (Toronto, CA) 17:30 - 17:45 Therapeutic management of cognitive impairment in MS L. Krupp (Stony Brook, US) Hot Topic Sessions, Hall D 17:00 - 17:45 Hot Topic 6: Gut microbiota in multiple sclerosis Chairs H. Weiner (Boston, US) R. Du Pasquier (Lausanne, CH) 17:00 - 17:15 How microbiota shapes mucosal immunity and immunopathology: the case of multiple sclerosis H. Wekerle (Munich, DE) Page 58 / 108
- 59. Scientific Programme 17:15 -17:30 In the Garden of Good and Evil: the role of the gut microbiome in CNS demyelinating disease L. Kasper (Hanover, US) 17:30 - 17:45 The gut microbiota in multiple sclerosis H. Tremlett (Vancouver, CA) Satellite Symposia, Hall A 18:00 - 19:00 Satellite Symposium - Balancing benefits and risks of DMDs in MS Supported by Merck 18:00 - 18:05 Welcome D. Bates (Newcastle upon Tyne, UK) P. Vermersch (Lille, FR) 18:05 - 18:10 Introduction: current and emerging treatment in MS D. Bates (Newcastle upon Tyne, UK) 18:10 - 18:25 Innovative approach to balance benefits and risks in MS P. Vermersch (Lille, FR) 18:25 - 18:45 Treatment approaches in MS S. Schippling (Zurich, CH) 18:45 - 18:55 Safety and tolerability profile of approved and emerging DMDs T. Leist (Philadelphia, US) 18:55 - 19:00 Conclusion D. Bates (Newcastle upon Tyne, UK) P. Vermersch (Lille, FR) Satellite Symposia, Hall B 19:15 - 20:15 Satellite Symposium - Navigating choice. Mastering the multiple facets of MS management Supported by Biogen International 19:15 - 19:30 Individualising patient management. Does reducing uncertainty and quantifying risk aid effective decision making? L. Kappos (Basel, CH) 19:30 - 19:45 Monitoring cognition in MS. Should this be implemented in everyday MS patient management? G. Giovannoni (London, UK) 19:45 - 20:00 The immune system in MS. Can we manage it? F. Giuliani (Edmonton, CA) Page 59 / 108
- 60. Scientific Programme 20:00 -20:15 Biogen and BIG DATA. Finding a PATH towards personalised medicine? B.C. Kieseier (Zug, CH) Page 60 / 108
- 61. Scientific Programme Friday, 27October 2017 Satellite Symposia, Hall A 08:00 - 09:00 Satellite Symposium - Potential solutions to treatment burden in MS Supported by Merck 08:00 - 08:05 Welcome: Recap of risk benefit/profile from symposium 1 G. Comi (Milan, IT) 08:05 - 08:20 Clinical decision making in MS: choosing the right treatment for the right patient H. Butzkueven (Melbourne, AU) 08:20 - 08:35 Current challenges in the clinical management of MS A. Chan (Bern, CH) 08:35 - 08:50 The importance of simplicity and convenience in the management of patients with MS X. Montalban (Barcelona, ES) 08:50 - 09:00 Next-generation MS treatment & conclusion M.S. Freedman (Ottawa, CA) Free Communications, Hall A 09:15 - 10:15 Free Communications 1 Chairs R. Franklin (Cambridge, UK) B. Segal (Ann Arbor, US) 09:15 - 09:27 Identification of oligodendroglial secreted factors inducing nodal protein clustering in the central nervous system A.-L. Dubessy (Paris, FR) 09:27 - 09:39 Reduced microglial activation through the inhibition of colony- stimulating factor 1 receptor (CSF1R) to promote remyelination and neuroprotection J. Correale (Buenos Aires, AR) 09:39 - 09:51 Side effects of long-term rituximab treatment in NMOSD patients: hypogammaglobulinemia and impairment of specific humoral immunity A. Bertolotto (Orbassano, IT) 09:51 - 10:03 The potency of the interaction between smoking and HLA MS risk genes depends on number of HLA risk alleles L. Alfredsson (Stockholm, SE) Page 61 / 108
- 62. Scientific Programme 10:03 -10:15 Autoantibody profile (MOG-IgG-seropositive, AQP4-IgG-seropositive and seronegativity) as a visual outcome predictor after optic neuritis L.M. Ventura (São Paulo, BR) Free Communications, Hall B 09:15 - 10:15 Free Communications 2 Chairs F. Barkhof (Amsterdam, NL) S. Ludwin (Kingston, CA) 09:15 - 09:27 Detection and characterisation of slowly evolving lesions in multiple sclerosis using conventional brain MRI C. Elliott (Montreal, CA) 09:27 - 09:39 Lesion activity relates to clinical course and gender in the multiple sclerosis autopsy cohort of the Netherlands Brain Bank I. Huitinga (Amsterdam, NL) 09:39 - 09:51 The varying contribution of normal aging atrophy to MS brain volume measurements across adulthood C. Azevedo (Los Angeles, US) 09:51 - 10:03 Progression of regional grey matter atrophy in multiple sclerosis A. Eshaghi (London, UK) 10:03 - 10:15 Inhomogeneous magnetization transfer (ihMT) in normal-appearing tissue correlates with disability of multiple sclerosis patients S. Mchinda (Marseille, FR) Free Communications, Hall C 09:15 - 10:15 Free Communications 3 Chairs R. Gold (Bochum, DE) T. Kilpatrick (Melbourne, AU) 09:15 - 09:27 Biosensor measures in clinic and free-living settings correlate with multiple sclerosis disease severity T. Chitnis (Boston, US) 09:27 - 09:39 Effect of ocrelizumab vs that of interferon beta-1a on visual outcomes in patients with relapsing multiple sclerosis in the OPERA studies L. Balcer (New York, US) 09:39 - 09:51 Peripapillary retinal nerve fibre layer as measured by optical coherence tomography is a prognostic biomarker for disability progression in multiple sclerosis G. Bsteh (Innsbruck, AT) Page 62 / 108
- 63. Scientific Programme 09:51 -10:03 Effects of high frequency repetitive transcranial magnetic stimulation on gait and balance in patients with relapsing remitting multiple sclerosis H.S. Shehata (Cairo, EG) 10:03 - 10:15 Multiple sclerosis disease course prediction: a machine learning model based on patient reported and clinician assessed outcomes A. Tacchino (Genova, IT) Free Communications, Hall D 09:15 - 10:15 Free Communications 4 Chairs H.-P. Hartung (Duesseldorf, DE) E. Havrdová (Prague, CZ) 09:15 - 09:27 Patients with paediatric-onset multiple sclerosis are at higher risk of cognitive impairment in adulthood: an Italian collaborative study L. Ruano (Porto, PT) 09:27 - 09:39 Long-term multiple sclerosis prognosis as a consequence of treatment pattern changes: a recent update C. Cordioli (Montichiari, IT) 09:39 - 09:51 Relapses in patients with secondary progressive MS: a matter of disease duration or age? K. Ahrweiller (Rennes, FR) 09:51 - 10:03 Does 'benign' multiple sclerosis exist? A 30-year follow-up study of people presenting with clinically isolated syndrome K.K. Chung (London, UK) 10:03 - 10:15 Course of disease of initially benign multiple sclerosis patients: long- term follow-up results of physical disability and cognitive impairment A. Manouchehrinia (Stockholm, SE) Parallel Sessions, Hall A 10:45 - 12:15 Parallel Session 10: Safety issues in MS therapeutic management Chairs M.S. Freedman (Ottawa, CA) P.S. Sørensen (Copenhagen, DK) 10:45 - 11:05 Safety issues of MS therapeutics (excluding PML) M. Clanet (Toulouse, FR) 11:05 - 11:25 PML risk in MS therapeutics D.B. Clifford (St Louis, US) Page 63 / 108
- 64. Scientific Programme 11:25 -11:40 Preventable side effects of alemtuzumab N. Scolding (Bristol, UK) 11:40 - 11:52 Long-term exposure to natalizumab during pregnancy - a prospective case series from the German Multiple Sclerosis and Pregnancy Registry T. Kümpfel (Munich, DE) 11:52 - 12:04 Pregnancy outcomes in patients with MS treated with teriflunomide: clinical study and post-marketing data S. Vukusic (Lyon, FR) 12:04 - 12:16 Long-term safety of daclizumab beta in patients with relapsing MS in EXTEND: Interim results from treatment up to 6 years S. Cohan (Portland, US) Parallel Sessions, Hall B 10:45 - 12:15 Parallel Session 11: Genes and environment in MS Chairs J. Correale (Buenos Aires, AR) P. De Jager (New York, US) 10:45 - 11:05 Gene-environment interactions in MS P. Stridh (Stockholm, SE) 11:05 - 11:25 Viral infections as triggers of MS J. Lünemann (Zurich, CH) 11:25 - 11:37 Incidence of multiple sclerosis in Danish women has doubled over the last sixty with an only modest increase in men M. Magyari (Copenhagen, DK) 11:37 - 11:49 Whole-genome sequencing in primary progressive multiple sclerosis uncovers mutations in genes for inherited leukodystrophies and other MS phenocopies X. Jia (San Francisco, US) 11:49 - 12:01 Epstein-Barr virus, 25-hydroxyvitamin D and risk of multiple sclerosis among women in the Finnish Maternity Cohort K. Munger (Boston, US) 12:01 - 12:13 Promoting healthier lifestyle contributes to averting multiple sclerosis long-term societal and healthcare costs: results from the VoT project M. Pugliatti (Ferrara, IT) Page 64 / 108
- 65. Scientific Programme Parallel Sessions,Hall C 10:45 - 12:15 Parallel Session 12: Long term disability evolution: contributions from cohorts and clinical trials Chairs S. Dhib Jalbut (New Brunswick, US) L. Kappos (Basel, CH) 10:45 - 11:05 Disability progression in MS: insight from MS cohorts S. Vukusic (Lyon, FR) 11:05 - 11:25 Disability progression in MS: contribution from clinical trials B.A. Cree (San Francisco, US) 11:25 - 11:37 Risk of multiple sclerosis disability milestones decreased over the last decade: a nationwide population-based cohort study in Sweden O. Beiki (Stockholm, SE) 11:37 - 11:49 Impact of oral contraceptives and menopause on MS risk and prognosis: results from the Barcelona CIS cohort S. Otero-Romero (Barcelona, ES) 11:49 - 12:01 Longitudinal changes in quantitative spinal cord MRI in multiple sclerosis patients: preliminary results of a 5-year study J. Oh (Toronto, CA) 12:01 - 12:13 Beta-interferon and mortality in multiple sclerosis: a population-based international study E. Kingwell (Vancouver, CA) Satellite Symposia, Hall A 12:45 - 13:45 Satellite Symposium - The evolution of MS treatment: moving towards optimised treatments Supported by Celgene Chairs P. Vermersch (Lille, FR) 12:45 - 12:55 Welcome and introductions P. Vermersch (Lille, FR) 12:55 - 13:10 Exploring the underlying mechanism of disease A. Bar-Or (Philadelphia, US) 13:10 - 13:25 Unmet medical needs in the changing treatment landscape H.-P. Hartung (Duesseldorf, DE) 13:25 - 13:40 Evolution of treatment approaches and potential role of S1PR immunomodulators in the emerging landscape G. Comi (Milan, IT) 13:40 - 13:45 Close Page 65 / 108
- 66. Scientific Programme Satellite Symposia,Hall C 12:45 - 13:45 Satellite Symposium - Maintaining ability in the context of disability: can we do more for patients? Supported by Teva Chairs O. Ciccarelli (London, UK) M. Porter (London, UK) 12:45 - 12:50 Welcome & introduction M. Porter (London, UK) 12:50 - 13:05 Are we meeting patient expectations on disability? O. Ciccarelli (London, UK) 13:05 - 13:15 Why do patients progress to irreversible disability? W. Brück (Göttingen, DE) 13:15 - 13:25 Panel discussion F. Paul (Berlin, DE) C. Enzinger (Graz, AT) 13:25 - 13:40 How well do we assess disability progression in patients? S. Schippling (Zurich, CH) 13:40 - 13:45 Panel discussion, conclusions & close O. Ciccarelli (London, UK) F. Paul (Berlin, DE) C. Enzinger (Graz, AT) Parallel Sessions, Hall A 14:00 - 15:30 Parallel Session 13: Update on relapsing-remitting MS management Chairs G. Comi (Milan, IT) P. Vermersch (Lille, FR) 14:00 - 14:20 The American Academy of Neurology (AAN) guideline on the use of disease modifying therapy in multiple sclerosis A. Rae-Grant (Cleveland, US) 14:20 - 14:40 ECTRIMS-EAN guidelines X. Montalban (Barcelona, ES) 14:40 - 14:52 Timing of high-efficacy disease modifying therapies for relapsing- remitting multiple sclerosis T. Kalincik (Melbourne, AU) 14:52 - 15:04 Ozanimod demonstrates efficacy and safety in a phase 3 trial of relapsing multiple sclerosis (SUNBEAM) G. Comi (Milan, IT) Page 66 / 108
- 67. Scientific Programme 15:04 -15:16 CONCERTO: a placebo-controlled trial of oral laquinimod in patients with relapsing-remitting multiple sclerosis G. Comi (Milan, IT) 15:16 - 15:28 Aerobic exercise induces functional and structural reorganisation of the brain network: Results from a randomized controlled trial in relapsing- remitting multiple sclerosis J.-P. Stellmann (Hamburg, DE) Parallel Sessions, Hall B 14:00 - 15:30 Parallel Session 14: Remyelination: from biology to clinical trials Chairs P. Casaccia (New York, US) B. Zalc (Paris, FR) 14:00 - 14:20 From drug screening to myelin regeneration therapies in multiple sclerosis B. Nait Oumesmar (Paris, FR) 14:20 - 14:40 Muscarinic receptor M3R signaling prevents efficient remyelination by human and mouse oligodendrocyte progenitor cells F. Sim (Buffalo, US) 14:40 - 14:52 NFAT as a key regulator of oligodendroglial differentiation K. Groll (Münster, DE) 14:52 - 15:04 Sigma 1 receptor agonists as potential protective and reparative therapy in multiple sclerosis R.P. Lisak (Detroit, US) 15:04 - 15:16 Single-cell RNA-sequencing profiling of oligodendrocyte lineage cells isolated from the multiple sclerosis mouse model EAE A.M. Falcao (Stockholm, SE) 15:16 - 15:28 Pathological correlates of magnetization transfer ratio in multiple sclerosis M. Moccia (London, UK) Parallel Sessions, Hall C 14:00 - 15:30 Parallel Session 15: Metabolic and molecular imaging of MS Chairs J. Pelletier (Marseille, FR) M.A. Rocca (Milan, IT) Page 67 / 108
- 68. Scientific Programme 14:00 -14:20 Myelin repair and neurodegeneration in MS: lessons from PET studies B. Bodini (Paris, FR) 14:20 - 14:40 Ultra-high field MRI in multiple sclerosis M. Inglese (New York, US) 14:40 - 14:52 3T MRI detection of 7T paramagnetic rims in multiple sclerosis lesions: a step toward the clinical application M. Absinta (Bethesda, US) 14:52 - 15:04 A gradient of periventricular microglial activation suggests a CSF-derived neurodegenerative component in MS E. Poirion (Paris, FR) 15:04 - 15:16 Two years progression of neurodegeneration in RRMS: metabolic abnormalities topography using 3D MRSI M. Donadieu (Marseille, FR) 15:16 - 15:28 [18F]GE-180, a novel TSPO-PET tracer for visualization of inflammatory CNS-activity in MS C. Mahler (München, DE) Poster Sessions, Poster Exhibition Poster Session 2 Characteristics of acute transverse myelitis in CLIPPERS G. Taieb (Montpellier, FR) Neuromyelitis optica spectrum disorders: short myelitis lesions on magnetic resonance imaging in a cohort of Latin American patients E.G. Carnero Contentti (Buenos Aires, AR) 2015 International Panel for NMO diagnosis criteria improves early NMOSD diagnosis in a Colombian cohort M. Zuluaga (Medellin, CO) HoxB3, a novel biomarker that predicts conversion to multiple sclerosis E. Tüzün (Istanbul, TR) Omics-based approach reveals complement-mediated inflammation in CLIPPERS and potential biomarkers differentiating from RRMS Z. Illes (Odense, DK) The utility of brain lesion distribution criteria at onset in the distinction of multiple sclerosis, neuromyelitis optica spectrum disorder and MOG-IgG encephalomyelitis J.-W. Hyun (Goyang, KR) Rates and predictors of misdiagnosis in primary progressive multiple sclerosis (PPMS) in Europe and the United States J. White (London, UK) Page 68 / 108
- 69. Scientific Programme Are thepatterns of visual evoked potential in patients with relapsing inflammatory optic neuritis similar to those of multiple sclerosis or optical neuromyelitis? S. Pessanha Neto (Rio de Janeiro, BR) Clinical characteristics of MOG associated central nervous system inflammatory disorders in adulthood A. Bertolotto (Orbassano, IT) 'Sixteen syndrome'- three cases of multiple sclerosis presenting with pontine lesions M. Hu (Swansea, UK) Accuracy of the central vein sign evaluation by brain MRi for the pathologic characterization of multiple sclerosis cases with markers of “better explanation” of the diagnosis L. Massacesi (Florence, IT) Sensitivity and specificity of cerebrospinal fluid free light chains in Argentinean patients with suspected multiple sclerosis M.S. Sáez (Buenos Aires, AR) The diagnostic utility of screening for multiple sclerosis mimics A. Shah (Ann Arbor, US) Specificity of 3T FLAIR* MRI demonstration of central vessel sign in three lesions for diagnosis of multiple sclerosis A.J. Solomon (Burlington, US) The clinical and radiological outcomes of tumefactive multiple sclerosis A. Fontes-Villalba (St Leonards, AU) A retrospective comparison of rituximab vs cyclophosphamide in neuromyelitis optica spectrum disorders patients M. Radaelli (Milan, IT) "Unicuique suum": cerebellar lobule atrophy and disability in multiple sclerosis phenotypes M. Petracca (New York, US) Neuromyelitis optica spectrum disorder and rituximab: a multi-center analysis G. Novi (Genoa, IT) Motor progression from a single critically located demyelinating lesion in paucisclerotic MS M. Keegan (Rochester, US) Survival in patients with neuromyelitis optica spectrum disorders: data from the Belgrade cohort J. Drulovic (Belgrade, RS) MOG-antibody-positive CNS demyelinating disease: a clinical study in Chinese Han patients J. Zhangbao (Shanghai, CN) Month or season of birth effect on developing neuromyelitis optica spectrum disorder in Korea W. Kim (Seoul, KR) Page 69 / 108
- 70. Scientific Programme The diagnosisof OCB-negative MS-patients - an inventory of the Swedish MS register in Uppsala, Sweden A.-M. Landtblom (uppsala, SE) Autoimmune encephalitis in patients with anti-myelin oligodendrocyte glycoprotein- antibody R. Ogawa (Sendaishi, JP) Cortical grey matter thickness is more impaired in primary progressive multiple sclerosis as compared to relapsing-remitting disease course K. Pardo (Tel Aviv, IL) Brain volume loss in radiologically isolated syndromes compared with early stages of multiple sclerosis patients under DMD treatment J.I. Rojas (Buenos Aires, AR) Environmental toxic exposures are associated with risk for pediatric-onset multiple sclerosis S. Mar (St. Louis, US) Treatment of highly active multiple sclerosis in pediatric patients P. Huppke (Göttingen, DE) Relationship of sex and physical activity level to depression and fatigue in pediatric demyelinating disease: a longitudinal study S. Stephens (Toronto, CA) Altered adipocytokine levels in pediatric multiple sclerosis K. Keyhanian (Boston, US) Anti-JC virus antibodies in pediatric multiple sclerosis patients K. Sadowski (Warsaw, PL) Diagnostic criteria in the evaluation of children with a first demyelinating episode: prospective Spanish national cohort G. Arrambide (Barcelona, ES) Neuroimaging profile in pediatric Neuromyelitis Optica Spectrum Disorders (NMOSD) R. Paolilo (São Paulo, BR) Multiple sclerosis: the impact in the newborn J. Ribeiro (Coimbra, PT) Systematic literature review on the effectiveness and safety of treatments in paediatric multiple sclerosis M.C. Vieira (East Hanover, US) Spectrum of Late onset Neuromyelitis Optica (L-NMOSD): experience from NIMHANS Bengaluru, South India H. Bollampalli (Bangalore, IN) Benign multiple sclerosis: does the initial outcome predict a favorable long term evolution? E. Matas (L'Hospitalet de Llobregat, ES) Page 70 / 108
- 71. Scientific Programme Association betweenquality of life and self-reported disability in MS PATHS patients D. Miller (Cleveland, US) Disease activity persists in long-term progressive MS B. Rodríguez-Acevedo (Barcelona, ES) Disability progression variability in different ages at diagnosis of multiple sclerosis B. Wong (Providence, US) Diffusion tensor imaging in multiple sclerosis at different final outcomes O. Andersen (Göteborg, SE) SUMMIT: Initial insights from a repository of deeply phenotyped multiple sclerosis cohorts R. Bove (San Francisco, US) Baseline and time-dependent predictors of clinical disability progression in a pooled sample of phase 3 clinical trial placebo arms B.C. Kieseier (Zug, CH) The influence of menopause in multiple sclerosis course A.F. de Freitas Ladeira (Lisbon, PT) Disability severity in a real world MS population: results from the MS PATHS learning health system T. Ziemssen (Dresden, DE) Prescription medication exposure and the risk of multiple sclerosis: a systematic review H.Y. Yong (Vancouver, CA) Age at diagnosis over the last decades - analysis of the German MS Registry J. Haas (Berlin, DE) The prevalence and incidence of MS and familial MS in Tehran province, Iran S. Eskandarieh (Tehran, IR) Using algorithms to identify high disease activity relapsing-remitting multiple sclerosis patients using electronic health record data with natural language processing A.W. Kamauu (Salt Lake City, US) Developing United States Integrated Delivery Network (IDN) claims-based algorithms to identify relapses in relapsing-remitting multiple sclerosis (RRMS) patients A.W. Kamauu (Salt Lake City, US) A population-based prospective study of optic neuritis K.K. Soelberg (Vejle, DK) Five decades of epidemiological survey definitely discloses a real increase in the incidence of multiple sclerosis in the Veneto Region (North-East) of Italy F. Grassivaro (Padua, IT) The body mass index in neuromyelitis optica with aquaporin4-immunoglubulinG: association with disease onset and outcomes S.-H. Baek (Seoul, KR) Page 71 / 108
- 72. Scientific Programme Prodromal symptomsof multiple sclerosis in primary care: a case-control study using the UK Clinical Practice Research Datalink (CPRD) G. Disanto (Lugano, CH) Cross-sectional study in German MS patients reveals unmet needs with regard to psychiatric comorbidity H. Faber (München, DE) Lethality rates in multiple sclerosis and neuromyelitis optic spectrum disorders patients in a Brazilian cohort of mixed ancestrality J.G.D. Farinhas (Rio de Janeiro, BR) Using United States Integrated Delivery Network (IDN) Electronic Health Records (EHR) / Natural Language Processing (NLP)-based algorithms to identify relapses in relapsing- remitting multiple sclerosis (RRMS) patients A.W. Kamauu (Salt Lake City, US) Frequency of cognitive impairment in relapsing-remitting multiple sclerosis patients in Turkey and affecting factors S. Ozakbas (Izmir, TR) Cancer risk assessment in multiple sclerosis patients in the Eastern Sicily F. Patti (Catania, IT) Multiple sclerosis research dissemination in the web: news, blogs, or tweets? M.A.A. Sahraian (Tehran, IR) The impact of menopause on multiple sclerosis: a multicentre retrospective observational study D. Baroncini (Gallarate, IT) Rates of pregnancy in women with and without multiple sclerosis over time M.K. Houtchens (Brookline, US) Infertility treatment and live birth rates in women with and without multiple sclerosis M.K. Houtchens (Brookline, US) Methylprednisolone concentrations in breast milk and serum in patients with multiple sclerosis treated with IV pulse methylprednisolone C. Boz (Trabzon, TR) Impact of body size on MS risk and prognosis: results from the Barcelona CIS cohort S. Otero-Romero (Barcelona, ES) Clinical outcomes in male and female patients with multiple sclerosis in the treatment era A. Bouley (Providence, US) Impact of brain atrophy on cognitive motor interference in multiple sclerosis: a dual task study G. Coghe (Cagliari, IT) Cognitive rehabilitation for attention and memory in people with multiple sclerosis: the CRAMMS trial R. das Nair (Nottingham, UK) Page 72 / 108
- 73. Scientific Programme Tonic spasmsin multiple sclerosis: A case series J.M. Gutman (New York, US) Abnormal functional connectivity of thalamic sub-regions contributes to fatigue in multiple sclerosis M. Hidalgo de la Cruz (Milan, IT) A randomized controlled pilot trial of a group spasticity management program versus usual care in people with multiple sclerosis C. Hugos (Portland, US) Association between exercise capacity and cognitive functions in persons with multiple sclerosis T. Kahraman (Izmir, TR) A double blind, randomized, placebo controlled, crossover study of the effectiveness of oral fampridine in improving upper limb function in progressive multiple sclerosis N. McNicholas (Dublin, IE) Subclinical speech signs correlate with MS disease severity and differentiates patients with and without clinical cerebellar dysfunction G. Noffs (Melbourne, AU) Brain reserve and cognitive reserve in progressive multiple sclerosis: resilience against cognitive effects of neurodegeneration A. Pepe (New York, US) Olfactory dysfunction in patients with primary progressive multiple sclerosis F.A. Schmidt (Berlin, DE) Dual task cost of walking: an unreliable measurement among people with MS and controls M. Ploughman (St. John's, CA) Evaluation of dysautonomic symptoms in MS patients: use of the Composite Autonomic Symptom Score (COMPASS)-31 questionnaire L. Mancinelli (Chieti, IT) Expert consensus on standards for multiple sclerosis care: results from a modified Delphi process J. Hobart (Plymouth, UK) Creation of a normative data set on subjective and objective measures for upper limb function in a large MS population C. Solaro (Genova, IT) Cognitive impairment in MS, performance in daily activity and perception: a patient/caregiver study G. Fenu (Cagliari, IT) An engineered glove allows a quantitative integrated assessment of motor and cognitive impairment in multiple sclerosis E. Gallo (Genova, IT) The use of distractors within a computerized version of the SDMT reduces practice effects E. Donaldson (Toronto, CA) Page 73 / 108
- 74. Scientific Programme Investigation ofcladribine treatment rules in subjects with relapsing-remitting multiple sclerosis (RRMS) by means of modelling & simulation N. Terranova (Lausanne, CH) Long-term predictors of disability worsening in patients with multiple sclerosis in the phase 3 FREEDOMS and FREEDOMS II studies P. Repovic (Seattle, US) A Kinect-based perceptive assessment battery for motor dysfunction in multiple sclerosis and other neuroinflammatory disorders K. Otte (Berlin, DE) Retinal measures correlate with cognitive impairment in patients with MS compared to healthy controls K.S. Pandey (Livingston, US) MRI brain atrophy measures and processing speed in a cohort of MS patients R. Fakih (Beirut, LB) Improved clinical detection of cerebellar lesions in early MS patients O. Ayeni (New York, US) Is the EDSS a proxy for non-motor disability across multiple sclerosis disease types? R.J. Mills (Preston, UK) Validation of stroop color word test as a cognitive task for evaluating cognitive motor interference during walking in Multiple sclerosis G. Coghe (Cagliari, IT) Validity and reliability of smartphone-accelerometry for the measurement of postural control in people with multiple sclerosis D. Barbado (Elche, ES) Validity of self-assessment of functional performance in by MS patients as part of routine patient care R.A. Bermel (Cleveland, US) Clinic to in-home telemedicine reduces barriers to care for MS/neuroimmunology patients R. Bove (San Francisco, US) Model (PHREND) for personalized prediction of treatment response in relapsing remitting multiple sclerosis (RRMS) S. Braune (Prien, DE) The effectiveness of computerized screening in detecting cognitive deficits in people with multiple sclerosis M. Gudesblatt (Patchogue, US) Cognitive function predicts work disability among multiple sclerosis patients A. Kavaliunas (Stockholm, SE) The impact of fingolimod on the economic burden of multiple sclerosis: results from two non- interventional studies conducted in Germany C. Cornelissen (Nürnberg, DE) Page 74 / 108
- 75. Scientific Programme Out ofpocket costs for healthcare in the US: a NARCOMS, NMSS, iConquerMS survey S.S. Cofield (Birmingham, US) Disease modifying therapy and health care resource utilization in multiple sclerosis J.J. Marriott (Winnipeg, CA) Cost utility of oral high-dose corticosteroid treatment for multiple sclerosis relapses D. Veillard (Rennes, FR) Subclinical retinal pathology resembling multiple sclerosis in myelin-oligodendrocyte- glycoprotein antibody-positive patients during follow-up J. Havla (Munich, DE) In vivo detection of retinal arteriolar occlusions in neuromyelitis optica: a case-control study with multicolor optical coherence tomography J.M. Lam (Philadelphia, US) Optimal inter-eye difference thresholds in retinal nerve fiber layer thickness for predicting a unilateral optic nerve lesion in MS L. Balcer (New York, US) Study of subclinical oculomotor disturbances by video-oculography in individuals with radiological isolated syndrome M. De Verdal (Nimes, FR) Are saccadic eye movements related to cognitive function in multiple sclerosis? J.A. Nij Bijvank (Amsterdam, NL) Comorbidity in multiple sclerosis in northeastern Poland K. Kapica-Topczewska (Bialystok, PL) Multiple sclerosis in Chile: demographics, clinical phenotypes and comorbidities E. Ciampi (Barcelona, ES) Comorbid autoimmunity is not a prognostic factor in multiple sclerosis T. Gündüz (Istanbul, TR) Cancer risk in multiple sclerosis N. Grytten (Bergen, NO) Impact of insulin resistance and metabolic syndrome on disability and disease progression in patients with multiple sclerosis A. Hassan (Cairo, EG) Symptoms of depression and use of anti-depressants in MS PATHS (multiple sclerosis partners advancing technology and health solutions) patients D. Miller (Cleveland, US) Prevalence of comorbidities in patients with and without multiple sclerosis by age and sex: a US retrospective claims database analysis A.L. Phillips (Rockland, US) Corpus Callosum Index in MS patients with and without epilepsy R. Uribe-San-Martin (Santiago, CL) Page 75 / 108
- 76. Scientific Programme A phenome-wideexamination of the comorbidity burden associated with multiple sclerosis disease severity Z. Xia (Boston, US) Glial iron dysregulation in multiple sclerosis brains S. Hametner (Vienna, AT) Molecular signature of Epstein-Barr virus infection in multiple sclerosis brain lesions M.H. Han (Stanford, US) Systemic vascular disease burden and multiple sclerosis pathology: a post mortem study R. Geraldes (Oxford, UK) Disease activity and site related expression of microRNAs in astrocytes in multiple sclerosis V.T. Rao (Montreal, CA) The meningeal compartment supports tertiary lymphoid organogenesis in a natural model of multiple sclerosis J. Alvarez (Philadelphia, US) Metabolomic screening of cerebrospinal fluid from multiple sclerosis patients reveals a distinct signature F. Mir (New York, US) Dynamics of tissue regulatory T cells in neuromyelitis optica spectrum disorders lesions F. Yanagimura (Niigata, JP) Association between CD20+ B-cells and age at death in multiple sclerosis M. Moccia (London, UK) Fingolimod activates the 5-HT1A receptor in S1P3R/5-HT1A heterooligomer complexes in vivo K. Dines (San Diego, US) Experimental autoimmune encephalomyelitis (EAE) on a background of chronic microglia activation, iron accumulation and neurodegeneration: unexpected neuropathological findings in the Zitter rat model I. Wimmer (Vienna, AT) Altered quality and quantity of axon initial segment and nodes of ranvier in different MS mouse models C. Ertl (Munich, DE) Evaluation of the impact of reducing A20 expression in myeloid cells: study in a murine model F. Montarolo (Orbassano, IT) The effect of glatiramer acetate (GA) on cognitive function in an animal model of multiple sclerosis R. Aharoni (Rehovot, IL) Sensitization of superior dominant peptide may eradicate relapsing and progressive multiple sclerosis by sequential induction of stabilized antigen-specific hybrid regulatory T cells reactive to disease-associated antigens with tissue-repair capacity Y. Lin (Tokyo, JP) Page 76 / 108
- 77. Scientific Programme Evaluation ofvitamin D on the activation of neurogenesis and adult gliogenesis in a model of acute demyelination V. Pytel (Madrid, ES) Establishing an in vitro human cell culture based model for inflammation-related neuronal damage and regeneration in multiple sclerosis S. Rasehorn (Berlin, DE) Meningeal inflammation correlates with neurodegeneration and glial activation in a chronic cortical focal animal model of multiple sclerosis B.A. Silva (Buenos Aires, AR) The NKG2D ligand RAE-1 is induced in the CNS during experimental autoimmune encephalomyelitis and its expression correlates with microglia cell proliferation J. Boucraut (Marseille, FR) Expanding the behavioural characterization of the cuprizone mouse model: what changes will be most sensitive to early remyelination? F. Palavra (Coimbra, PT) CD44 as a trigger for inflammatory lesion formation T. Hochstrasser (Munich, DE) Effect of MS associated IL2RA gene variants on CD4+ T cell subsets in genotype-selected healthy controls S. Buhelt (Copenhagen, DK) Epigenetic profiling of bronchoalveolar lavage cells in multiple sclerosis and associations to cigarette smoking M.V. Ringh (Stockholm, SE) HLA-DRB1 polymorphism and susceptibility to multiple sclerosis in the Middle East North Africa region: systematic review and meta-analysis reveals similarities with Caucasians B. Mohajer (Tehran, IR) miR-29b: microRNA biogenesis and dysregulation meets DNA hypermethylation in SPMS K.A. Sanders (Hull, UK) Multiple sclerosis and HLA genotypes: a possible influence on brain atrophy L. Lorefice (Cagliari, IT) The distribution of courses of multiple sclerosis (MS) in familial MS. A population based Danish register study M. Steenhof (Odense, DK) Genetic variation in the gene LRP2 increases relapse risk in multiple sclerosis Y. Zhou (Hobart, AU) MicroRNA-155 circulating levels in Portuguese multiple sclerosis patients A. Bettencourt (Porto, PT) Plasma platelet microparticle counts are elevated in multiple sclerosis and regulated by the function of the platelet P2X7 receptor J. Wong (Melbourne, AU) Page 77 / 108
- 78. Scientific Programme Differential intrathecalinflammatory markers in acute optic neuritis and later conversion to multiple sclerosis M.N. Olesen (Vejle, DK) Investigation of the function and phenotype of CD20+ T cells in MS and control patients E. Rathbone (Birmingham, UK) Dysregulation of granulocyte-macrophage colony-stimulating factor in multiple sclerosis occurs across immune cell lineages J. Aram (Nottingham, UK) Discovering a new pathogenic CD20+ T cell population implicated in multiple sclerosis M.R. von Essen (Copenhagen, DK) GPR15+ CD4+ T cells are more reactive in smokers and enriched in CSF from patients with RRMS C. Ammitzbøll (Copenhagen, DK) T follicular helper/regulatory lymphocyte ratio (TFH/TFR) correlates with the intrathecal IgG synthesis in multiple sclerosis patients at clinical onset M. Puthenparampil (Padua, IT) Leukocyte repopulation following alemtuzumab treatment in relapsing-remitting MS contains multiple regulatory immune cell types W. Gilmore (Los Angeles, US) Characterization of ILC subsets in CNS and small intestine during EAE D. Brunotte-Strecker (Berlin, DE) CD161 intermediate expression defines a novel activated, inflammatory and pathogenic subset of CD8+ T cells involved in multiple sclerosis D. Laplaud (Nantes Cédex, FR) Detection of myelin-reactive CD8+ T cells in multiple sclerosis J.J. Sabatino, Jr (San Francisco, US) Enhanced expression of IL-22 and GM-CSF by IL-17-producing cerebrospinal fluid T cells in RRMS L. Ghezzi (Milano, IT) Mitochondrial dysfunction in peripheral blood mononuclear cells from multiple sclerosis patients L. Nogueras Penabad (Lleida, ES) The role of neutrophil-to-lymphocyte ratio in multiple sclerosis and optic neuritis J.L. Frederiksen (Copenhagen, DK) Compartmental constraints on B cell antigen presentation in an MHCII-dependent model of autoimmune neuroinflammation C.R. Parker Harp (St. Louis, US) Cross-reactivity of antibodies with neural precursor cells in Experimental Autoimmune Encephalomyelitis N. Grigoriadis (Thessaloniki, GR) Page 78 / 108
- 79. Scientific Programme Early, norepinephrine-dependent,activation of the hematopoietic niche and thymus precedes the onset of EAE A. Uccelli (Genova, IT) PRN2246, a potent and selective blood brain barrier penetrating BTK inhibitor, exhibits efficacy in central nervous system immunity M.R. Francesco (South San Francisco, US) Cytometry by Time of Flight (CyTOF) shows an increase of T follicular helper-like cells in the CSF of MS patients N.S. Sanderson (Basel, CH) Cerebrospinal fluid microvesicles: are they useful in multiple sclerosis? T. Croese (Milano, IT) Comprehensive analysis of the intrathecal B-cell response in patients with MS S.A. Sadiq (New York, US) Increased concentrations of exosomes in MS patients - are they involved in the pathophysiology of MS? M. Axelsson (Gothenburg, SE) Th17 cell mediated neuronal excitotoxicity K. Birkner (Mainz, DE) Deep sequencing of TCR β-chain repertoire reveals an immune profile signature in MS patients A. De Paula A. Sousa (Bethesda, US) The anti-myelin antibody response in MS is primarily directed against myelin oligodendrocyte glycoprotein J. Lin (New York, US) Th17.1 cells as selective contributors to MS disease activity: new perspectives for early intervention M.M. van Luijn (Rotterdam, NL) Association of human endogenous retroviruses type W with multiple sclerosis S. Macías-Redondo (Zaragoza, ES) Human herpesvirus 6 and cytomegalovirus IgG and IgM antibodies in multiple sclerosis patients: an inverse correlation with age R. Alvarez-Lafuente (Madrid, ES) Can antiretroviral drugs suppress endogenous retrovirus expression and protect from MS? E. Morandi (Nottingham, UK) Wellness factors are related to cerebral grey matter and clinical outcomes in multiple sclerosis I. Katz Sand (New York, US) Case report: fecal microbiota transplantation associated with 10 years of disease stability in a patient with secondary progressive multiple sclerosis S. Makkawi (Calgary, CA) Page 79 / 108
- 80. Scientific Programme Dietary habits,nutritional status and risk of a diagnosis of a first demyelinating event: a single center incident case-control study P. Cavalla (Torino, IT) The gut microbiome in active and stable relapsing multiple sclerosis E. Eleftheriou (Worcester, US) Environmental and genetic factors in MS susceptibility in Spain M.J. Pinto-Medel (Málaga, ES) Smoking modulates the immune response in experimental autoimmune encephalomyelitis by activating the aryl hydrocarbon receptor J. Berg (Bochum, DE) Vitamin D serum levels and viral load of human herpesvirus 6 and Epstein-Barr virus in patients with multiple sclerosis after one year of follow-up R. Alvarez-Lafuente (Madrid, ES) Epstein-Barr virus immune response and candidate genetic loci in multiple sclerosis patients and their family members J.Y. Mescheriakova (Rotterdam, NL) Beneficial effect of short-chain fatty acids administration in the clinical course of experimental autoimmune encephalomyelitis L. Calvo-Barreiro (Barcelona, ES) ebv-miR-BART22 is up-regulated in tobacco smoking MS patients M. Muñoz-San Martín (Girona, ES) Oligodendroglial potassium channel Kir4.1 is essential for white matter function L. Schirmer (San Francisco, US) Microscopic cellular correlates of macroscopic MRI-measured structural network properties in multiple sclerosis S. Kiljan (Amsterdam, NL) Oligodendrocyte-encoded glutamine synthetase is required for neuro-axonal function L. Ben Haim (San Francisco, US) Localization of the neuroprotective factor ARNT2 to astrocytes and characterization of its regulation in experimental models of MS and by inflammatory mediators in vitro J. Quandt (Vancouver, CA) The cuprizone model as a valuable tool to study progressive multiple sclerosis K. Fabisch (Munich, DE) Longitudinal association between deep gray matter atrophy and lesion-based disruptions in connected white matter tracts T. Fuchs (Buffalo, US) Aging is accelerating central atrophy in MS patients E. Ghione (Buffalo, US) Page 80 / 108
- 81. Scientific Programme Novel molecularmechanisms of antibody induced neurodegeneration and spasticity in CNS autoimmune inflammatory disease H.E. Salapa (Saskatoon, CA) Corpus callosum atrophy develops within 3 months since CIS trial enrolment L. Tang (Vancouver, CA) Accelerated loss of chronically demyelinated axons in relapsing-remitting multiple sclerosis C. Wang (Sydney, AU) Beneficial effects of testosterone administration following the onset of clinical symptoms in experimental model of multiple sclerosis B. Bielecki (Lodz, PL) Direct and indirect neuroprotective effects of the short-chain fatty acid propionate on human primary neurons in the context of multiple sclerosis B. Gisevius (Bochum, DE) Continuous reorganisation of cortical information flow in MS patients: a longitudinal effective connectivity study V. Fleischer (Mainz, DE) Quantitative comparison of brain volumes as assessed by SPM, SIENA/X and MorphoBox software packages D. Pareto (Barcelona, ES) Evolution of new lesions and its temporal patterns in patients with clinically isolated syndrome treated with subcutaneous interferon beta-1a H. Vrenken (Amsterdam, NL) Metabolites in the posterior cingulate cortex are correlated to clinical symptoms in relapsing remitting multiple sclerosis K.A. Ribbons (New Lambton, AU) Grouping multiple sclerosis patients based on cross-sectional volumetry of whole brain and thalamus A. Raji (Hamburg, DE) A deep learning approach for multiple sclerosis lesion segmentation X. Llado (Girona, ES) INSPIRATION: an approach to brain volume and quantitative lesion load assessments from standardized MRI acquisition in daily clinical routine of MS patients C. Cornelissen (Nürnberg, DE) Impact of spinal cord atrophy on daily activity in multiple sclerosis N. Sola-Valls (Barcelona, ES) Automated lobe-specific classification of lesions: correlation with grey matter atrophy B.E. Dewey (Baltimore, US) Iron loss of thalamic nuclei evaluated with quantitative susceptibility mapping is related to intrathecal macrophages activity and cortical pathology of multiple sclerosis M. Castellaro (Padova, IT) Page 81 / 108
- 82. Scientific Programme Brain volumeloss in individuals over time: sources of variance and limits of detectability K. Nakamura (Cleveland, US) The clinical relevance of the network-derived metrics in multiple sclerosis T. Charalambous (London, UK) CSF markers of blood-brain barrier integrity forecast disease progression in early MS J. Kroth (Mainz, DE) Ultrasmall superparamagnetic iron oxide nanoparticle-enhanced MRI at 7-tesla in multiple sclerosis M.K. Schindler (Bethesda, US) [18F]GE180 PET as a sensitive imaging tool to monitor diffuse brain injury A. Nack (Munich, DE) Thalamic white matter in MS: an MRI study combining DTI and quantitative susceptibility mapping N. Bergsland (Buffalo, US) Corpus callosum alterations revealed by Diffusion Basis Spectrum Imaging (DBSI) in all stages of multiple sclerosis A.H. Cross (St. Louis, US) Depression in multiple sclerosis: structural and functional disconnection in the fronto-limbic system Q. van Geest (Amsterdam, NL) Whole white matter integrity predicts information processing speed in clinically isolated syndrome and early MS R.M. Giess (Berlin, DE) Morphologic MRI phenotyping of multiple sclerosis associates with altered brain function D. Pinter (Graz, AT) On the construction of a 3D-printed brain phantom as gold standard for the validation of brain segmentations A. Altermatt (Basel, CH) Cognitive impairment in MS: between cognitive reserve and cerebral atrophy: a neuropsychological and MRI study G. Fenu (Cagliari, IT) Disrupted cerebellar network dynamics and cognitive impairment in progressive multiple sclerosis M.M. Schoonheim (Amsterdam, NL) Diffuse reduced axonal density in normal appearing white matter in early multiple sclerosis: novel insights from multi-shell diffusion MRI C. Mainero (Boston, US) Deep learning to normalize conventional T1w MRI for quantitative longitudinal assessment of tissue health in MS R.A. Brown (Montreal, CA) Page 82 / 108
- 83. Scientific Programme Brain structuralconnectivity in different clinical forms of multiple sclerosis F. Durand-Dubief (Bron Lyon Cedex, FR) Diffuse frontal, parietal, temporal and occipital networks play a role in the pathophysiology of fatigue in multiple sclerosis M. Palotai (Boston, US) Neuronal dysfunction is less frequent in benign multiple sclerosis: a sodium MRI study A. Maarouf (Marseille, FR) Is glucose metabolism a proxy for neuroinflammation in MS? A comparative study between 18F-FDG and 18F-DPA714 PET M. Tonietto (Paris, FR) Relationship between clinical manifestation of MS relapse and Gadolinium enhancing lesions in brain MRI L. Martín-Aguilar (Badalona, ES) Dorsal attention network and cognition in MS: a graph theoretical approach at 7-Tesla A.W. Russo (Charlestown, US) Comparative multi-modal MRI study to examine the effect of Natalizumab, Galtitamer acetate and Fingolimod on brain tissue injury in patients with relapsing remitting multiple sclerosis S. Razmjou (Detroit, US) The relationship between oxidative stress and symptoms of fatigue and depression in multiple sclerosis: a pilot study I.-Y. Choi (Kansas City, US) Measuring spinal cord atrophy in chronic progressive inflammatory neurologic diseases S. Azodi (Bethesda, US) Conversion to clinically definite multiple sclerosis is associated with lobule-specific atrophy of the cerebellum N. Bergsland (Buffalo, US) Identification of structural imaging correlates of disability in neuromyelitis optica: a graph theory based approach C. Chien (Berlin, DE) Estimating brain atrophy from incompletely acquired clinical MR scans in MS M. Clarke (Nottingham, UK) Alterations in individual cortical networks of CIS patients: a longitudinal multi-centre MAGNIMS study S. Collorone (London, UK) Longitudinal study of MS lesion evolution using neurite orientation dispersion and density imaging, relaxometry and magnetization transfer imaging E. Fischi-Gomez (Boston, US) Results from the Brazilian Brain Volume Studies (B-BRAVOS) database confirm the association of volumetric and clinical parameters in multiple sclerosis Y.D. Fragoso (Santos, BR) Page 83 / 108
- 84. Scientific Programme Location ofnew white matter lesions in multiple sclerosis: Insights from a large dataset L. Gaetano (Basel, CH) Multiple sclerosis: brain atrophy and computerized cognitive testing - a cross-sectional pilot investigation M. Gudesblatt (Patchogue, US) Reduced iron levels in the DGM of MS patients compared to healthy controls E. Hernández-Torres (Vancouver, CA) Combined MRI study of perfusion, cerebrovascular reactivity and neurodegeneration in multiple sclerosis M.M. Laganà (Milan, IT) Ex-vivo MR microscopy of cortical lesions reveal iron loss in individual oligodendrocytes G. Nair (Bethesda, US) Brain network organisation and cognitive performance in clinically isolated syndromes J. Ooi (London, UK) Combined analysis of T1- and T2-weighted images to assess microstructural damage. Preliminary results in patients with a clinically isolated syndrome D. Pareto (Barcelona, ES) Impaired structural brain connectome in patients with systemic lupus erythematosus and multiple sclerosis: a graph theory study P. Preziosa (Milan, IT) Impact of vitamin D and cotinine levels on brain atrophy J. Sastre-Garriga (Barcelona, ES) Relevance of functional connectivity abnormalities to cognitive impairment in neuromyelitis optica spectrum disoders F. Savoldi (Milano, IT) Multi-view convolutional neural networks using batch normalization outperform human raters during automatic white matter lesion segmentation M.D. Steenwijk (Amsterdam, NL) MS cortical lesions classification in different brain areas: comparison between 3D-DIR and magnetisation-prepared 3D-FLAIR at 3T F. Tona (London, UK) Age-dependent whole brain and grey matter annual atrophy rates in healthy adults W. Van Hecke (Leuven, BE) Declines of N-acetylaspartate (NAA) within 6 month measured by a new MRI-spectroscopy approach in the brains of patients with early MS predicts subsequent disability progression M. Wahl (Frankfurt am Main, DE) Evidence for neural-vascular uncoupling in multiple sclerosis: a calibrated fMRI study in motor cortex K.L. West (Dallas, US) Page 84 / 108
- 85. Scientific Programme Retinal damagebegins in the ganglion cell layer and correlates with brain atrophy from the very early stages of the disease in MS patients T. Carandini (Milan, IT) Visual evoked potentials in acute optic neuritis predict the severity of subsequent neurodegeneration at optical coherence tomography S.-C. Huang (Milan, IT) Optical coherence tomography measures correlate with spinal cord area and with disability in relapsing multiple sclerosis patients À. Vidal-Jordana (Barcelona, ES) Durable neuroprotective effects of alemtuzumab over 5 years on retinal nerve fibre layer and ganglion cell layers in relapsing-remitting multiple sclerosis (RRMS) patients J.K. Chan (Vancouver, CA) A preliminary investigation into the relationship between Visual Evoked Potential Latency (VEP-L) and outcome parameters from Optical Coherence Tomography (OCT) in people with multiple sclerosis M. Gudesblatt (Patchogue, US) Updates in OCT segmentation software influence longitudinal assessment of retinal atrophy D. Coric (Amsterdam, NL) Visual pathway involvement in progressive multiple sclerosis: demyelination and neurodegeneration are higher in secondary progressive than primary progressive patients S. Guerrieri (Milan, IT) Optical coherence tomography and magnetic resonance imaging correlates with cognitive impairment in patients with relapsing remitting multiple sclerosis S. Razmjou (Detroit, US) Frequent retinal ganglion cell damage after acute optic neuritis A.U. Brandt (Berlin, DE) The relationship between optical coherence tomography and early neurocognitive changes in pediatric multiple sclerosis N.M. Shukla (Houston, US) Revising the Advised Protocol for Optical coherence tomography Study Terminology and Elements (APOSTEL): from recommendations to formal guidelines P. Albrecht (Düsseldorf, DE) Defining the anatomical & physiological hierarchy of neuro-degeneration of the afferent visual system in multiple sclerosis: a cross-sectional study with spectral domain OCT, visual fields MultiFocal ERG, EDSS, regional & whole brain atrophy R. Sergott (Philadelphia, US) Upper limb motor evoked potentials as outcome of corticospinal involvement in progressive MS M. Pisa (Milan, IT) Measuring cognitive fatigue: PASAT 3” as a quantitative measure in healthy controls and multiple sclerosis patients F. García-Vaz (Madrid, ES) Page 85 / 108
- 86. Scientific Programme Calibrated fMRIstudy reveals neural-vascular uncoupling in the visual cortex of multiple sclerosis patients D.K. Sivakolundu (Richardson, US) Hyperstable EEG-vigilance is associated with activated hypothalamo-pituitary-adrenal (HPA) axis in multiple sclerosis patients M.G. Stoppe (Leipzig, DE) How feasible is the application and scoring of BICAMS in daily clinical routine? M. Filser (Düsseldorf, DE) Detection of cognitive decline in MS using BICAMS: Is there substantial value in applying the full battery? S. Baetge (Düsseldorf, DE) Education level and the characteristics cognitive impairment in a Brazilian cohort of multiple sclerosis patients C.M. Rimkus (Amsterdam, NL) Word finding deficits in early multiple sclerosis: a behavioral and neuroimaging investigation R. Brandstadter (New York, US) Towards a better understanding of the perception of cognitive symptoms in patients with multiple sclerosis S. Vanotti (Buenos Aires, AR) Cognitive impairment in MS: are white matter lesions the main driver? C. Engl (Munich, DE) Impact of MRI activity on cognitive functions in multiple sclerosis G. Fenu (Cagliari, IT) Different cognitive and pathological substrata of positive and negative emotion recognition in subjects with multiple sclerosis M. Pardini (Genoa, IT) Cognitive and behavioural impact of sleep quality in newly diagnosed multiple sclerosis M. Rottoli (Bergamo, IT) Cognitive theory of mind in multiple sclerosis K. Zebenholzer (Vienna, AT) Cognitive assessment should be considered in clinical trials in association with other clinical outcome measures S. Ziccardi (Verona, IT) Word list generation test predicts conversion to disease progression in relapsing remitting multiple sclerosis. A 6 year longitudinal study A. Riccardi (Padua, IT) Novelty seeking assessment and symptomatic treatment for cognitive deficits in MS M. Pardini (Genoa, IT) Page 86 / 108
- 87. Scientific Programme Cognition inmultiple sclerosis: an international multidisciplinary consensus group identifies obstacles in the field and research priorities for the future J.F. Sumowski (New York, US) Accessing early neurodegeneration in multiple sclerosis: biomarkers for diagnostics and phenotypic characterization L. Novakova (Gothenburg, SE) Intrathecal autologous cell therapy is associated with changes in cerebrospinal fluid biomarkers in patients with progressive multiple sclerosis V.K. Harris (New York, US) Cerebrospinal fluid levels of cell-free mitochondrial DNA in patients with multiple sclerosis M. Comabella (Barcelona, ES) Long non coding RNA expression profile in Peripheral Blood Mononuclear Cells from multiple sclerosis patients: potential biomarkers of disease susceptibility and progression E. Oldoni (Milan, IT) CircularRNA profiling reveals that circularRNAs from ANXA2 could be new biomarkers for multiple sclerosis L. Iparraguirre (San Sebastian, ES) Metabolic imaging of hyperpolarized [1-13C] pyruvate can detected neuroinflammation in the cuprizone model of MS M. Chaumeil (San Francisco, US) Altered erythrocyte MicroRNA profiles in relapsing-remitting multiple sclerosis K. Groen (Callaghan, AU) Normalization of neurofilament light chain levels after treatment with dimethyl fumarate T. Sejbaek (Odense, DK) Serum exosomes microRNA-122-5p, miRNA-196b-5p, miRNA-301a-3p and miRNA-532-5p represent a biomarkers of multiple sclerosis I. Selmaj (Lodz, PL) Capillary isoelectric focusing immunoassay for the detection of oligoclonal IgG- and IgM bands in cerebrospinal fluid S. Halbgebauer (Ulm, DE) Novel molecular markers associated with cognitive dysfunction in multiple sclerosis A. Iacoangeli (New York, US) Utility of fMRI metrics in assessment of RRMS disease progress and severity M.P. Turner (Richardson, US) Cerebrospilnal fluid-Actin related protein 2/3 complex subunit 4 as an astrocytic foot process damage marker of aquaporin-4-IgG positive neuromyelitis optica spectrum disorders S. Nishiyama (Sendai, JP) Page 87 / 108
- 88. Scientific Programme Biomarker forprogressive multiple sclerosis: cross-sectional relationship between disability, multimodal evoked potentials and serum neurofilament light chain in a multicenter study M. Hardmeier (Basel, CH) Serum nitric oxide is increased in untreated multiple sclerosis patients F. Hallwirth (Graz, AT) Assessment of chitinase-3-like 1 and neurofilaments as biomarkers of cognitive function E. Quintana (Girona, ES) Free light chains in cerebrospinal fluid: determination of normal values of concentration, ratio and index and their interests in a 2 years prospective study J. Boucraut (Marseille, FR) Cerebrospinal fluid neurofilament light chain protein is associated with radiological markers of disease activity and severity in patients with early multiple sclerosis A. Ungureanu (Colmar, FR) Identification of blood brain barrier permeability mechanisms in multiple sclerosis: the role of CNS derived endothelial microparticles J.R. Linden (New York, US) Serum neurofilament light chain predicts disease activity in relapsing remitting multiple sclerosis K. Varhaug (Bergen, NO) Gene expression profiling study of coding and non-coding genes in peripheral blood mononuclear cells from multiple sclerosis patients exposed to teriflunomide in vitro S. Malhotra (Barcelona, ES) Predicting conversion from clinically isolated syndrome to multiple sclerosis: identification of a cerebrospinal fluid neurofilament light cut-off value L. Gaetani (Perugia, IT) Kappa free light chains: an automated alternative to oligoclonal bands for CIS and MS diagnosis? C.E. Leurs (Amsterdam, NL) A metabolomic study of MS patients treated with fingolimod by high resolution NMR L. Lorefice (Cagliari, IT) Method for assessing quality of lesion volume and brain atrophy measurements Z. Spiclin (Ljubljana, SI) Autologous haematopoietic stem cell transplantation (AHSCT) in relapse remitting (RR-MS) and secondary progressive multiple sclerosis (SP-MS): a phase II trial from St Vincent's Hospital, Sydney Australia J. Massey (Sydney, AU) Effectiveness of dimethyl fumarate on disease activity and patient-reported outcomes in French subjects with relapsing-remitting multiple sclerosis in the real-world: a subgroup analysis of PROTEC B. Brochet (Bordeaux, FR) Page 88 / 108
- 89. Scientific Programme First interimresults of PANGAEA 2.0: patients switching to fingolimod from other oral DMTs in daily clinical routine C. Cornelissen (Nürnberg, DE) The fingolimod patient profile 2011 and 2017: a comparison of two non-interventional studies PANGAEA and PANGAEA 2.0 C. Cornelissen (Nürnberg, DE) Cladribine versus fingolimod, natalizumab and interferon β for multiple sclerosis T. Kalincik (Melbourne, AU) Teriflunomide induces immunomodulatory properties by its impact on antigen-presenting cells K. Akgün (Dresden, DE) Interferon-beta and regulatory cells: evaluation of treatment-induced modulation of Treg, Breg and CD56bright NK cell levels in multiple sclerosis patients S. Martire (Orbassano, IT) Innate immune cell counts in patients with relapsing-remitting multiple sclerosis (RRMS) treated with cladribine tablets 3.5 mg/kg in CLARITY and CLARITY extension P. Soelberg Sorensen (Copenhagen, DK) Infections during periods of grade 3 or 4 lymphopenia in patients taking cladribine tablets 3.5 mg/kg: data from an integrated safety analysis S. Cook (Newark, US) Proportions of patients with highly active RMS achieving no evidence of disease activity (NEDA) in response to cladribine tablets in CLARITY G. Giovannoni (London, UK) Impact of the presence of gadolinium-enhancing lesions at baseline on no evidence of disease activity status in patients treated with subcutaneous interferon beta-1a: A Post-hoc analysis of REFLEXION M.S. Freedman (Ottawa, CA) Fingolimod vs. dimethyl fumarate in relapsing-remitting multiple sclerosis: propensity score matched comparison in a large observational data set J. Lorscheider (Melbourne, AU) Immunmodulatory effects of intrathecal administration of human immunoglobulins in experimental autoimmune encephalomyelitis model in Lewis rats K. Pitarokoili (Bochum, DE) Preferential reconstitution of regulatory B cell subsets following alemtuzumab treatment in multiple sclerosis Y. Kim (Goyang-si, KR) Tolerogenic dendritic cells engineered to express multiple MOG epitopes using mRNA electroporation effectively suppress MOG-specific splenocytes in vitro and in vivo J. Derdelinckx (Edegem, BE) Efficacy and safety of alemtuzumab in 150 patients with active relapsing-remitting MS: two- year follow-up in France X. Ayrignac (Montpellier, FR) Page 89 / 108
- 90. Scientific Programme Heterogeneity ofperipheral blood NK cells behaviour in relapsing-remitting multiple sclerosis patients treated with dimethylfumarate D. Marastoni (Verona, IT) Efficacy and safety of 2 doses of ponesimod (10 and 20 mg o.d.): interim analysis of a phase II extension trial in relapsing-remitting multiple sclerosis E. Havrdová (Prague, CZ) Transfer of natalizumab into fetal circulation and breastmilk U. Proschmann (Dresden, DE) Rituximab treatment in antiAQP4 positive patients with a 6-month reinfusion protocol S.L. Apóstolos-Pereira (São Paulo, BR) Efficacy of rituximab as a rescue therapy after the failure of second line treatment in relapsing remitting multiple sclerosis: a retrospective observational monocenter study P. Durozard (Marseille, FR) Safety and efficacy of rituximab in multiple sclerosis: a retrospective observational study M.M. Zeineddine (Beirut, LB) Cladribine personalised dosing to treat multiple sclerosis Z. Mao (London, UK) Placebo controlled, phase 2a multicenter study of ublituximab (UTX), a novel glycoengineered anti-CD20 monoclonal antibody (mAb), in patients with relapsing forms of multiple sclerosis (RMS): 6 months analysis of B cell subsets A. Lovett-Racke (Columbus, US) Real world comparative effectiveness data of natalizumab vs fingolimod for the treatment of relapsing-remitting multiple sclerosis: results from a systematic literature review C. Acosta (Zug, CH) Treatment with delayed-release dimethyl fumarate is associated with fewer relapses versus glatiramer acetate in patients with relapsing remitting multiple sclerosis: real-world comparative effectiveness analyses from the EFFECT study A. Chan (Bern, CH) The real-world efficacy of natalizumab and fingolimod in relapsing-remitting multiple sclerosis. An observational, multicentre Italian study E. Curti (Parma, IT) Efficacy of alemtuzumab in patients who switched from fingolimod S. Eichau (Sevilla, ES) Efficacy of delayed-release dimethyl fumarate in newly diagnosed and other early MS patients, and patients switching from interferon or glatiramer acetate, in routine medical practice: interim results from ESTEEM N.J. Everage (Cambridge, US) Effects of cladribine tablets on radiological outcomes in high disease activity (HDA) subgroups of patients with relapsing multiple sclerosis (RMS) in the CLARITY study G. Giovannoni (London, UK) Page 90 / 108
- 91. Scientific Programme PREFERMS Study:fingolimod switch effect on volumetric MRI and cognitive outcomes S.F. Hunter (Franklin, US) Pharmacodynamics of intravenous and subcutaneous doses of the anti-CD52 antibody GLD52 in patients with progressive MS: effects on innate and adaptive immune cells D.H. Margolin (Cambridge, US) Glatiramer acetate depot (extended-release) phase IIA study in patients with relapsing remitting multiple sclerosis: six months' interim analysis A. Miller (Haifa, IL) Safety, tolerability and effectiveness of dimethyl fumarate in multiple sclerosis: an independent, multicenter, real-world study M. Mirabella (Rome, IT) Dimethyl fumarate reduces the frequency and function of inflammatory immune cells in relapsing-remitting multiple sclerosis patients G. Montes Diaz (Diepenbeek, BE) EVOLVE-MS-1: a phase 3, open-label, long-term safety study of ALKS 8700 in relapsing- remitting multiple sclerosis R.T. Naismith (Saint Louis, US) Characterization of lymphopenia in relapsing-remitting multiple sclerosis patients treated with dimethyl fumarate and fingolimod M. Nakhaei-Nejad (Edmonton, CA) Influence of aging and comorbidities on EDSS progression in a cohort of italian MS patients S. Ruggieri (Rome, IT) Laquinimod induces B-cell down-regulation in primary progressive multiple sclerosis: in- vitro gene expression study R. Zilkha-Falb (Ramat-Gan, IL) Neuroprotective role of alemtuzumab in a chronic autoimmune mouse model with immune cell targeted deletion of BDNF S. Demir (Bochum, DE) Population pharmacokinetics of opicinumab (Anti-LINGO-1) guides the phase IIb dose selection L.-H. Chu (Cambridge, US) The effect of Gilenya on focal and diffuse grey matter damage in active MS patients A. Bajrami (Verona, IT) Impact of teriflunomide on oligodendroglial homeostasis and differentiation P. Göttle (Düsseldorf, DE) Neuroprotection in an experimental model of multiple sclerosis, via opening of big conductance, calcium-activated potassium channels D. Baker (London, UK) Remyelination following oral administration of dimethyl fumarate in the Theiler's murine encephalomyelitis virus model of multiple sclerosis N.G. Carlson (Salt Lake City, US) Page 91 / 108
- 92. Scientific Programme Vagus nervestimulation attenuates demyelination and accelerates remyelination in a lysolecithin-induced multiple sclerosis model N. Hamlin (Valencia, US) Ozanimod (RPC1063) is potentially neuroprotective through direct activity on Th1 and Th17 T cell expansion and migration, monocyte migration and microglia expansion D. Guimond (San Diego, US) Blockage of BMP-2 signaling, either by neutralizing ab, or by small molecules, ameliorates relapsing- experimental autoimmune encephalomyelitis by induction of neurogenesis and oligodendrogenesis A. Karni (Tel Aviv, IL) Ozanimod (RPC1063) is potentially neuroprotective through direct CNS effects K.R. Taylor Meadows (San Diego, US) Recombinant human growth hormone for remyelination in MS: results of a pilot trial in patients with chronically delayed VEP F. Then Bergh (Leipzig, DE) Selection of first-line therapy in multiple sclerosis using risk-benefit decision analysis Z. Xia (Boston, US) Long-term effect of fingolimod on disability: 8-year disease outcomes by EDSS categories A.T. Reder (Chicago, US) Real-world longitudinal data of peginterferon beta-1a from a Swedish national post- marketing surveillance study (IMSE 6) - efficacy and safety profile S. Kågström (Stockholm, SE) Alemtuzumab durably improves clinical outcomes in patients with active RRMS in the absence of continuous treatment: 7-year follow-up of CARE-MS-I patients (TOPAZ study) A.J. Coles (Cambridge, UK) Durable reduction in MRI disease activity and slowing of brain volume loss with alemtuzumab in patients with active RRMS: 7-year follow-up of CARE-MS I patients (TOPAZ study) D.L. Arnold (Montréal, CA) Alemtuzumab demonstrated durable efficacy and safety in CARE-MS I patients switching from SC IFNB-1a: 5-year follow-up after alemtuzumab (TOPAZ study) C. Oreja-Guevara (Madrid, ES) Baseline characteristics and long-term disability outcomes: subgroup analysis of the TEMSO and TOWER core and extension studies P. Vermersch (Lille, FR) 5 years safety experience with fingolimod in real world: results from PANGAEA, a non- interventional study of RRMS patients treated in Germany C. Cornelissen (Nürnberg, DE) Persistence to fingolimod compared with other disease modifying therapies in the Australian real-world setting using the MS base registry T. Spelman (Parkville, AU) Page 92 / 108
- 93. Scientific Programme Alemtuzumab efficacyand safety were durable over 5 years after switching from SC IFNB-1a: follow-up of patients from CARE-MS II (TOPAZ study) B. Van Wijmeersch (Hasselt, BE) Alemtuzumab-treated patients with relapsing-remitting MS show low rates of conversion to secondary progressive MS: 6-year follow-up of CARE-MS I and II D. Horakova (Prague, CZ) Early versus late treatment start in patients with multiple sclerosis - a nationwide register- based study T.A. Chalmer (Copenhagen, DK) Long-term effect of interferon-β use in real-world settings on disability progression: a series of 2,451 relapsing-remitting multiple sclerosis patients, Rennes, France M. Lefort (Rennes, FR) Patient-reported disability in patients with multiple sclerosis on baseline therapy: results from the non-interventional PEARL study over 2 years R. Haase (Dresden, DE) Real-time monitoring of MS-immunotherapy discontinuation, switching, and restarting with a visualisation and analysis platform (VAP) implemented in the Swedish MS-registry L. Stawiarz (Stockholm, SE) A Swedish nationwide pharmaco-epidemiological study of the long-term safety and effectiveness of teriflunomid (IMSE 4) L. Forsberg (Stockholm, SE) Long term extended interval dosing of Natalizumab does not change its clinico-radiological efficacy nor saturation capacity of CD49d: a real life study in a French MS center D. Ciocanu (Caen, FR) Effect of comorbidities on dimethyl fumarate persistence and effectiveness in patients with relapsing remitting multiple sclerosis in a real world clinic setting T.L. Campbell (Halifax, CA) Long-term disability outcomes in patients treated with teriflunomide for up to 14 years: group- and patient-level data from the phase 2 extension study M.S. Freedman (Ottawa, CA) Long-term Improvement in clinical outcomes in alemtuzumab-treated RRMS patients who relapsed between courses 1 and 2 (CARE-MS I) H. Wiendl (Münster, DE) Identifying barriers to effective communication between individuals with MS and healthcare professionals: a global survey of MS healthcare professionals A. Montague (Cherry Hill, US) Early diagnosis of PML: results from the Italian cohort C. Scarpazza (Brescia, IT) A case of fulminant Goodpasture syndrome following alemtuzumab treatment for multiple sclerosis E. Lapointe (Vancouver, CA) Page 93 / 108
- 94. Scientific Programme Hepatic microabscessesduring CMV reactivation in a multiple sclerosis patient after alemtuzumab treatment S. Barone (Catanzaro, IT) Recurrent immune thrombocytopenic purpura secondary to rituximab administered as neuromyelitis optica treatment: a case report presentation J. Meca-Lallana (Murcia, ES) Higher medication satisfaction and treatment adherence in relapsing-remitting multiple sclerosis patients treated with glatiramer acetate 40 mg/ml three-times weekly compared with 20 mg/ml daily: 6-month results of the CONFIDENCE study A. Veneziano (Frazer, US) Design and implementation of an automated platform supporting the alemtuzumab risk management plan: the Alemtuzumab MS Safety Systems (AMS3) study S. Reddel (Sydney, AU) ABO blood groups and secretion status is associated with JC polyomavirus antibody levels in plasma: a genome-wide association study T. Olsson (Stockholm, SE) Effectiveness and safety of fingolimod in patients with multiple sclerosis switched from natalizumab: results from TRANSITION − a 2-year observational study H. Butzkueven (Melbourne, AU) Which total lymphocyte count may predict a low number of CD4 T cells under dimethyl fumarate? J. Boucher (Lille, FR) Severe reactivation of multiple sclerosis following withdrawal of fingolimod: a case series M. Gaughan (Dublin, IE) Stability of a negative JCV test E. Williamson (Philadelphia, US) Reductions in immunoglobulin levels following natalizumab-to-rituximab crossover in a multiple sclerosis cohort: implications for next generation B cell-targeted therapies M.M. Foley (Salt Lake City, US) Switching from natalizumab to alemtuzumab: a case series N.A. John (London, UK) Comparison of reproductive and juvenile nonclinical findings between ozanimod and fingolimod S. Meier-Davis (San Diego, US) Lateral ventricular volume measurement is feasible on low-resolution T2-FLAIR MRI in pediatric MS M.G. Dwyer (Buffalo, US) Impact of fingolimod on MRI brain volume measures in RRMS patients with active disease at baseline: results from MS-MRIUS, a longitudinal observational, multicenter real-world outcome study in a clinical routine R. Zivadinov (Buffalo, US) Page 94 / 108
- 95. Scientific Programme Early biomarkersof response in multiple sclerosis patients treated with natalizumab: clinical, genetic and environmental R. Alvarez-Lafuente (Madrid, ES) Prediction of treatment response in alemtuzumab treated RRMS patients by distinct immune phenotypes and deep immune sequencing T. Ruck (Münster, DE) MIMoSA: a method for inter-modal segmentation analysis of T2 hyperintensities and T1 black holes in multiple sclerosis A. Valcarcel (Philadelphia, US) Differential effect on lymphocyte subsets and transcriptome sequencing after treatment with fingolimod in relapsing-remitting multiple sclerosis patients. Prognostic implications I. Moreno Torres (Majadahonda, ES) Interim analysis from FLOODLIGHT: a prospective pilot study to evaluate the feasibility of conducting remote patient monitoring with the use of digital technology in patients with multiple sclerosis P. Mulero (Barcelona, ES) Establishing pathological cut-offs for lateral ventricular volume expansion rates M.G. Dwyer (Buffalo, US) Predicting disease activity and disability progression in RRMS patients on natalizumab I. Dekker (Amsterdam, NL) The role of geographic location as a treatment effect modifier in multiple sclerosis E. Sgarlata (Rome, IT) Fampridine improves horizontal eye movements in patients with multiple sclerosis and internuclear ophthalmoplegia: a double-blind, placebo-controlled crossover study K.M.S. Kanhai (Leiden, NL) Abrogation of the lymphocyte depleting action of Alemtuzumab by neutralizing antibodies - a case report C. Eggers (Linz, AT) Effect of fingolimod 0.5 mg/day vs placebo on two newly developed expanded disability status scale (EDSS) subscales for relapsing-remitting MS patients: EDSS factor analysis G. Cutter (Birmingham, US) MRI diffusion metrics are sensitive to changes due to fingolimod treatment Q. Yu (Brisbane, AU) Sustained and durable reduction in confirmed disability progression in patients with primary progressive multiple sclerosis receiving ocrelizumab: findings from the phase III ORATORIO study extended control period J.S. Wolinsky (Houston, US) Enhancing brain plasticity to contrast clinical progression in MS: a pilot study assessing the safety and efficacy of D-Aspartate C.G. Nicoletti (Rome, IT) Page 95 / 108
- 96. Scientific Programme Effect ofocrelizumab on upper limb function in patients with primary progressive multiple sclerosis in the ORATORIO study E.J. Fox (Round Rock, US) Disease-modifying therapies use in primary progressive multiple sclerosis patients in France: data from the OFSEP cohort over the 1996 - 2017 period E. Leray (Rennes, FR) Longitudinal changes in lymphocyte subsets of siponimod-treated patients with SPMS A. Bar-Or (Philadelphia, US) Impact of primary endpoint definitions and patient baseline characteristics on study outcomes in progressive multiple sclerosis R. Gold (Bochum, DE) Fingolimod treatment increase peroxisome proliferator-activated receptor (PPAR) γ and CD36 receptor gene expression in blood leukocytes of multiple sclerosis patients C. Capela (Lisboa, PT) Neurologists' understanding of advances in multiple sclerosis (MS) across Europe, South America, and the United States G. Comi (Milan, IT) Recombinant protein analogous to human sIFNAR2 as a potential new drug for multiple sclerosis B. Oliver-Martos (Málaga, ES) Disease modifying therapies: trending choices and the what's and why's to switching D. Lux (Canterbury, UK) Calorie restriction diets and changes in the metabolome in people with multiple sclerosis K.C. Fitzgerald (Baltimore, US) Real-world assessment of relapse in patients with multiple sclerosis newly initiating scIFNβ1a compared with oral disease-modifying drugs J. Bowen (Seattle, US) Cardiorespiratory fitness and cardiovascular autonomic control in patients with mild to moderate relapsing remitting multiple sclerosis following 6 week endurance exercise program M. Abolhasani (Tehran, IR) A risk aversion calculator for augmenting the disease modifier selection process L. Hartsell (Durham, US) Disease activity following pregnancy-related discontinuation of natalizumab in multiple sclerosis I. Kleerekooper (Amsterdam, NL) A post-marketing observational monocentric study of efficacy and tolerability of dimetilfumarate L. Moiola (Milan, IT) Page 96 / 108
- 97. Scientific Programme Evaluation ofpostural balance in women with multiple sclerosis in different sensory conditions using force platform C. Ramari (Brasília, BR) An evaluation of adherence using panel survey data from patients with multiple sclerosis treated with subcutaneous interferon β-1a or dimethyl fumarate A. Perrin Ross (Maywood, US) Treatment patterns of relapsing remitting multiple sclerosis (RRMS) in Europe and the United States J. White (London, UK) Physician and patient treatment decision-making in relapsing-remitting multiple sclerosis in Europe and the United States J. White (London, UK) Switching to natalizumab is associated with improvements in cognitive function as measured by NeuroTrax M. Gudesblatt (Patchogue, US) Acupuncture for patients with multiple sclerosis associated fatigue - a randomized controlled trial J. Bellmann-Strobl (Berlin, DE) Evidenced based cognitive rehabilitation for persons with multiple sclerosis: an updated review of the literature from 2007-2016 Y. Goverover (New York, US) The Adult Spasticity International Registry (ASPIRE) Study: treatment utilization patterns in patients with multiple sclerosis patients treated for spasticity D. Bandari (Newport Beach, US) A pilot randomized controlled trial evaluating the effects of a resilience intervention on adults aging with multiple sclerosis D.M. Ehde (Seattle, US) Effects of a maximum strength training program on perceived fatigue and functional ability in patients with multiple sclerosis R. Gomez-Illan (Elche, ES) Is the effect of personalized multidisciplinary rehabilitation on physical function dependent on multiple sclerosis phenotype? - Part of the Danish MS Hospitals Rehabilitation Study L.G. Hvid (Aarhus, DK) Magnitude of response to dalfampridine correlates with diffusion tensor imaging metrics S. Klineova (New York, US) Effects of normobaric hypoxic training on physical fitness and immunoregulatory functions in patients with multiple sclerosis: a pilot study A. Mähler (Berlin, DE) Effect of videogame-based physical activity training in persons with multiple sclerosis: a randomised controlled trial T. Kahraman (Izmir, TR) Page 97 / 108
- 98. Scientific Programme Natalizumab isassociated with stable or improved cognitive function, health-related quality of life, and work capacity in anti-JC virus seronegative patients with early relapsing- remitting multiple sclerosis: a 2-year analysis of STRIVE J. Perumal (New York, US) Everyday technology use in MS: limitations and opportunities in using everyday technology in persons with MS Y. Goverover (New York, US) Qualitative factors on initiation, satisfaction and adherence to aquatic exercise in the community among persons with multiple sclerosis C. Santoyo (Barcelona, ES) Understanding patient underreporting of MS relapses: insights from patients with multiple sclerosis from the Harris Poll 2017 survey E.N. Banfe (Hampton, US) Increased adherence and better satisfaction outcomes with oral treatments in relapsing- remitting multiple sclerosis patients I. González-Suárez (Madrid, ES) Employment status and health-related quality of life of MS patients in a never treated and only ever treated with IFNβ-1a sc cohorts: an exploratory study S. Hum (Montreal, CA) The association between energy cost of walking and leisure-time physical activity in people with multiple sclerosis A. Kalron (Herzeliya, IL) Evaluation of a web-based fall prevention program among people with multiple sclerosis M. Kannan (Portland, US) Expanding our understanding of daily life activity impact in patients with multiple sclerosis J. Petrillo (Cambridge, US) Multicenter open-label non-interventional study assessing the alteration of activity in ambulatory patients with relapsing forms of MS (RMS) under treatment with COPAXONE® 40 mg tiw - results of an interim analysis of the NIS COPTIVITY T. Ziemssen (Dresden, DE) Enhanced regional cerebral perfusion following acetazolamide: preliminary results J.A. Lincoln (Houston, US) [F-18]PBR06 PET to assess TSPO binding and its association with brain atrophy and disability in multiple sclerosis T. Singhal (Boston, US) Elevated adiponectin levels induce pro-inflammatory myeloid- and T-cell responses linking adiposity and predisposition to pediatric MS G. Fadda (Montreal, CA) Big Multiple Sclerosis Data Network: impact of early treatment on long term disability accumulation in relapsing remitting multiple sclerosis patients P. Iaffaldano (Bari, IT) Page 98 / 108
- 99. Scientific Programme Cesarean deliveryand artificial lactation are associated with an earlier age of disease onset in multiple sclerosis G. Dalla Costa (Milan, IT) Prognostic value of cerebrospinal fluid neurofilament light chain and chitinase-3-like-1 in newly diagnosed multiple sclerosis F. Sellebjerg (Copenhagen, DK) Ozanimod demonstrates preservation of brain volume at 1 and 2 years in two Phase 3 trials of relapsing multiple sclerosis (SUNBEAM and RADIANCE) D.L. Arnold (Montréal, CA) Optic nerve involvement for establishing dissemination in space: is it worth assessing the visual pathway with VEP? À. Vidal-Jordana (Barcelona, ES) Long term disease progression in disease activity-free relapsing MS B.A. Cree (San Francisco, US) ATL1102 treatment reduces conversion of active multiple sclerosis lesions into persistent black holes F. Barkhof (Amsterdam, NL) Prognostic value of MRI activity in treatment failure A.C. Kunchok (Melbourne, AU) Sativex® as Add-on therapy Vs. further optimized first-line ANTispastics (SAVANT) in resistant multiple sclerosis spasticity double blind randomized clinical trial J. Markova (Prague, CZ) Lipocalin-2 is upregulated in reactive astrocytes in neuromyelitis optica S. Hwang (Rochester, US) Comparison of the efficacy of azathioprine and rituximab in neuromyelitis optica spectrum disorder: a randomized clinical trial V. Shaygannejad (Isfahan, IR) Comorbidity increases the risk of relapse in multiple sclerosis: a prospective study K. Kowalec (Solna, SE) Centrifugal pattern of progressive water diffusion increase in chronic MS lesions C. Wang (Sydney, AU) The risk of relapse following on-treatment clinically silent lesions in patients with relapsing- remitting multiple sclerosis J.W.L. Brown (Cambridge, UK) Oligoclonal immunoglobulin gamma bands in the cerebrospinal fluid confers higher risk to reach EDSS milestones and to convert to secondary progression V.D. Karrenbauer (Stockholm, SE) Can the BBB be targeted for treatment of MS? Evidence that IL-6 is actively transported across the BBB in vivo by an IL-6 specific transporter reveals a novel target linked to inflammatory immunity S.M. Metcalfe (UK, UK) Page 99 / 108
- 100. Scientific Programme Exome sequencingin multiple sclerosis families defines biological pathways for patients with primary progressive and relapsing remitting disease course C. Vilarino-Guell (Vancouver, CA) A behavioral test to evaluate the funtional consequences in a Xenopus laevis model of inducible-demyelination and myelin repair B. Zalc (Paris, FR) Quercetin enhances myelin repair and ameliorated astrocytes activation in lysolecithin- induced focal demyelination M. Ghasemi-Kasman (Babol, IR) "Taste", a pilot study: Palatability and oral cavity tolerability of Sativex and possible improvement measures in multiple sclerosis patients with resistant spasticity G. Lus (Naples, IT) Pregnancy outcomes during the clinical development programme of cladribine in multiple sclerosis (MS): an integrated analysis of safety for all exposed patients A. Galazka (Aubonne, CH) Development of a new chronic model of T cell-driven CNS autoimmunity M. Rangachari (Québec, CA) Histopathological features of “cavitary” or “cystic” multiple sclerosis (MS) compared to classical MS E. Bahn (Göttingen, DE) The effect of alemtuzumab on periventricular magnetisation transfer ratio gradients J.W.L. Brown (Cambridge, UK) An analysis of malignancy risk in the clinical development programme of cladribine tablets in patients with relapsing multiple sclerosis (RMS) A. Galazka (Aubonne, CH) Long-term efficacy and safety of fingolimod in patients with RRMS: 10-year experience from LONGTERMS study J.A. Cohen (Cleveland, US) Examining the role of MS-associated genetic risk factors in a humanized mouse model of Epstein-Barr virus infection H. Zdimerova (Zurich, CH) Switching to alemtuzumab from fingolimod or other therapies: impact of wash-out period on disease activity J. Frau (Cagliari, IT) Clinical, demographic and laboratory data associated with PML risk in patients treated with natalizumab L.M. Villar (Madrid, ES) Multiple sclerosis associated cytotoxic CD4+ T cells escape regulatory T cell mediated suppression N. Hellings (Hasselt, BE) Page 100 / 108
- 101. Scientific Programme Vitamin Dlevels in a multiple sclerosis population treated with rituximab P. Sundström (Umeå, SE) Short-term memory loss correlates with mean diffusivity and free-water in recently diagnosed multiple sclerosis patients Ø. Bergmann (Bergen, NO) An antigen-specific semi-therapeutic treatment with local delivery of tolerogenic factors through a dual-sized microparticle system blocks experimental autoimmune encephalomyelitis, a mouse model of multiple sclerosis J. Cho (Gainesville, US) Advanced imaging detects variations in myelin content and thickness in the corpus callosum of neuromyelitis optica patients and healthy controls S. Abel (Vancouver, CA) Corpus callosum atrophy in MS is halted by autologous haematopoietic stem cell transplantation A. Tolf (Uppsala, SE) Epstein-Barr virus induced G-protein coupled receptor 2 (GPR 183) in B lymphocyte can be associated with the relapse of neuromyelitis optica spectrum disorder with AQP4-IgG S.-M. Kim (Seoul, KR) Comparison of skin cell immunity in patients receiving treatment with gilenya (fingolimod) and healthy controls S. Newman (Plainview, US) Comparative effectiveness of dimethyl fumarate, teriflunomide, interferon-beta and glatiramer acetate on newly diagnosed patients: a propensity score-matched analysis from a multicenter Italian group A. Signori (Genova, IT) Repeated administrations of macrocyclic gadolinium based contrast agents do not cause increased signal intensity in dentate nucleus and globus pallidus on T1-weighted unenhanced magnetic resonance images: confirmed safety in multiple sclerosis A. Sartori (Trieste, IT) Flowy cytometric assay for antibody to myelin oligodendrocyte glycoprotein in chronic relapsing inflammatory optic neuropathy (CRION) B. Kim (Seoul, KR) What is the best home-based walking exercise prescription for people with multiple sclerosis? A randomized controlled clinical trial N. Aghaei (Tehran, IR) [F-18]PBR06 vs. [C-11]PBR28 PET for assessing white matter TSPO binding in multiple sclerosis T. Singhal (Boston, US) Cladribine controls multiple sclerosis via memory B cell depletion B. Ceronie (London, UK) Pro-inflammatory monocyte subsets are augmented in incipient and progressed multiple sclerosis M.C. Gjelstrup (Aarhus, DK) Page 101 / 108
- 102. Scientific Programme THC: CBD(Nabiximols) has a beneficial effect on resistant MS related spasticity and reduces the need for Intrathecal baclofen S. De Trane (London, UK) Glatiramer acetate depot (extended-release) phase IIa one-year study in patients with relapsing remitting multiple sclerosis: safety, tolerability and efficacy (no evidence of disease activity) analysis A. Miller (Haifa, IL) Online personalized education improves overall knowledge of multiple sclerosis in neurologists T.F. Finnegan (Glenside, US) Risk-benefit assessment of natalizumab therapy in multiple sclerosis patients and their treating physicians J. Krämer (Münster, DE) Basic immunological profile changes with BAF312 (siponimod) treatment in secondary progressive multiple sclerosis patients Y. Mao-Draayer (Ann Arbor, US) Effect of eight weeks DNS exercises quality of life and function in women with multiple sclerosis S. Shahbeigi (Tehran, IR) IgG from multiple sclerosis patients positive for antiphospholipid antibodies increases the activation of p38 MAPK and p65 NF-κB M. Pantzaris (Nicosia, CY) Oncostatin M and the inflamed blood brain barrier: good, bad or both? N. Hellings (Hasselt, BE) Serum NF-L in NMOSD and related disorders: comparison according to AQP4 and MOG antibodies status S. Mariotto (Verona, IT) Cortical grey matter ratio differentiates relapsing remitting multiple sclerosis from secondary progressive multiple sclerosis J. Fleer (Wilrijk, BE) Anti-myelin oligodendrocyte glycoprotein antibody detection in Korean patients of demyelinating disease S. Hwang (Rochester, US) Volume susceptibility increases as diamagnetic molecules breakdown: implications for myelin digestion during multiple sclerosis (MS) lesion formation Y. Wang (New York, US) Correlation between sensorimotor delay and microstructural integrity of the spinal cord in multiple sclerosis P. Lee (Kansas City, US) IFN-β therapy in MS patients changes the responses to IL-6, IL-10, and IFN-γ differently in leukocyte subsets of good and poor treatment responders A.H.H. van Boxel-Dezaire (Cleveland, US) Page 102 / 108
- 103. Scientific Programme Dimethylfumarate asan epigenetic immunomodulator: implications for T cell survival and function A. Ntranos (New York, US) Decreased serum levels of interleukin-35 among patients with clinically isolated syndrome and relapsing remitting multiple sclerosis V. Shaygannejad (Isfahan, IR) Tumefactive multiple sclerosis lesions associated with fingolimod treatment P. Sánchez (Madrid, ES) Disease course in adult patients with MOG antibody-associated demyelinating disease L.M. Oliveira (São Paulo, BR) Myeloid-derived suppressor cell activity is potentiated by IFN-ß ameliorating the disease course of the multiple sclerosis murine model experimental autoimmune encephalomyelitis D. Clemente (Toledo, ES) Risk of stroke in patients with multiple sclerosis treated with subcutaneous interferon beta-1a M. Sabidó-Espin (Darmstadt, DE) The incidence and severity of restless legs syndrome in patients with multiple sclerosis, and its clinical impact F.P. Balcı (Istanbul, TR) The role of metabolomics in multiple sclerosis sub-classification and clinical course: tryptophan and serotonin D.K. Kitsos (Athens, GR) Social Media Session, Hall D 15:45 - 16:45 Google Hangout - Online hangout with MS community A google hangout broadcast from MSParis2017 with Barts MS researchers with people with MS sharing highlights from the meeting. To watch visit <a href="http://www.youtube.com">www.youtube.com</a> and search for channel Barts MS Blog or see the broadcast in Hall D. Chairs A. Thomson (London, UK) M. Marta (London, UK) 15:45 - 16:45 MSParis2017 Highlights D. Baker (London, UK) S. Gnanapavan (London, UK) Page 103 / 108
- 104. Scientific Programme Hot TopicSessions, Hall A 17:00 - 17:45 Hot Topic 7: Controversy 2: Anti-MOG disease: a new entity different from NMO spectrum disorder? Chairs J. de Seze (Strasbourg, FR) A. Traboulsee (Vancouver, CA) 17:00 - 17:15 For D.K. Sato (Porto Alegre, BR) 17:15 - 17:30 Against R. Marignier (Lyon, FR) 17:30 - 17:40 Disease course and disability outcomes in MOG-antibody disease in the UK M. Jurynczyk (Oxford, UK) 17:40 - 17:45 Summary A. Traboulsee (Vancouver, CA) Hot Topic Sessions, Hall B 17:00 - 17:45 Hot Topic 8: Aging with MS Chairs T. Moreau (Dijon, FR) M. Tintoré (Barcelona, ES) 17:00 - 17:15 CIS: prognosis after 30 years D. Chard (London, UK) 17:15 - 17:30 Role of comorbidities in aging individuals with multiple sclerosis R.A. Marrie (Winnipeg, CA) 17:30 - 17:45 Disease modifying therapy in the aging multiple sclerosis patient J. Corboy (Aurora, US) Hot Topic Sessions, Hall C 17:00 - 17:45 Hot Topic 9: Immune cells on the move Chairs M. Kerschensteiner (Munich, DE) R. Liblau (Toulouse, FR) 17:00 - 17:15 Meningeal lymphatics in MS J. Kipnis (Charlottesville, US) 17:15 - 17:30 The role of B cells and antibodies on both sides of the blood brain barrier in MS M. Weber (Goettingen, DE) Page 104 / 108
- 105. Scientific Programme 17:30 -17:45 B cells from bench to bedside in MS B. Hemmer (Munich, DE) Hot Topic Sessions, Hall D 17:00 - 17:45 Hot Topic 10: Insight from new imaging methods Chairs B. Stankoff (Paris, FR) O. Ciccarelli (London, UK) 17:00 - 17:15 New insights in brain microstructure and metabolism using advanced MRI J.-P. Ranjeva (Marseille, FR) 17:15 - 17:30 Assessing lesion dynamics in the brain and spinal cord by high-field MRI D. Reich (Bethesda, US) 17:30 - 17:45 OCT and the course of MS F. Costello (Calgary, CA) Satellite Symposia, Hall B 18:00 - 19:00 Satellite Symposium - Turning the lights on: seeing is believing Supported by Roche Chairs M. Duddy (Newcastle upon Tyne, UK) 18:00 - 18:10 Welcome and introduction by the chair 18:10 - 18:25 Toward an evolving understanding of MS as a progressing disease M. Duddy (Newcastle upon Tyne, UK) 18:25 - 18:40 Panel discussion M. Duddy (Newcastle upon Tyne, UK) J. Oh (Toronto, CA) J. Overell (UK) 18:40 - 18:55 Patient cases: the manifold faces of progression across the MS continuum J. Overell (UK) 18:55 - 19:00 Closing Page 105 / 108
- 106. Scientific Programme Satellite Symposia,Hall B 19:15 - 20:15 Satellite Symposium - From days to decades: providing for patients throughout the MS disease course Supported by Novartis 19:15 - 19:20 Chair’s welcome J. de Seze (Strasbourg, FR) 19:20 - 19:35 Ahead of time: addressing the needs in paediatric MS T. Chitnis (Boston, US) 19:35 - 19:50 Watching the hourglass: disease monitoring and detecting disease activity in MS R. Zivadinov (Buffalo, US) 19:50 - 20:05 A ticking clock: managing progression in advanced disease H.-P. Hartung (Duesseldorf, DE) 20:05 - 20:15 Q&A and closing remarks Page 106 / 108
- 107. Scientific Programme Saturday, 28October 2017 Satellite Symposia, Hall A 07:45 - 08:15 Mini Satellite Symposium - The role of auto antibodies in CNC diseases: AQP4, NMDAR, MOG and others Supported by MedImmune Chairs A. Bar-Or (Philadelphia, US) J. Palace (Oxford, UK) 07:45 - 07:48 Opening remarks A. Bar-Or (Philadelphia, US) 07:48 - 07:58 Auto-antibodies in demyelinating cns diseases J. Palace (Oxford, UK) 07:58 - 08:08 The spectrum of auto-antibodies in autoimmune encephalitis M. Titulaer (Rotterdam, NL) 08:08 - 08:15 Open round table discusson A. Bar-Or (Philadelphia, US) Parallel Sessions, Hall A 08:30 - 10:00 Parallel Session 16: Late Breaking News Chairs J. Antel (Montreal, CA) R. Hohlfeld (Munich, DE) 08:30 - 08:42 Pathogenic mechanisms of human autoantibodies against myelin oligodendrocyte glycoprotein E. Meinl (Martinsried, DE) 08:42 - 08:54 The primate meninges harbor lymphatic vessels that can be visualized noninvasively by MRI M. Absinta (Bethesda, US) 08:54 - 09:06 PARADIGMS: a randomised double-blind study of fingolimod versus interferon β-1a in paediatric multiple sclerosis T. Chitnis (Boston, US) 09:06 - 09:18 Blood NfL as a potential endpoint in Phase 2 clinical studies in relapsing- remitting multiple sclerosis M.P. Sormani (Genoa, IT) 09:18 - 09:30 SPRINT-MS/NN 102 phase II trial of ibudilast in progressive MS: top-line results R.J. Fox (Cleveland, US) Page 107 / 108
- 108. Scientific Programme 09:30 -09:42 Week 24 results from a Phase IIb trial of GNbAC1 in patients with relapsing remitting multiple sclerosis (CHANGE-MS; Clinical trial assessing the HERV-W Env antagonist GNbAC1 for Efficacy in MS) H.-P. Hartung (Duesseldorf, DE) 09:42 - 09:54 Ozanimod vs interferon β-1a: clinical and MRI results of RADIANCE part B - A 2-year Phase 3 trial in relapsing multiple sclerosis J.A. Cohen (Cleveland, US) Plenary Sessions, Hall A 10:30 - 12:30 Plenary Session 2 - Awards, ECTRIMS Honorary Members, Charcot Lecture and MSParis2017 Highlights Chairs D. Miller (London, UK) J. Antel (Montreal, CA) B. Hemmer (Munich, DE) 10:30 - 11:10 Presentation of selected poster awards, awards for best oral presentations by young researchers, the MSIF award as well announcement of ECTRIMS Honorary Members 11:10 - 11:40 Charcot Lecture: Management of suboptimal therapeutic response in MS P. Soelberg Sorensen (Copenhagen, DK) 11:40 - 12:00 Clinical highlights R.J. Fox (Cleveland, US) A.J. Coles (Cambridge, UK) 12:00 - 12:20 Scientific highlights D. Laplaud (Nantes Cédex, FR) A. Green (San Francisco, US) 12:20 - 12:25 Welcome to Berlin R. Hohlfeld (Munich, DE) Powered by TCPDF (www.tcpdf.org) Page 108 / 108